<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock - Alejandria, MM - 2013 | Cochrane Library</title> <meta content="Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock - Alejandria, MM - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001090.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock - Alejandria, MM - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001090.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001090.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock" name="citation_title"/> <meta content="Marissa M Alejandria" name="citation_author"/> <meta content="University of the Philippines,College of Medicine" name="citation_author_institution"/> <meta content="mmalejandria@up.edu.ph" name="citation_author_email"/> <meta content="Mary Ann D Lansang" name="citation_author"/> <meta content="Department of Medicine, Philippine General Hospital, University of the Philippines" name="citation_author_institution"/> <meta content="Leonila F Dans" name="citation_author"/> <meta content="University of the Philippines Manila College of Medicine‐Philippine General Hospital" name="citation_author_institution"/> <meta content="Jacinto Blas Mantaring III" name="citation_author"/> <meta content="University of the Philippines" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD001090.pub2" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/09/16" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001090.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001090.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001090.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Age Factors; Immunoglobulins, Intravenous [*therapeutic use]; Randomized Controlled Trials as Topic; Sepsis [*drug therapy, mortality]; Shock, Septic [*drug therapy, mortality]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001090.pub2&amp;doi=10.1002/14651858.CD001090.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001090.pub2&amp;doi=10.1002/14651858.CD001090.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001090.pub2&amp;doi=10.1002/14651858.CD001090.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001090.pub2&amp;doi=10.1002/14651858.CD001090.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001090.pub2&amp;doi=10.1002/14651858.CD001090.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001090.pub2&amp;doi=10.1002/14651858.CD001090.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001090.pub2&amp;doi=10.1002/14651858.CD001090.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001090.pub2&amp;doi=10.1002/14651858.CD001090.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001090.pub2&amp;doi=10.1002/14651858.CD001090.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001090.pub2&amp;doi=10.1002/14651858.CD001090.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001090.pub2&amp;doi=10.1002/14651858.CD001090.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001090.pub2&amp;doi=10.1002/14651858.CD001090.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001090.pub2&amp;doi=10.1002/14651858.CD001090.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001090.pub2&amp;doi=10.1002/14651858.CD001090.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001090.pub2&amp;doi=10.1002/14651858.CD001090.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001090.pub2&amp;doi=10.1002/14651858.CD001090.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001090.pub2&amp;doi=10.1002/14651858.CD001090.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001090.pub2&amp;doi=10.1002/14651858.CD001090.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001090.pub2&amp;doi=10.1002/14651858.CD001090.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001090.pub2&amp;doi=10.1002/14651858.CD001090.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001090.pub2&amp;doi=10.1002/14651858.CD001090.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001090.pub2&amp;doi=10.1002/14651858.CD001090.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001090.pub2&amp;doi=10.1002/14651858.CD001090.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="7a2tKMcJ";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001090\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001090\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001090\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001090\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","ru","ms","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001090.pub2",title:"Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock",firstPublishedDate:"Sep 16, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Emergency and Critical Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=7a2tKMcJ&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001090.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001090.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001090.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001090.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001090.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001090.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001090.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001090.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001090.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001090.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>8828 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001090.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001090.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001090.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001090.pub2/full#CD001090-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001090.pub2/full#CD001090-sec-0084"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001090.pub2/full#CD001090-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001090.pub2/full#CD001090-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001090.pub2/full#CD001090-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001090.pub2/full#CD001090-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001090.pub2/full#CD001090-sec-0051"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001090.pub2/full#CD001090-sec-0079"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001090.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001090.pub2/appendices#CD001090-sec-0089"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001090.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001090.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/table_n/CD001090StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/table_n/CD001090StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001090.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001090.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001090.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001090.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001090.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001090.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001090.pub2/information#CD001090-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Marissa M Alejandria</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001090.pub2/information#CD001090-cr-0003">Mary Ann D Lansang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001090.pub2/information#CD001090-cr-0004">Leonila F Dans</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001090.pub2/information#CD001090-cr-0005">Jacinto Blas Mantaring III</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/information/en#CD001090-sec-0109">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 16 September 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001090.pub2">https://doi.org/10.1002/14651858.CD001090.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001090-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001090-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001090-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001090-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001090-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001090-abs-0001" lang="en"> <section id="CD001090-sec-0001"> <h3 class="title" id="CD001090-sec-0001">Background</h3> <p>Mortality from sepsis and septic shock remains high. Results of trials on intravenous immunoglobulins (IVIG) as adjunctive therapy for sepsis have been conflicting. This is an update of a Cochrane review that was originally published in 1999 and updated in 2002 and 2010. </p> </section> <section id="CD001090-sec-0002"> <h3 class="title" id="CD001090-sec-0002">Objectives</h3> <p>To estimate the effects of IVIG as adjunctive therapy in patients with bacterial sepsis or septic shock on mortality, bacteriological failure rates, and duration of stay in hospital. </p> </section> <section id="CD001090-sec-0003"> <h3 class="title" id="CD001090-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<i>The Cochrane Library</i> 2012, Issue 6), MEDLINE (1966 to December 2012), and EMBASE (1988 to December 2012). We contacted investigators in the field for unpublished data. The original search was performed in 1999 and updated in 2002 and 2008. </p> </section> <section id="CD001090-sec-0004"> <h3 class="title" id="CD001090-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials comparing IVIG (monoclonal or polyclonal) with placebo or no intervention in patients of any age with bacterial sepsis or septic shock. </p> </section> <section id="CD001090-sec-0005"> <h3 class="title" id="CD001090-sec-0005">Data collection and analysis</h3> <p>Two authors independently assessed the studies for inclusion and undertook methodologic quality assessment and data abstraction. We conducted pre‐specified subgroup analyses by type of immunoglobulin preparation. </p> </section> <section id="CD001090-sec-0006"> <h3 class="title" id="CD001090-sec-0006">Main results</h3> <p>We included 43 studies that met our inclusion criteria in this updated review out of 88 potentially eligible studies. The studies included a large polyclonal IVIG trial in neonates that was concluded in 2011 and classified as ongoing in the 2010 version of this review. Pooled analysis of polyclonal and monoclonal IVIG was not done due to clinical heterogeneity. Subgroup analysis of 10 polyclonal IVIG trials (n = 1430) and seven trials on IgM‐enriched polyclonal IVIG (n = 528) showed significant reductions in mortality in adults with sepsis compared to placebo or no intervention (relative risk (RR) 0.81; 95% confidence interval (CI) 0.70 to 0.93 and RR 0.66; 95% CI 0.51 to 0.85, respectively). Subgroup analysis of polyclonal IVIG in neonates, which now includes the recently concluded large polyclonal IVIG trial, showed no significant reduction in mortality for standard IVIG (RR 1.00; 95% CI 0.92 to 1.08; five trials, n = 3667) and IgM‐enriched polyclonal IVIG (RR 0.57; 95% CI 0.31 to 1.04; three trials, n = 164). Sensitivity analysis of trials with low risk of bias showed no reduction in mortality with polyclonal IVIG in adults (RR 0.97; 95% CI 0.81 to 1.15; five trials, n = 945) and neonates (RR 1.01; 95% CI 0.93 to 1.09; three trials, n = 3561). Mortality was not reduced among patients (eight trials, n = 4671) who received anti‐endotoxin antibodies (RR 0.99; 95% CI 0.91 to1.06) while anti‐cytokines (nine trials, n = 7893) demonstrated a marginal reduction in mortality (RR 0.92; 95% CI 0.86 to 0.97). </p> </section> <section id="CD001090-sec-0007"> <h3 class="title" id="CD001090-sec-0007">Authors' conclusions</h3> <p>Polyclonal IVIG reduced mortality among adults with sepsis but this benefit was not seen in trials with low risk of bias. Among neonates with sepsis, there is sufficient evidence that standard polyclonal IVIG, as adjunctive therapy, does not reduce mortality based on the inclusion of the large polyclonal IVIG trial on neonates. For Ig‐M enriched IVIG, the trials on neonates and adults were small and the totality of the evidence is still insufficient to support a robust conclusion of benefit. Adjunctive therapy with monoclonal IVIGs remains experimental. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001090-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001090-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD001090-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD001090-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001090-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD001090-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD001090-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD001090-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001090-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001090-abs-0004" lang="en"> <h3>Intravenous immunoglobulins for treating patients with severe sepsis and septic shock</h3> <p>Sepsis is the inflammatory response of the body to severe infection, which can be caused by a variety of micro‐organisms including bacteria, viruses and fungi. Signs of sepsis include fever, hypothermia, rapid heart rate and respiration; and a laboratory finding of increased or decreased white blood cell count. Deaths as a result of sepsis and septic shock remain high despite giving antibiotics, especially if the functions of a persons's vital organs such as the lungs, heart and kidneys are affected. Several studies have looked into other agents than antibiotics to help the body fight the effects of sepsis. Intravenous immunoglobulin preparations contain antibodies that help the body to neutralize bacterial toxins. There are two types of preparations. These are polyclonal immunoglobulins that contain several antibodies directed at endotoxin and inflammatory mediators, and monoclonal immunoglobulins which target a specific inflammatory mediator or antigen. Intravenous immunoglobulins are blood products, specifically pooled sera derived from human donor blood. </p> <p>For this updated Cochrane review, we searched the medical literature databases to January 2012. We included 43 randomized controlled trials (RCTs); 25 were RCTs of polyclonal intravenous immunoglobulins (IVIGs) with 17 in adults (1958 participants) and eight in newborn infants (3831 participants) including a large polyclonal IVIG trial on infants with sepsis that was published in 2011. The remaining 18 trials (a total of 13,413 participants) were of monoclonal antibodies. Both standard and immunoglobulin M (IgM)‐enriched polyclonal immunoglobulins decreased the number of deaths in adults but not in infants. However, no reductions in adult deaths were seen with polyclonal IVIG using high quality trials only. Among newborn infants with sepsis, there is definitive evidence that standard polyclonal IVIG does not reduce the number of deaths. In the monoclonal immunoglobulin trials, anti‐endotoxin antibodies showed no benefit while the anti‐cytokines showed a very small reduction in deaths among adults with sepsis. </p> <p>The polyclonal immunoglobulin trials in adults were small compared to the trials of monoclonal agents. The reduction in deaths observed with polyclonal IgM‐enriched preparations as add‐on therapy for sepsis needs to be confirmed in large studies that use high quality methods. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001090-sec-0084" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001090-sec-0084"></div> <h3 class="title" id="CD001090-sec-0085">Implications for practice</h3> <section id="CD001090-sec-0085"> <p>Intravenously administered polyclonal immunoglobulins, particularly standard polyclonal IVIG, do not provide benefit as adjuvant therapy in sepsis in terms of reducing mortality among neonates and adults with sepsis. Likewise, intravenous monoclonal immunoglobulins do not show clinically significant survival benefits. There is no good evidence that a combination of immunotherapeutic agents that target different mediators in the sepsis cascade is effective. </p> </section> <h3 class="title" id="CD001090-sec-0086">Implications for research</h3> <section id="CD001090-sec-0086"> <p>Large, multi‐centre studies are needed to confirm the effectiveness of IgM‐enriched polyclonal immunoglobulins in reducing mortality in adults. The current evidence for benefit is inconsistent and inconclusive. Among adults, septic patients other than surgical patients could be included in future trials. Further studies are also needed on the subgroup of patients with necrotizing fasciitis and streptococcal toxic shock syndrome (STSS) to provide evidence on clinical efficacy of IVIG in STSS. This is especially important because the European RCT on STSS was prematurely terminated (<a href="./references#CD001090-bbs2-0011" title="DarenbergJ , IhendyaneN , SjölinJ , AufwerberE , HaidlS , FollinP , et al. StreptIg Study Group. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double‐blind placebo‐controlled trial. Clinical Infectious Diseases2003;37:333‐40. [PUBMED: 12884156 ] ">Darenberg 2003</a>), and yet IVIG continues to be recommended as a promising adjuvant in STSS and necrotizing fasciitis. In addition, future trials should include the sepsis bundle of evidence‐based interventions as the standard of care, for example early goal‐directed therapy for severe sepsis and septic shock and antibiotic administration within one hour (<a href="./references#CD001090-bbs2-0095" title="DellingerRP , LevyMM , CarletJM , BionJ , ParkerMM , JaeschkeR , et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Medicine2008;34:17‐60. [PUBMED: 18058085] ">Dellinger 2008</a>; <a href="./references#CD001090-bbs2-0096" title="DellingerRP , LevyMM , RhodesA , AnnaneD , GerlachH , OpalS , et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2012. Critical Care Medicine2013;41:580‐637. ">Dellinger 2013</a>), to determine whether the addition of IVIG to the sepsis bundle of care would contribute to a further reduction in mortality. </p> <p>In summary, the design of future trials might be improved by the following:</p> <p> <ol id="CD001090-list-0013"> <li> <p>refining the clinical definition of sepsis and including only patients with definite sepsis, using standardized scoring systems, e.g. Sequential Organ Failure Assessment; </p> </li> <li> <p>stratifying patients to address intrinsic differences in the patient population and the severity of sepsis; </p> </li> <li> <p>adding endpoints besides the measurement of all‐cause mortality, such as the resolution or reversal of organ failure; </p> </li> <li> <p>lengthening the duration of observation and follow up;</p> </li> <li> <p>systematic reporting of adverse events; and</p> </li> <li> <p>instituting the sepsis bundle of care as the standard intervention in the control group. </p> </li> </ol> </p> <p>A recent health technology assessment report, however, argues that basic research on the mechanism of action of IVIG in severe sepsis should be reviewed and be done to appropriately guide the design of a future multi‐centre RCT rather than immediately embarking on a large RCT on the clinical effectiveness of IVIG (<a href="./references#CD001090-bbs2-0109" title="SoaresMO , WeltonNJ , HarrisonDA , PeuraP , Shankar‐HariM , HarveySE , et al. An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review,meta‐analysis and value of information analysis. Health Technology Assessment2012;16(7):1‐186. [DOI: 22361003] ">Soares 2012</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001090-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001090-sec-0022"></div> <div class="table" id="CD001090-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Polyclonal intravenous immunoglobulin (IVIG) versus placebo or no intervention for sepsis, severe sepsis and septic shock</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Polyclonal IVIG versus placebo or no intervention for sepsis, severe sepsis and septic shock</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> neonates with sepsis, severe sepsis and septic shock<br/> <b>Intervention:</b> polyclonal IVIG<br/> <b>Comparison:</b> placebo or no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo or no intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Polyclonal IVIG </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>All‐cause mortality, neonates, standard polyclonal IVIG</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1</b> <br/> (0.92 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3667<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>380 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>380 per 1000</b><br/> (349 to 410) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>280 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>280 per 1000</b><br/> (258 to 302) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>All‐cause mortality, neonates, IgM‐enriched polyclonal IVIG</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.57</b> <br/> (0.31 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>164<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>274 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>156 per 1000</b><br/> (85 to 285) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>267 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>152 per 1000</b><br/> (83 to 278) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Low risk of bias neonate studies, mortality all‐cause ‐ standard IVIG</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.01</b> <br/> (0.93 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3561<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>387 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>391 per 1000</b><br/> (360 to 421) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>294 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>297 per 1000</b><br/> (273 to 320) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Two studies are of low quality (Chen 1996; Shenoi 1999)<br/> <sup>2</sup> Two studies are of low quality (Erdem; Samatha)<br/> <sup>3</sup> Wide confidence intervals, small studies </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001090-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Polyclonal intravenous immunoglobulin (IVIG) versus placebo or no intervention for sepsis, severe sepsis and septic shock</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Polyclonal IVIG versus placebo or no intervention for sepsis, severe sepsis and septic shock</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> adult patients with sepsis, severe sepsis and septic shock<br/> <b>Intervention:</b> polyclonal IVIG<br/> <b>Comparison:</b> placebo or no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo or no intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Polyclonal IVIG </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>All‐cause mortality, adults, standard polyclonal IVIG</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.81</b> <br/> (0.7 to 0.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1430<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>365 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>296 per 1000</b><br/> (256 to 340) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>423 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>343 per 1000</b><br/> (296 to 393) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>All‐cause mortality, adults, IgM‐enriched polyclonal IVIG</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.66</b> <br/> (0.51 to 0.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>528<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>375 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>247 per 1000</b><br/> (191 to 318) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>412 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>272 per 1000</b><br/> (210 to 350) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Low risk of bias adult studies, by type of polyclonal IVIG, mortality all‐cause</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.97</b> <br/> (0.81 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>945<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>354 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>344 per 1000</b><br/> (287 to 408) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>364 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>353 per 1000</b><br/> (295 to 419) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Low risk of bias adult studies, mortality all‐cause ‐ standard IVIG</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.02</b> <br/> (0.84 to 1.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>683<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>367 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>374 per 1000</b><br/> (308 to 455) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>364 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>371 per 1000</b><br/> (306 to 451) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Low risk of bias adult studies, mortality all‐cause ‐ IgM‐enriched IVIG</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.82</b> <br/> (0.56 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>262<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>323 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>265 per 1000</b><br/> (181 to 384) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>382 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>313 per 1000</b><br/> (214 to 455) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Only 3 studies on standard polyclonal IVIG are of high quality (Burns 1991; Darenberg 2003; Werdan 2007)<br/> <sup>2</sup> Only 2 studies on IgM‐enriched IVIG are of high quality (Hentrich 2006; Rodriguez 2005)<br/> <sup>3</sup> There are only 2 studies, summary effect with wide confidence intervals </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001090-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Monoclonal antibodies compared to placebo for sepsis, severe sepsis, septic shock</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Anti‐endotoxins compared to placebo for sepsis, severe sepsis, septic shock</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with sepsis, severe sepsis, septic shock<br/> <b>Settings:</b> <br/> <b>Intervention:</b> anti‐endotoxins<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Anti‐endotoxins </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Anti‐endotoxins versus placebo, all‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.92</b> <br/> (0.79 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>4676<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>369 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>340 per 1000</b><br/> (292 to 391) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>406 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>374 per 1000</b><br/> (321 to 430) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Anti‐endotoxin E5 versus placebo, all‐ cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.98</b> <br/> (0.88 to 1.1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1975<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>385 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>377 per 1000</b><br/> (338 to 423) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>406 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>398 per 1000</b><br/> (357 to 447) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Anti‐endotoxin ‐ HA‐1A versus placebo, all‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.8</b> <br/> (0.54 to 1.2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2668<br/> (3 studies<sup>4</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>4,5</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>356 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>285 per 1000</b><br/> (192 to 428) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>356 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>285 per 1000</b><br/> (192 to 427) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Anti‐endotoxins Anti‐LPS versus placebo, all‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.15</b> <br/> (0.02 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>33<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>474 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>71 per 1000</b><br/> (9 to 502) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>474 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>71 per 1000</b><br/> (9 to 502) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Sensitivity analysis by quality, anti‐endotoxin, all‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.01</b> <br/> (0.94 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>4443<br/> (6 studies<sup>3</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>364 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>367 per 1000</b><br/> (342 to 397) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>380 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>384 per 1000</b><br/> (357 to 414) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Anti‐endotoxin, all‐cause mortality ‐ low risk of bias studies</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.67</b> <br/> (0.42 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>269<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>275 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>184 per 1000</b><br/> (116 to 289) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>275 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>184 per 1000</b><br/> (115 to 289) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Anti‐endotoxin, all‐cause mortality ‐ unclear risk of bias</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.03</b> <br/> (0.95 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>4174<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>370 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>381 per 1000</b><br/> (351 to 410) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>403 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>415 per 1000</b><br/> (383 to 447) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across the included studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Five studies with unclear allocation concealment<br/> <sup>2</sup> There is a significant subgroup difference<br/> <sup>3</sup> Unclear allocation concealment<br/> <sup>4</sup> Two studies with unclear allocation concealment<br/> <sup>5</sup> Significant heterogeneity of the three trials<br/> <sup>6</sup> One trial only, with wide confidence interval </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001090-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Monoclonal antibodies compared to placebo for sepsis, severe sepsis, septic shock</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Anti‐cytokines compared to placebo for sepsis, severe sepsis, septic shock</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with sepsis, severe sepsis, septic shock<br/> <b>Settings:</b> <br/> <b>Intervention:</b> anti‐cytokines<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Anti‐cytokines </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Anti‐cytokines versus placebo, all‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.92</b> <br/> (0.86 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>7893<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>377 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>347 per 1000</b><br/> (324 to 366) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>395 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>363 per 1000</b><br/> (340 to 383) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Anticytokine ‐ anti‐TNF‐alpha versus placebo, all‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.92</b> <br/> (0.87 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>6200<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>382 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>352 per 1000</b><br/> (333 to 378) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>405 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>373 per 1000</b><br/> (352 to 401) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Anti‐cytokines ‐ human interleukin‐1receptor antagonist versus placebo, all‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.88</b> <br/> (0.76 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1693<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>355 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>313 per 1000</b><br/> (270 to 359) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>364 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>320 per 1000</b><br/> (277 to 368) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Sensitivity analysis by quality, anti‐cytokine, all‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.91</b> <br/> (0.86 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>7752<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>376 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>342 per 1000</b><br/> (323 to 365) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>364 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>331 per 1000</b><br/> (313 to 353) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Anti‐cytokine, all‐cause mortality ‐ low risk of bias studies</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.92</b> <br/> (0.86 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>5065<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>388 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>357 per 1000</b><br/> (334 to 384) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>395 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>363 per 1000</b><br/> (340 to 391) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Anti‐cytokine, all‐cause mortality ‐ uncertain risk of bias</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.89</b> <br/> (0.8 to 1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2687<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>347 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>309 per 1000</b><br/> (278 to 347) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>351 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>312 per 1000</b><br/> (281 to 351) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Six studies with unclear allocation concealment<br/> <sup>2</sup> Three studies with unclear allocation concealment<br/> <sup>3</sup> Unclear allocation concealment 4 studies </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001090-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD001090-sec-0023"></div> <section id="CD001090-sec-0024"> <h3 class="title" id="CD001090-sec-0024">Description of the condition</h3> <p>Sepsis is a systemic inflammatory response of the body to severe infection caused by various micro‐organisms including bacteria, viruses and fungi. It is detected through a constellation of signs such as fever, hypothermia, tachycardia and rapid respiration; and a laboratory finding of an increased or decreased white blood cell count. Overwhelming sepsis can lead to multiorgan dysfunction and shock. Despite the development of new and effective antibiotics, hospital mortality from sepsis ranges from 18% in a developed country (<a href="./references#CD001090-bbs2-0110" title="SundararajanV , KormanT , MacisaacC , PresneillJJ , CadeJF , VisvanathanK . The microbiology and outcome of sepsis in Victoria, Australia. Epidemiology and Infection2006;134:307‐14. [PUBMED: 16490135] ">Sundararajan 2006</a>) to 87% in a developing country setting (<a href="./references#CD001090-bbs2-0112" title="TanrioverMD , GuvenGS , SenD , UnalS , UzunO . Epidemiology and outcome of sepsis in a tertiary care hospital in a developing country. Epidemiology and Infection2006;134:315‐22. [PUBMED: 16490136 ] ">Tanriover 2006</a>), with a stepwise increase in mortality as sepsis progresses to septic shock (<a href="./references#CD001090-bbs2-0105" title="Rangel‐FraustoMS , PittetD , CostiganM , HwangT , DavisCS , WenzelRP . The natural history of the systemic inflammatory response syndrome (SIRS). JAMA1995;274:968‐74. [PUBMED: 7799491 ] ">Rangel‐Frausto 1995</a>). Two tertiary hospitals in metropolitan Manila, Philippines reported mortality rates of 34% and 50% among sepsis patients (<a href="./references#CD001090-bbs2-0089" title="AlejandriaMM , LansangMA , FonbuenaGE , FadreguilanE , TimbrezaF , deLunaM , et al. Epidemiology and predictors of mortality from sepsis in medical patients at UP‐PGH. Philippine Journal of Microbiology and Infectious Diseases2000;29:23‐32. ">Alejandria 2000</a>; <a href="./references#CD001090-bbs2-0113" title="VillaL , BalevaE , TiuD , CoronelR . Sepsis profile among patients in a tertiary care hospital. St Luke's Medical Journal1995;2:45‐9. ">Villa 1995</a>), which increased to 59% among patients with severe sepsis (<a href="./references#CD001090-bbs2-0111" title="Taguiang‐AbuCU , AlejandriaMM . Clinical determinants of outcome of severe sepsis among adult patients at the Philippine General Hospital Intensive Care Units. Philippine Journal of Internal Medicine2008;46:103‐12. ">Taguiang‐Abu 2008</a>). A recent multinational prospective cohort study on the management of severe sepsis in 150 intensive care units in 16 Asian countries reported a hospital mortality of 44.5% out of 1285 adult patients (<a href="./references#CD001090-bbs2-0103" title="PhuaJ , DuB , TangY , DivatiaJV , TanCC , GomersallCD , et al. Management of severe sepsis in patients admitted to Asian intensive care units: prospective cohort study. BMJ2011;342:d3245. ">Phua 2011</a>). </p> </section> <section id="CD001090-sec-0025"> <h3 class="title" id="CD001090-sec-0025">Description of the intervention</h3> <p>The cascade of harmful effects from sepsis and septic shock has been postulated to be largely due to the lipid‐A component of the endotoxin molecule in gram‐negative bacteria. Thus the use of antibodies against different components of the endotoxin molecule as adjunctive therapy for sepsis has been the target of various investigations. A number of these studies have been randomized controlled trials of various types of human immunoglobulin preparations in the treatment of patients with septic shock. The most commonly used interventions in these studies were monoclonal and polyclonal immunoglobulin preparations given intravenously. Monoclonal preparations contain immunoglobulins developed from a single cell line targeting a specific antigen; while polyclonal preparations are from pooled human sera containing different immunoglobulins (Ig), mainly IgG and IgM, not necessarily directed at specific antigen sites. Intravenous immunoglobulins are biological products derived from human blood. </p> </section> <section id="CD001090-sec-0026"> <h3 class="title" id="CD001090-sec-0026">How the intervention might work</h3> <p>It is postulated that neutralizing and opsonizing antibodies contained in polyclonal immunoglobulin preparations inactivate bacterial endotoxins and exotoxins, stimulate leukocytes, and increase serum bactericidal activity. It is also hypothesized that immunoglobulins interfere with cytokine effects by modulating the release of cytokine and cytokine antagonists by endotoxins, attenuating the effects of the complement cascade (<a href="./references#CD001090-bbs2-0116" title="WerdanK . Pathophysiology of septic shock and multiorgan dysfunction syndrome and various therapeutic approaches with special emphasis on immunoglobulins. Therapeutic Apheresis2001;5:115‐22. [PUBMED: 11354295] ">Werdan 2001</a>). Results from trials on the effects of the different types of immunoglobulin preparations in reducing mortality from septic shock have been conflicting. A meta‐analysis (<a href="./references#CD001090-bbs2-0069" title="LacyJB , OhlssonA . Administration of intravenous immunoglobulins for prophylaxis or treatment of infection in preterm infants: meta‐analyses. Archives of Disease in Childhood. Fetal and Neonatal Edition1995;72:F151‐5. [PUBMED: 7796228 ] ">Lacy 1995</a>) reviewing the prophylactic effect of IVIG on infection in preterm infants did not recommend its routine use. Another meta‐analysis (<a href="./references#CD001090-bbs2-0061" title="JensonHB , PollockBH . Meta‐analyses of intravenous immune globulin for prevention and treatment of neonatal sepsis. Pediatrics1997;99(2):E2. [PUBMED: 9099759 ] ">Jenson 1997</a>), however, concluded that there was a significant benefit to giving IVIG shortly after birth in preventing sepsis among premature low birth‐weight newborns and in reducing deaths among neonates with early‐onset sepsis. An update of a Cochrane review (<a href="./references#CD001090-bbs2-0102" title="OhlssonA , LacyJB . Intravenous immunoglobulin for suspected or proven infection in neonates. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD001239.pub4] ">Ohlsson 2013</a>) concluded that there is insufficient evidence to support the routine use of polyclonal IVIG for infants with suspected or proven neonatal infection. </p> <p>Adverse effects from IVIG therapy have also been reported and can be classified into three types according to their onset. These are immediate, delayed, and late onset. Immediate adverse effects occur during infusion, for example anaphylactoid reactions; delayed adverse effects occur hours or days after infusion, for example pulmonary, renal, haematologic and neurologic events; and late adverse effects include transmission of infectious agents such as hepatitis C and prion diseases (<a href="./references#CD001090-bbs2-0101" title="NydeggerUE , SturzeneggerM . Adverse effects of intravenous immunoglobulin therapy. Drug Safety1999;21:171‐85. ">Nydegger 1999</a>). </p> </section> <section id="CD001090-sec-0027"> <h3 class="title" id="CD001090-sec-0027">Why it is important to do this review</h3> <p>The use of IVIG in sepsis has major implications for developing countries such as the Philippines where sepsis is a common cause of hospital mortalities and where medical practitioners use IVIG indiscriminately for both prophylaxis and the treatment of infections and sepsis. A survey of prescribing patterns for immunoglobulin use among paediatricians in three hospitals in Manila, Philippines showed that neonatal sepsis was the third most common condition for which IVIG was used (<a href="./references#CD001090-bbs2-0118" title="ZabalaMLB , DansLF . Prescribing patterns for immunoglobulin use among pediatricians in 3 Metro Manila hospitals. Conference Proceedings 2nd World Congress of Pediatric Infectious Diseases. 1999 Nov 2‐6. ">Zabala 1999</a>). Considering the high cost of IVIG, potential adverse effects, and conflicting reports on its benefits in sepsis, we should continually assess the evidence from randomized controlled trials. </p> <p>This review updates our existing Cochrane review, which was first published in 1999 and was updated in 2002 (<a href="./references#CD001090-bbs2-0119" title="AlejandriaMM , LansangMA , DansLF , MantaringJBV . Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database of Systematic Reviews2002, Issue 1. [DOI: 10.1002/14651858.CD001090] ">Alejandria 2002</a>) and 2010. The 2010 update included the large polyclonal IVIG trial on adults that was conducted in 1995 (<a href="./references#CD001090-bbs2-0115" title="WerdanK , PilzG , the SBITs Study Group. Polyvalent immune globulins [Abstract 18]. Shock1997; Vol. 7 Suppl 5:1918. ">Werdan 1997</a> abstract) and published 10 years after its completion (<a href="./references#CD001090-bbs2-0040" title="WerdanK , PilzG , BujdosoO , FraubergerP , NeeserG , SchmeiderRE , et al. Score‐based immunoglobulin G therapy of patients with sepsis: The SBITS study. Critical Care Medicine2007;35:2693‐701. [PUBMED: 18074471] ">Werdan 2007</a>). This was the main point of difference between our 2002 review (<a href="./references#CD001090-bbs2-0119" title="AlejandriaMM , LansangMA , DansLF , MantaringJBV . Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database of Systematic Reviews2002, Issue 1. [DOI: 10.1002/14651858.CD001090] ">Alejandria 2002</a> ) and the subsequent meta‐analysis by Pildal and Goetzsche in 2004 (<a href="./references#CD001090-bbs2-0104" title="PildalJ , GøtzschePC . Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. Clinical Infectious Diseases2004;39:38‐46. [PUBMED: 15206051] ">Pildal 2004</a>). In this update (2013) we have included the large polyclonal IVIG trial on neonates which was completed and published in 2011 (<a href="./references#CD001090-bbs2-0007" title="The INIS Collaborative Group. Treatment of neonatal sepsis with intravenous immune globulin. The New England Journal of Medicine2011;365:1201‐11. The INIS Study Collaborative Group. The INIS Study. International Neonatal Immunotherapy Study: Non‐specific intravenous immunoglobulin therapy for suspected or proven neonatal sepsis: an international, placebo‐controlled, multicentre randomised trial. BMC Pregnancy and Childbirth2008;8:1‐13. ">Brocklehurst 2011</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001090-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001090-sec-0028"></div> <p>To estimate the effects of intravenous immunoglobulin (IVIG) as adjunctive therapy in patients with bacterial sepsis or septic shock on mortality, bacteriological failure rates, and duration of stay in hospital. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001090-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001090-sec-0029"></div> <section id="CD001090-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001090-sec-0031"> <h4 class="title">Types of studies</h4> <p>We included randomized controlled trials (RCTs) comparing IVIG with a control group that received placebo or no intervention. We excluded quasi‐randomized studies. </p> </section> <section id="CD001090-sec-0032"> <h4 class="title">Types of participants</h4> <p>We included studies on patients of any age with sepsis or septic shock caused by bacteria.</p> <p>The 1992 and 2001 consensus conference definitions of sepsis, severe sepsis and septic shock (<a href="./references#CD001090-bbs2-0092" title="BoneRC , BalkRA , CerraFB , DellingerRP , FeinAM , KnausWA , et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis: The ACCP/SCCM Consensus Conference Committee. Chest1992;101:1644‐55. ">Bone 1992</a>; <a href="./references#CD001090-bbs2-0098" title="LevyMM , FinkMP , MarshallJC , AbrahamE , AngusD , CookD , et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International sepsis definitions conference. Critical Care Medicine2003;31:1250‐6. ">Levy 2003</a>) are as follows. </p> <p>Sepsis is the presence of two or more of the following systemic inflammatory responses to a documented infection: a) temperature &gt; 38 °C or &lt; 36 °C; b) heart rate &gt; 90 beats/min; c) respiratory rate &gt; 20 breaths/min or PaCo<sub>2</sub> &lt; 32 mmHg; d) white blood cell count &gt; 12,000/mm, &lt; 4000/mm, or &gt; 10% immature forms. </p> <p>Severe sepsis is sepsis associated with organ dysfunction, hypoperfusion, or hypotension. Hypoperfusion abnormalities may include lactic acidosis, oliguria, or an acute alteration in mental status. </p> <p>Septic shock is a subset of severe sepsis, defined as persistence of sepsis‐induced hypotension despite adequate fluid resuscitation. </p> </section> <section id="CD001090-sec-0033"> <h4 class="title">Types of interventions</h4> <p>The experimental intervention was any monoclonal or polyclonal intravenous immunoglobulin (IVIG) for the treatment of sepsis and septic shock.<br/> The control group received placebo or no immunoglobulin. </p> </section> <section id="CD001090-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD001090-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD001090-list-0001"> <li> <p>All‐cause mortality at the end of the follow‐up period</p> </li> <li> <p>Short‐term mortality: mortality measured at 30 days (30‐day mortality)</p> </li> <li> <p>Long‐term mortality: mortality measured at time periods greater than 30 days</p> </li> </ol> </p> </section> <section id="CD001090-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD001090-list-0002"> <li> <p>Bacteriological failure rate</p> </li> <li> <p>Development of organ failure</p> </li> <li> <p>Length of hospital stay among survivors</p> </li> <li> <p>Mortality from septic shock</p> </li> <li> <p>Adverse effects</p> </li> </ol> </p> </section> </section> </section> <section id="CD001090-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD001090-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in <i>The Cochrane Library</i> (2012, Issue 6) (using the search terms listed in <a href="./appendices#CD001090-sec-0090">Appendix 1</a>); MEDLINE (1966 to December 2012) (<a href="./appendices#CD001090-sec-0091">Appendix 2</a>); EMBASE (1988 to December 2012) (<a href="./appendices#CD001090-sec-0092">Appendix 3</a>). The topic search terms were used in combination with the Cochrane highly sensitive search strategy for identifying RCTs. </p> <p>We used the following free text and MeSH terms to search all trials registers and databases: immunoglobulin* near (monoclon* or polyclon*), IVIG, immunoglobulins‐intravenous, sepsis, septic shock, septicaemia or septicaemia. </p> <p>We did not apply language restrictions.</p> </section> <section id="CD001090-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We reviewed citations in the trial reports identified by the above methods. Investigators or organizations working in this field were also contacted for more information on published and unpublished RCTs. We requested extraction of information from foreign language trials that met the inclusion criteria. </p> </section> </section> <section id="CD001090-sec-0040"> <h3 class="title" id="CD001090-sec-0040">Data collection and analysis</h3> <section id="CD001090-sec-0041"> <h4 class="title">Selection of studies</h4> <p>Two authors (MAL, MMA) independently assessed the titles (and abstracts when available) identified in the search printouts for eligibility. Articles that might have met the selection criteria or could have referred to a possible trial were all retrieved and examined. </p> </section> <section id="CD001090-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>Data abstraction forms and operational definitions for outcomes and explanatory variables were developed. Two authors (LFD, JVM) independently abstracted information from each study prior to pooling of results. Data abstraction included the time period and geographical location of the study, baseline patient characteristics, inclusion and exclusion criteria, type of IVIG preparation and the dosing regimen, and the type of placebo used, if any. Information on each of the following outcome measures were also abstracted: mortality, bacteriological failures, duration of hospitalisation, and the number or per cent of affected patients. </p> </section> <section id="CD001090-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two authors (LFD, JVM) independently appraised the quality of the included studies by assessing allocation concealment, generation of the allocation sequence, and inclusion of all randomized participants. The 2010 update of this review used the standards set by the Cochrane Anaesthesia Group while the previously published version of this review (<a href="./references#CD001090-bbs2-0119" title="AlejandriaMM , LansangMA , DansLF , MantaringJBV . Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database of Systematic Reviews2002, Issue 1. [DOI: 10.1002/14651858.CD001090] ">Alejandria 2002</a>) used the criteria set by the Cochrane Infectious Diseases Group, available on the Group Module in <i>The Cochrane Library</i>. In addition to the standards set by both review groups, we assessed the comparability of the baseline characteristics and the care received by the treatment and control groups in terms of co‐interventions, frequency of follow up, and general quality of care. </p> <p>In this update, the risk of bias assessment was updated using the Cochrane Collaboration's tool in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001090-bbs2-0097" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org, [updated March 2011]. ">Higgins 2011</a>). The following domains were used: sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and other potential sources of bias, for example comparability of baseline characteristics and the care received by the treatment and control groups in terms of co‐interventions, frequency of follow up, and general quality of care. Judgments on the risk of bias for each component were as follows. </p> <p>1. Generation of allocation sequence</p> <p> <ul id="CD001090-list-0003"> <li> <p>Low risk: if appropriate methods such as random numbers generated by a computer or table of random numbers, drawing of lots, coin toss, or throwing dice were used. </p> </li> <li> <p>High risk: if sequences such as case record number; date of birth; day, month, or years of admission were used. </p> </li> <li> <p>Unclear risk: if the methods were not described.</p> </li> </ul> </p> <p>2. Concealment of allocation</p> <p> <ul id="CD001090-list-0004"> <li> <p>Low risk: if measures were used to prevent foreknowledge of assignment, such as centralized randomization; or numbered, sealed, opaque envelopes. </p> </li> <li> <p>HIgh risk: if researchers and participants could foresee an upcoming assignment e.g. by alternation. </p> </li> <li> <p>Unclear risk: if the methods were not described.</p> </li> </ul> </p> <p>3. Blinding of participants and personnel</p> <p> <ul id="CD001090-list-0005"> <li> <p>Low risk: no blinding, or incomplete blinding but review authors judge that the outcome is not likely to be influenced by lack of blinding, or blinding of participants and key personnel ensured and unlikely that the blinding could have been broken. </p> </li> <li> <p>High risk: no blinding, or incomplete blinding and the outcome is likely to be influenced by lack of blinding, or blinding of participants and key personnel attempted but likely that the blinding could have been broken and the outcome is likely to be influenced by lack of blinding. </p> </li> <li> <p>Unclear risk: insufficient information to permit judgment, or the study did not address the outcome. </p> </li> </ul> </p> <p>4. Blinding of outcome assessment</p> <p> <ul id="CD001090-list-0006"> <li> <p>Low risk: blinding of outcome assessment ensured and unlikely that blinding could have been broken; outcome detection methods are the same for both groups. </p> </li> <li> <p>High risk: no blinding of outcome assessment and the outcome measurement is likely to be influenced by lack of blinding, or blinding of outcome assessment done but likely that the blinding could have been broken and the outcome measurement is likely to be influenced by lack of blinding. </p> </li> <li> <p>Unclear risk: insufficient information to permit judgment.</p> </li> </ul> </p> <p>5. Incomplete outcome data</p> <p> <ul id="CD001090-list-0007"> <li> <p>Low risk: no missing outcome data; reasons for missing data unlikely to be related to true outcome; missing outcome data balanced in numbers across intervention groups with similar reasons for missing data across groups; for dichotomous data, the proportion of missing outcomes compared with observed event risk not likely to have a clinically relevant impact on the intervention effect estimate; for continuous data, plausible effect size among missing outcomes not likely to have a clinically relevant impact on the observed effect size; intention‐to‐treat analysis was done. </p> </li> <li> <p>High risk: reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; for dichotomous data, proportion of missing outcomes compared with observed event risk likely to cause clinically relevant bias in the intervention effect estimate; for continuous data, plausible effect size among missing outcomes likely to cause a clinically relevant bias in the observed effect size; efficacy analysis done with substantial departure of the intervention received from that assigned during randomization; intention‐to‐treat analysis was not done. </p> </li> <li> <p>Unclear risk: insufficient reporting of attrition and exclusions to permit judgment (e.g. number of participants randomized not stated; reasons for missing data not stated). </p> </li> </ul> </p> <p>6. Selective outcome reporting</p> <p> <ul id="CD001090-list-0008"> <li> <p>Low risk: study protocol is available and all of the study's pre‐specified outcomes that are of interest in the review were reported in a pre‐specified way; study protocol is not available but published reports include all expected outcomes, including those that were pre‐specified. </p> </li> <li> <p>HIgh risk: not all of the study's pre‐specified primary outcomes were reported; one or more primary outcomes are reported using measurements, analysis methods or subsets of the data that were not pre‐specified; one or more reported primary outcomes were not pre‐specified, unless clear justification is provided; one or more outcomes of interest in the review are reported incompletely; failure to include a key outcome that would be expected to have been reported in such a study. </p> </li> <li> <p>Unclear risk: insufficient information to permit judgment.</p> </li> </ul> </p> <p>7. Other sources of bias</p> <p> <ul id="CD001090-list-0009"> <li> <p>Low risk: study appears free of other sources of bias, e.g. treatment and control groups were treated equally in terms of other therapies and co‐interventions received, frequency of follow up, and general quality of care; the magnitude of any difference in baseline characteristics of the treatment and control groups was not significant in terms of known determinants of outcome. </p> </li> <li> <p>HIgh risk: study had a potential source of bias related to study design used or has been claimed to be fraudulent; study had significant differences between the treatment and control groups in terms of baseline characteristics that are known predictors of outcome; overt differences in the general quality of care received by the groups, such as differential administration of co‐interventions. </p> </li> <li> <p>Unclear risk: insufficient information to assess whether an important risk of bias exists, or insufficient evidence or rationale that an identified problem will introduce bias. </p> </li> </ul> </p> </section> <section id="CD001090-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>For statistical analysis of dichotomous outcomes, relative risk (RR) and risk difference (RD) with 95% confidence interval (CI) were calculated using the fixed‐effect model. For continuous outcomes, the mean difference (MD) with 95% CI was calculated. </p> </section> <section id="CD001090-sec-0045"> <h4 class="title">Dealing with missing data</h4> <p>We contacted authors of studies with unclear or missing data.</p> </section> <section id="CD001090-sec-0046"> <h4 class="title">Assessment of heterogeneity</h4> <p>To test for statistical heterogeneity across studies we used the Chi<sup>2</sup> statistic. A value of P &lt; 0.10 was used to reject the null hypothesis of homogeneity between studies. To quantify the degree of inconsistency, we used the I<sup>2</sup> statistic. </p> </section> <section id="CD001090-sec-0047"> <h4 class="title">Assessment of reporting biases</h4> <p>We constructed a funnel plot to assess for evidence of publication bias.</p> </section> <section id="CD001090-sec-0048"> <h4 class="title">Data synthesis</h4> <p>We synthesised and analysed the data using Review Manager 5.2 (<a href="./references#CD001090-bbs2-0106" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 5.2</a>). We combined dichotomous data using the Mantel‐Haenszel method, and we analysed continuous data using the inverse variance approach. Depending on the degree of heterogeneity of the data, we used either a fixed‐effect model or a random‐effects model (Der Simonian and Laird model). </p> </section> <section id="CD001090-sec-0049"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Recognizing that polyclonal and monoclonal IVIG preparations differ structurally and that they act through different immunopathologic mechanisms, a priori subgroup analyses were planned to compare the following explanatory variables: polyclonal IVIG versus placebo or no intervention; monoclonal IVIG versus placebo or no intervention; severity of sepsis; and duration of sepsis. We performed additional subgroup analyses post hoc according to the type of polyclonal IVIG and age group (standard IVIG and immunoglobulin M (IgM)‐enriched for adults and neonates) and types of monoclonal antibodies (anti‐endotoxins and anti‐cytokines). A subgroup analysis of adult and neonatal polyclonal IVIG trials was performed because of the recognized inherent physiologic, pathophysiologic and prognostic differences between adults and neonates with sepsis. No subgroup analysis was done for the monoclonal antibody studies according to study participant (adult or neonate) because all the trials were performed on adults except for one study done with children. To explore the effects of patients' characteristics on IVIG effects, post hoc subgroup analysis of polyclonal trials on adults with surgical and non‐surgical conditions was done. </p> </section> <section id="CD001090-sec-0050"> <h4 class="title">Sensitivity analysis</h4> <p>We also conducted sensitivity analyses of the polyclonal and monoclonal studies by removing the trials with high risk of bias and by doing random‐effects meta‐analysis. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001090-sec-0051" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001090-sec-0051"></div> <section id="CD001090-sec-0052"> <h3 class="title">Description of studies</h3> <section id="CD001090-sec-0053"> <h4 class="title">Results of the search</h4> <p>We retrieved 88 potentially eligible studies, 43 of which fulfilled the inclusion criteria. Of the 25 studies on polyclonal IVIG, 17 were on adults (10 standard IVIG, 7 IgM‐enriched) and eight were on neonates (5 standard IVIG, 3 IgM‐enriched). There were 18 studies on monoclonal preparations, eight on anti‐endotoxins, nine on anti‐cytokines, and one study on a human monoclonal antibody to Enterobacteriaceae common antigen. The search flow diagram shows the results of the search from 2003 to 2012 (<a href="#CD001090-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD001090-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Search flow diagram." data-id="CD001090-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Search flow diagram.</p> </div> </div> </div> </section> <section id="CD001090-sec-0054"> <h4 class="title">Included studies</h4> <p>Details of the included studies are provided in the table <a href="./references#CD001090-sec-0115" title="">Characteristics of included studies</a>. Forty‐three published studies met the inclusion criteria. </p> <section id="CD001090-sec-0055"> <h5 class="title">Participants</h5> <p>The clinical trials were performed mainly in intensive care units and academic medical centres, in 23 countries. The polyclonal IVIG trials were conducted in Argentina, Australia, Belgium, Denmark, Finland, Germany, Greece, Ireland, Japan, India, Ireland, Italy, Mexico, Netherlands, New Zealand, Norway, Saudi Arabia, Serbia, Sweden, Spain, Taiwan, Turkey, United Kingdom, and the United States of America. The monoclonal trials were mostly multi‐centre studies conducted in Austria, Belgium, Canada, England, France, Germany, Greece, Israel, Italy, the Netherlands, Norway, South Africa, Spain, Sweden, Switzerland, and the United States of America. </p> <p>There were eight polyclonal IVIG trials on neonatal sepsis (<a href="./references#CD001090-bbs2-0007" title="The INIS Collaborative Group. Treatment of neonatal sepsis with intravenous immune globulin. The New England Journal of Medicine2011;365:1201‐11. The INIS Study Collaborative Group. The INIS Study. International Neonatal Immunotherapy Study: Non‐specific intravenous immunoglobulin therapy for suspected or proven neonatal sepsis: an international, placebo‐controlled, multicentre randomised trial. BMC Pregnancy and Childbirth2008;8:1‐13. ">Brocklehurst 2011</a>; <a href="./references#CD001090-bbs2-0009" title="ChenJY . Intravenous immunoglobulin in the treatment of full term and premature newborns with sepsis. Journal of the Formosan Medical Association: Taiwan Yi Zhi1996;11:839‐44. [PUBMED: 8990771] ">Chen 1996</a>; <a href="./references#CD001090-bbs2-0016" title="ErdemG , YurdakökM , TekinalpG , ErsoyF . The use of IgM‐enriched intravenous immunoglobulin for the treatment of neonatal sepsis in preterm infants. The Turkish Journal of Pediatrics1993;35:277‐81. [PUBMED: 8160279] ">Erdem 1993</a>; <a href="./references#CD001090-bbs2-0022" title="HaqueKN , ZaidiMH , BahakimH . IgM‐enriched intravenous immunoglobulin therapy in neonatal sepsis. American Journal of Diseases of Childhood1988;142:1293‐6. [PUBMED: 3195529] ">Haque 1988</a>; <a href="./references#CD001090-bbs2-0028" title="Mancilla‐RamírezJ , González‐YunesR , Castellanos‐CruzC , García‐RocaP , Santos‐PreciadoJI . Intravenous immunoglobulin in the treatment of neonatal septicemia [Inmunoglobulina intravenosa en el tratamiento de septicemia neonatal.]. Boletín Médico del Hospital Infantil de México1992;49:4‐11. [PUBMED: 1304766] ">Mancilla‐Ramirez 1992</a>; <a href="./references#CD001090-bbs2-0035" title="SamathaS , JalaluMP , HegdeRK , VishwanathD , MaiyaPP . Role of IgM‐enriched intravenous immunoglobulin as an adjuvant to antibiotics in neonatal sepsis. Karnataka Pediatric Journal1997;11:1‐6. ">Samatha 1997</a>; <a href="./references#CD001090-bbs2-0037" title="ShenoiA , NageshNK , MaiyaPP , BhatSR , Subba RaoSD . Multicenter randomized placebo controlled trial of therapy with intravenous immunoglobulin in decreasing mortality due to neonatal sepsis. Indian Pediatrics1999;36:1113‐8. [PUBMED: 10745332] ">Shenoi 1999</a>; <a href="./references#CD001090-bbs2-0039" title="WeismanLE , StollBJ , KueserTJ , RubioTT , FrankCG , HeimanHS , et al. Intravenous immune globulin therapy for early onset sepsis in premature neonates. Journal of Pediatrics1992;121:434‐43. [PUBMED: 1517923 ] ">Weisman 1992</a>); one anti‐endotoxin trial on children with meningococcal septic shock (<a href="./references#CD001090-bbs2-0012" title="DerkxB , WittesJ , McCloskeyR . Randomized, placebo‐controlled trial of HA‐1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group. Clinical Infectious Diseases1999;28:770‐7. [PUBMED: 10825037] ">Derkx 1999</a>); five polyclonal IVIG trials on adults with post‐operative sepsis (<a href="./references#CD001090-bbs2-0015" title="DominioniL , BianchiV , ImperatoriA , MinoiaG , DionigiR . High‐dose intravenous IgG for treatment of severe surgical infections. Digestive Surgery1996;13:430‐4. [CENTRAL: CN‐00169903; PUBMED: 1996308558] ">Dominioni 1996</a>; <a href="./references#CD001090-bbs2-0021" title="GrundmannR , HornungM . Immunoglobulin therapy in patients with endotoxemia and postoperative sepsis ‐ a prospective randomized study. Progress in Clinical and Biological Research1988;272:339‐49. [PUBMED: 3293080] ">Grundmann 1988</a>; <a href="./references#CD001090-bbs2-0034" title="RodriguezA , RelloJ , NeiraJ , MaskinB , CerasoD , VastaL , et al. Effects of high‐dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery. Shock2005;23:298‐304. [PUBMED: 15803051 ] ">Rodriguez 2005</a>; <a href="./references#CD001090-bbs2-0041" title="WesolyC , KippingN , GrundmannR . Immunoglobulin therapy of postoperative sepsis [Immunglobulintherapie der postoperativen Sepsis]. Zeitschrift für experimentelle Chirurgie, Transplantation, und künstliche Organe: Organ der Sektion Experimentelle Chirurgie der Gesellschaft für Chirurgie der DDR1990;23:213‐6. [CENTRAL: CN‐00075746; PUBMED: 2095647] ">Wesoly 1990</a>; <a href="./references#CD001090-bbs2-0042" title="YakutM , CetinerS , AkinA , TanA , KaymakciogluN , SimsekA , et al. Effects of immunoglobulin G on surgical sepsis and septic shock [Sepsisdeki hastalarda immunoglobulin G (IGG) kulianiminin mortalite oranina etkisi]. Bulletin of Gulhane Military Medical Academy1998;40:76‐81. [CENTRAL: CN‐00200598] ">Yakut 1998</a>); one polyclonal IVIG trial on adults with streptococcal toxic shock syndrome (<a href="./references#CD001090-bbs2-0011" title="DarenbergJ , IhendyaneN , SjölinJ , AufwerberE , HaidlS , FollinP , et al. StreptIg Study Group. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double‐blind placebo‐controlled trial. Clinical Infectious Diseases2003;37:333‐40. [PUBMED: 12884156 ] ">Darenberg 2003</a>); two polyclonal IVIG trials on neutropenic patients with haematologic malignancies and sepsis syndrome or septic shock (<a href="./references#CD001090-bbs2-0005" title="BehreG , OstermannH , SchedelI , HelmerkingM , SchielX , RothenburgerM , et al. Endotoxin concentrations and therapy with polyclonal IgM‐enriched immunoglobulins in neutropenic cancer patients with sepsis syndrome: Pilot study and interim analysis of a randomized trial. Antiinfective Drugs and Chemotherapy1995;13:129‐34. [CENTRAL: CN‐00168897; EMBASE: 1996075665] ">Behre 1995</a>; <a href="./references#CD001090-bbs2-0023" title="HentrichM , FehnleK , OstermannH , KlenastJ , CornelyO , SalatC , et al. IgMA‐enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple‐center trial. Critical Care Medicine2006;34:1319‐25. [PUBMED: 16540956] ">Hentrich 2006</a>); and one anti‐endotoxin study on obstetric and gynaecologic patients with septic shock (<a href="./references#CD001090-bbs2-0026" title="LachmanE , PitsoeSB , GaffinSL . Anti‐lipopolysaccharide immunotherapy in management of septic shock of obstetric and gynecological origin. Lancet1984;1:981‐3. [PUBMED: 6143965] ">Lachman 1984</a>). The rest of the trials involved adults with sepsis or septic shock, either of gram‐positive or gram‐negative etiology. </p> <p>The polyclonal IVIG trials on neonatal sepsis included pre‐term infants (<a href="./references#CD001090-bbs2-0007" title="The INIS Collaborative Group. Treatment of neonatal sepsis with intravenous immune globulin. The New England Journal of Medicine2011;365:1201‐11. The INIS Study Collaborative Group. The INIS Study. International Neonatal Immunotherapy Study: Non‐specific intravenous immunoglobulin therapy for suspected or proven neonatal sepsis: an international, placebo‐controlled, multicentre randomised trial. BMC Pregnancy and Childbirth2008;8:1‐13. ">Brocklehurst 2011</a>; <a href="./references#CD001090-bbs2-0016" title="ErdemG , YurdakökM , TekinalpG , ErsoyF . The use of IgM‐enriched intravenous immunoglobulin for the treatment of neonatal sepsis in preterm infants. The Turkish Journal of Pediatrics1993;35:277‐81. [PUBMED: 8160279] ">Erdem 1993</a>; <a href="./references#CD001090-bbs2-0022" title="HaqueKN , ZaidiMH , BahakimH . IgM‐enriched intravenous immunoglobulin therapy in neonatal sepsis. American Journal of Diseases of Childhood1988;142:1293‐6. [PUBMED: 3195529] ">Haque 1988</a>; <a href="./references#CD001090-bbs2-0039" title="WeismanLE , StollBJ , KueserTJ , RubioTT , FrankCG , HeimanHS , et al. Intravenous immune globulin therapy for early onset sepsis in premature neonates. Journal of Pediatrics1992;121:434‐43. [PUBMED: 1517923 ] ">Weisman 1992</a>); full‐term and pre‐term infants (<a href="./references#CD001090-bbs2-0009" title="ChenJY . Intravenous immunoglobulin in the treatment of full term and premature newborns with sepsis. Journal of the Formosan Medical Association: Taiwan Yi Zhi1996;11:839‐44. [PUBMED: 8990771] ">Chen 1996</a>; <a href="./references#CD001090-bbs2-0035" title="SamathaS , JalaluMP , HegdeRK , VishwanathD , MaiyaPP . Role of IgM‐enriched intravenous immunoglobulin as an adjuvant to antibiotics in neonatal sepsis. Karnataka Pediatric Journal1997;11:1‐6. ">Samatha 1997</a>; <a href="./references#CD001090-bbs2-0037" title="ShenoiA , NageshNK , MaiyaPP , BhatSR , Subba RaoSD . Multicenter randomized placebo controlled trial of therapy with intravenous immunoglobulin in decreasing mortality due to neonatal sepsis. Indian Pediatrics1999;36:1113‐8. [PUBMED: 10745332] ">Shenoi 1999</a>); and full‐term neonates (<a href="./references#CD001090-bbs2-0028" title="Mancilla‐RamírezJ , González‐YunesR , Castellanos‐CruzC , García‐RocaP , Santos‐PreciadoJI . Intravenous immunoglobulin in the treatment of neonatal septicemia [Inmunoglobulina intravenosa en el tratamiento de septicemia neonatal.]. Boletín Médico del Hospital Infantil de México1992;49:4‐11. [PUBMED: 1304766] ">Mancilla‐Ramirez 1992</a>). Most of the polyclonal IVIG trials on adults included participants who were aged 18 years and above, except for some trials which had participants &lt; 18 years old (<a href="./references#CD001090-bbs2-0015" title="DominioniL , BianchiV , ImperatoriA , MinoiaG , DionigiR . High‐dose intravenous IgG for treatment of severe surgical infections. Digestive Surgery1996;13:430‐4. [CENTRAL: CN‐00169903; PUBMED: 1996308558] ">Dominioni 1996</a>; <a href="./references#CD001090-bbs2-0021" title="GrundmannR , HornungM . Immunoglobulin therapy in patients with endotoxemia and postoperative sepsis ‐ a prospective randomized study. Progress in Clinical and Biological Research1988;272:339‐49. [PUBMED: 3293080] ">Grundmann 1988</a>; <a href="./references#CD001090-bbs2-0029" title="MasaokaT , HasegawaH , TakakuF , MizoguchiH , AsanoS , IkedaY , et al. The efficacy of intravenous immunoglobulin in combination therapy with antibiotics for severe infections. Japanese Journal of Chemotherapy2000;48:199‐217. [CENTRAL: CN‐00418781; EMBASE: 2000159529] ">Masaoka 2000</a>; <a href="./references#CD001090-bbs2-0036" title="SchedelI , DreikhausenU , NentwigB , HöckenschniederM , RauthmannD , BalikciogluS , et al. Treatment of Gram‐negative septic shock and an immunoglobulin preparation: A prospective randomized clinical trial. Critical Care Medicine1991;10:1104‐13. [PUBMED: 1884609] ">Schedel 1991</a>; <a href="./references#CD001090-bbs2-0038" title="TugrulS , OzcanPE , AkinciO , SeyhunY , CagatayA , CakarN , et al. The effects of IgM‐enriched immunoglobulin preparations in patients with severe sepsis [ISRCTN28863830]. Critical Care2002;6:357‐62. [PUBMED: 12225613] ">Tugrul 2002</a>). The monoclonal studies included adults 18 years and above except for one anti‐endotoxin (HA‐1A) trial, which included children aged from three months up to 18 years (<a href="./references#CD001090-bbs2-0012" title="DerkxB , WittesJ , McCloskeyR . Randomized, placebo‐controlled trial of HA‐1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group. Clinical Infectious Diseases1999;28:770‐7. [PUBMED: 10825037] ">Derkx 1999</a>). </p> </section> <section id="CD001090-sec-0056"> <h5 class="title">Interventions</h5> <p>The IVIG preparations used were monoclonal (18 studies) or polyclonal immunoglobulins (25 studies). </p> <p>The monoclonal preparations were:</p> <p> <ol id="CD001090-list-0010"> <li> <p>anti‐endotoxins such as E5 (<a href="./references#CD001090-bbs2-0004" title="AngusDC , BirminghamMC , BalkRA , ScannonPJ , CollinsD , KruseJA , et al. E5 murine monoclonal antiendotoxin antibody in gram‐negative sepsis: a randomized controlled trial. E5 Study Investigators. JAMA2000;283:1723‐30. [PUBMED: 10755499] ">Angus 2000</a>; <a href="./references#CD001090-bbs2-0006" title="BoneRC , BalkRA , FeinAM , PerlTM , WenzelRP , ReinesHD , et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized controlled trial. The E5 Sepsis Study Group. Critical Care Medicine1995;23:994‐1005. [PUBMED: 7774238] ">Bone 1995</a>; <a href="./references#CD001090-bbs2-0019" title="GreenbergRN , WilsonKM , KunzAY , WedelNI , GorelickKJ . Observations using antiendotoxin antibody (E5) as adjuvant therapy in humans with suspected with suspected serious, gram‐negative sepsis. Critical Care Medicine1992;20:730‐5. [PUBMED: 1597023] ">Greenberg 1992</a>; <a href="./references#CD001090-bbs2-0020" title="GreenmanRL , ScheinRM , MartinMA , WenzelRP , MacIntyreNR , EmmanuelG , et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram‐negative sepsis. The XOMA Sepsis Study Group. JAMA1991;266:1097‐102. [PUBMED: 1865542] ">Greenman 1991</a>), anti‐lipopolysaccharide (anti‐LPS) (<a href="./references#CD001090-bbs2-0026" title="LachmanE , PitsoeSB , GaffinSL . Anti‐lipopolysaccharide immunotherapy in management of septic shock of obstetric and gynecological origin. Lancet1984;1:981‐3. [PUBMED: 6143965] ">Lachman 1984</a>), and HA‐1A (<a href="./references#CD001090-bbs2-0012" title="DerkxB , WittesJ , McCloskeyR . Randomized, placebo‐controlled trial of HA‐1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group. Clinical Infectious Diseases1999;28:770‐7. [PUBMED: 10825037] ">Derkx 1999</a>; <a href="./references#CD001090-bbs2-0030" title="MacCloskeyRV , StraubeRC , SandersC , SmithSM , SmithCR . Treatment of septic shock with human monoclonal antibody HA‐1A. A randomized, double‐blind, placebo‐controlled trial. CHESS Trial Study Group. Annals of Internal Medicine1994;121:1‐5. [PUBMED: 8198341] ">McCloskey 1994</a>; <a href="./references#CD001090-bbs2-0043" title="ZieglerEJ , FisherCJ , SprungCL , StraubeRC , SadoffJC , FoulkeGE , et al. Treatment of gram‐negative bacteremia and septic shock with HA‐1A human monoclonal antibody against endotoxin. A randomized, double‐blind, placebo‐controlled trial. The HA‐1A Sepsis Study Group.l. The New England Journal of Medicine1991;324:429‐36. [PUBMED: 1988827] ">Ziegler 1991</a>); </p> </li> <li> <p>anti‐cytokines such as interleukin‐1 (IL‐1) (<a href="./references#CD001090-bbs2-0017" title="FisherCJJr , SlotmanGJ , OpalSM , PribbleJP , BoneRC , EmmanuelG , et al. IL‐1RA Sepsis Syndrome Study Group. Initial evaluation of human recombinant interleukin‐1 receptor antagonist in the treatment of sepsis syndrome: a randomized open‐label, placebo‐controlled multicenter trial. Critical Care Medicine1994;22:12‐21. [PUBMED: 8124953] ">Fisher 1994a</a>; <a href="./references#CD001090-bbs2-0018" title="FisherCJJr , DhainautJF , OpalSM , PribbleJP , BalkRA , SlotmanGJ , et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: Results from a randomized double‐blind, placebo‐controlled trial. Phase III rhIL‐1ra Sepsis Syndrome Study Group. JAMA1994;271:1836‐43. ">Fisher 1994b</a>; <a href="./references#CD001090-bbs2-0031" title="OpalSM , FisherCJ , DhainautJF , VincentJL , BraseR , LowrySF , et al. Confirmatory interleukin‐1 receptor antagonist trial in severe sepsis: A phase III, randomized, double‐blind, placebo‐controlled, multicenter trial. The Interleukin‐1 Receptor Antagonist Sepsis Investigator Group. Critical Care Medicine1997;25:1115‐24. [PUBMED: 9233735] ">Opal 1997</a>) and anti‐tumour necrosis factor (TNF) alpha (<a href="./references#CD001090-bbs2-0001" title="AbrahamE , WunderinkR , SilvermanH , PerlTM , NasrawayS , LevyH , et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled double‐blind, multicenter clinical trial. TNF‐alpha MAb Sepsis Study group. JAMA1995;273:934‐41. [PUBMED: 7884952] ">Abraham 1995</a>; <a href="./references#CD001090-bbs2-0002" title="AbrahamE , AnzuetoA , GutierrezG , TesslerS , San PedroG , WunderinkR , et al. Double‐blind randomized controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock.NORASEPT II Study Group. Lancet1998;351:929‐33. [PUBMED: 9734938] ">Abraham 1998</a>; <a href="./references#CD001090-bbs2-0010" title="CohenJ , CarletJ . INTERSEPT: an international, multicenter, placebo‐controlled‐trial of monoclonal antibody to human tumor necrosis factor‐alpha in patients with sepsis. International Sepsis Trial Study Group. Critical Care Medicine1996;24:1431‐40. [PUBMED: 8797612 ] ">Cohen 1996</a>; <a href="./references#CD001090-bbs2-0014" title="DhainautJF , VincentJL , RichardC , LejeuneP , MartinC , FierobeL , et al. CDP 571, a humanized antibody to human tumor necrosis factor alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group. Critical Care Medicine1995;23:1461‐9. [PUBMED: 7664546 ] ">Dhainaut 1995</a>; <a href="./references#CD001090-bbs2-0032" title="PanacekEA , MarshallJC , AlbertsonTE , JohnsonDH , JohnsonS , MacArthurRD , et al. Monoclonal Anti‐TNF: Randomized Controlled Sepsis Study Investigators. Efficacy and safety of the monoclonal anti‐‐tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin‐6 levels. Critical Care Medicine2004;32:2173‐82. [PUBMED: 15640628 ] ">Panacek 2004</a>; <a href="./references#CD001090-bbs2-0033" title="ReinhartK , Wiegand‐LöhnertC , GrimmingerF , KaulM , WithingtonS , TreacherD , et al. Assessment of the safety and efficacy of the monoclonal anti‐tumor necrosis factor antibody‐fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo‐controlled, dose ranging study. Critical Care Medicine1996;24:733‐42. [PUBMED: 8706447] ">Reinhart 1996</a>); and </p> </li> <li> <p>human monoclonal antibody to Enterobacteriaceae common antigen (<a href="./references#CD001090-bbs2-0003" title="AlbertsonTE , PanacekEA , MacArthurRD , JohnsonSB , BenjaminE , MatsuchakG , et al. Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram‐negative sepsis. Critical Care Medicine2003;31:419‐27. [PUBMED: 12576946 ] ">Albertson 2003</a>). </p> </li> </ol> </p> <p>Polyclonal IVIG preparations were standard IVIG in 10 trials on adults (<a href="./references#CD001090-bbs2-0008" title="BurnsER , LeeV , RubinsteinA . Treatment of septic thrombocytopenia with immune globulin. Journal of Clinical Immunology1991;11:363‐8. [PUBMED: 1761642] ">Burns 1991</a>; <a href="./references#CD001090-bbs2-0011" title="DarenbergJ , IhendyaneN , SjölinJ , AufwerberE , HaidlS , FollinP , et al. StreptIg Study Group. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double‐blind placebo‐controlled trial. Clinical Infectious Diseases2003;37:333‐40. [PUBMED: 12884156 ] ">Darenberg 2003</a>; <a href="./references#CD001090-bbs2-0013" title="DeSimoneC , DeloguG , CorbettaG . Intravenous immunoglobulins in association with antibiotics: a therapeutic trial in septic intensive care unit patients. Critical Care Medicine1988;16:23‐6. [PUBMED: 3276446] ">De Simone 1988</a>; <a href="./references#CD001090-bbs2-0050" title="DominioniL , DionigiR , ZanelloM , ChiarandaM , DionigiR , AcquaroloA , et al. Effects of high‐dose IgG on survival of surgical patients with sepsis scores of 20 or greater. Archives of Surgery1991;126:236‐40. [PUBMED: 1992998] ">Dominioni 1991</a>; <a href="./references#CD001090-bbs2-0021" title="GrundmannR , HornungM . Immunoglobulin therapy in patients with endotoxemia and postoperative sepsis ‐ a prospective randomized study. Progress in Clinical and Biological Research1988;272:339‐49. [PUBMED: 3293080] ">Grundmann 1988</a>; <a href="./references#CD001090-bbs2-0024" title="JustHM , MetzgerM , VogelW , PelkaRB . Effect of adjuvant immunoglobulin therapy in patients in a surgical intensive care unit. Results of a randomized controlled study [Einfluss einer adjuvanten Immunglobulintherapie auf Infektionen bei Patienten einer operativen Intensiv‐Therapie‐Station.]. Klinische Wochenschrift1986;64:245‐56. [PUBMED: 3713101] ">Just 1986</a>; <a href="./references#CD001090-bbs2-0027" title="LindquistL , LundberghP , MaasingR . Pepsin‐treated human gamma globulin in bacterial infections. A randomized study in patients with septicemia and pneumonia. Vox Sanguinis1981;40:329‐37. [PUBMED: 6166128 ] ">Lindquist 1981</a>; <a href="./references#CD001090-bbs2-0029" title="MasaokaT , HasegawaH , TakakuF , MizoguchiH , AsanoS , IkedaY , et al. The efficacy of intravenous immunoglobulin in combination therapy with antibiotics for severe infections. Japanese Journal of Chemotherapy2000;48:199‐217. [CENTRAL: CN‐00418781; EMBASE: 2000159529] ">Masaoka 2000</a>; <a href="./references#CD001090-bbs2-0040" title="WerdanK , PilzG , BujdosoO , FraubergerP , NeeserG , SchmeiderRE , et al. Score‐based immunoglobulin G therapy of patients with sepsis: The SBITS study. Critical Care Medicine2007;35:2693‐701. [PUBMED: 18074471] ">Werdan 2007</a>; <a href="./references#CD001090-bbs2-0042" title="YakutM , CetinerS , AkinA , TanA , KaymakciogluN , SimsekA , et al. Effects of immunoglobulin G on surgical sepsis and septic shock [Sepsisdeki hastalarda immunoglobulin G (IGG) kulianiminin mortalite oranina etkisi]. Bulletin of Gulhane Military Medical Academy1998;40:76‐81. [CENTRAL: CN‐00200598] ">Yakut 1998</a>) and five trials on neonates (<a href="./references#CD001090-bbs2-0007" title="The INIS Collaborative Group. Treatment of neonatal sepsis with intravenous immune globulin. The New England Journal of Medicine2011;365:1201‐11. The INIS Study Collaborative Group. The INIS Study. International Neonatal Immunotherapy Study: Non‐specific intravenous immunoglobulin therapy for suspected or proven neonatal sepsis: an international, placebo‐controlled, multicentre randomised trial. BMC Pregnancy and Childbirth2008;8:1‐13. ">Brocklehurst 2011</a>; <a href="./references#CD001090-bbs2-0009" title="ChenJY . Intravenous immunoglobulin in the treatment of full term and premature newborns with sepsis. Journal of the Formosan Medical Association: Taiwan Yi Zhi1996;11:839‐44. [PUBMED: 8990771] ">Chen 1996</a>; <a href="./references#CD001090-bbs2-0028" title="Mancilla‐RamírezJ , González‐YunesR , Castellanos‐CruzC , García‐RocaP , Santos‐PreciadoJI . Intravenous immunoglobulin in the treatment of neonatal septicemia [Inmunoglobulina intravenosa en el tratamiento de septicemia neonatal.]. Boletín Médico del Hospital Infantil de México1992;49:4‐11. [PUBMED: 1304766] ">Mancilla‐Ramirez 1992</a>; <a href="./references#CD001090-bbs2-0037" title="ShenoiA , NageshNK , MaiyaPP , BhatSR , Subba RaoSD . Multicenter randomized placebo controlled trial of therapy with intravenous immunoglobulin in decreasing mortality due to neonatal sepsis. Indian Pediatrics1999;36:1113‐8. [PUBMED: 10745332] ">Shenoi 1999</a>; <a href="./references#CD001090-bbs2-0039" title="WeismanLE , StollBJ , KueserTJ , RubioTT , FrankCG , HeimanHS , et al. Intravenous immune globulin therapy for early onset sepsis in premature neonates. Journal of Pediatrics1992;121:434‐43. [PUBMED: 1517923 ] ">Weisman 1992</a>), and IgM‐enriched immunoglobulin in seven trials on adults (<a href="./references#CD001090-bbs2-0005" title="BehreG , OstermannH , SchedelI , HelmerkingM , SchielX , RothenburgerM , et al. Endotoxin concentrations and therapy with polyclonal IgM‐enriched immunoglobulins in neutropenic cancer patients with sepsis syndrome: Pilot study and interim analysis of a randomized trial. Antiinfective Drugs and Chemotherapy1995;13:129‐34. [CENTRAL: CN‐00168897; EMBASE: 1996075665] ">Behre 1995</a>; <a href="./references#CD001090-bbs2-0023" title="HentrichM , FehnleK , OstermannH , KlenastJ , CornelyO , SalatC , et al. IgMA‐enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple‐center trial. Critical Care Medicine2006;34:1319‐25. [PUBMED: 16540956] ">Hentrich 2006</a>; <a href="./references#CD001090-bbs2-0025" title="KaratzasS , BoutzoukaE , VenetsanouK , MyrianthefsP , FildisisG , BaltopoulosG . The effects of IgM‐enriched immunoglobulin preparations in patients with severe sepsis: another point of view. Critical Care2002;6:543‐4. [PUBMED: 12512504] ">Karatzas 2002</a>; <a href="./references#CD001090-bbs2-0034" title="RodriguezA , RelloJ , NeiraJ , MaskinB , CerasoD , VastaL , et al. Effects of high‐dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery. Shock2005;23:298‐304. [PUBMED: 15803051 ] ">Rodriguez 2005</a>; <a href="./references#CD001090-bbs2-0038" title="TugrulS , OzcanPE , AkinciO , SeyhunY , CagatayA , CakarN , et al. The effects of IgM‐enriched immunoglobulin preparations in patients with severe sepsis [ISRCTN28863830]. Critical Care2002;6:357‐62. [PUBMED: 12225613] ">Tugrul 2002</a>; <a href="./references#CD001090-bbs2-0041" title="WesolyC , KippingN , GrundmannR . Immunoglobulin therapy of postoperative sepsis [Immunglobulintherapie der postoperativen Sepsis]. Zeitschrift für experimentelle Chirurgie, Transplantation, und künstliche Organe: Organ der Sektion Experimentelle Chirurgie der Gesellschaft für Chirurgie der DDR1990;23:213‐6. [CENTRAL: CN‐00075746; PUBMED: 2095647] ">Wesoly 1990</a>) and three trials on neonates (<a href="./references#CD001090-bbs2-0016" title="ErdemG , YurdakökM , TekinalpG , ErsoyF . The use of IgM‐enriched intravenous immunoglobulin for the treatment of neonatal sepsis in preterm infants. The Turkish Journal of Pediatrics1993;35:277‐81. [PUBMED: 8160279] ">Erdem 1993</a>; <a href="./references#CD001090-bbs2-0022" title="HaqueKN , ZaidiMH , BahakimH . IgM‐enriched intravenous immunoglobulin therapy in neonatal sepsis. American Journal of Diseases of Childhood1988;142:1293‐6. [PUBMED: 3195529] ">Haque 1988</a>; <a href="./references#CD001090-bbs2-0035" title="SamathaS , JalaluMP , HegdeRK , VishwanathD , MaiyaPP . Role of IgM‐enriched intravenous immunoglobulin as an adjuvant to antibiotics in neonatal sepsis. Karnataka Pediatric Journal1997;11:1‐6. ">Samatha 1997</a>). </p> <p>For neonates, the dose of standard polyclonal IVIG ranged from 500 mg/kg as a single infusion over two hours (<a href="./references#CD001090-bbs2-0009" title="ChenJY . Intravenous immunoglobulin in the treatment of full term and premature newborns with sepsis. Journal of the Formosan Medical Association: Taiwan Yi Zhi1996;11:839‐44. [PUBMED: 8990771] ">Chen 1996</a>; <a href="./references#CD001090-bbs2-0022" title="HaqueKN , ZaidiMH , BahakimH . IgM‐enriched intravenous immunoglobulin therapy in neonatal sepsis. American Journal of Diseases of Childhood1988;142:1293‐6. [PUBMED: 3195529] ">Haque 1988</a>; <a href="./references#CD001090-bbs2-0028" title="Mancilla‐RamírezJ , González‐YunesR , Castellanos‐CruzC , García‐RocaP , Santos‐PreciadoJI . Intravenous immunoglobulin in the treatment of neonatal septicemia [Inmunoglobulina intravenosa en el tratamiento de septicemia neonatal.]. Boletín Médico del Hospital Infantil de México1992;49:4‐11. [PUBMED: 1304766] ">Mancilla‐Ramirez 1992</a>; <a href="./references#CD001090-bbs2-0039" title="WeismanLE , StollBJ , KueserTJ , RubioTT , FrankCG , HeimanHS , et al. Intravenous immune globulin therapy for early onset sepsis in premature neonates. Journal of Pediatrics1992;121:434‐43. [PUBMED: 1517923 ] ">Weisman 1992</a>) to 500 mg/kg infused over four to six hours then repeated 48 hours later (<a href="./references#CD001090-bbs2-0007" title="The INIS Collaborative Group. Treatment of neonatal sepsis with intravenous immune globulin. The New England Journal of Medicine2011;365:1201‐11. The INIS Study Collaborative Group. The INIS Study. International Neonatal Immunotherapy Study: Non‐specific intravenous immunoglobulin therapy for suspected or proven neonatal sepsis: an international, placebo‐controlled, multicentre randomised trial. BMC Pregnancy and Childbirth2008;8:1‐13. ">Brocklehurst 2011</a>) and up to 1 g/kg for three days (<a href="./references#CD001090-bbs2-0037" title="ShenoiA , NageshNK , MaiyaPP , BhatSR , Subba RaoSD . Multicenter randomized placebo controlled trial of therapy with intravenous immunoglobulin in decreasing mortality due to neonatal sepsis. Indian Pediatrics1999;36:1113‐8. [PUBMED: 10745332] ">Shenoi 1999</a>); while IgM‐enriched IVIG was given at 5 ml/kg/day for three days (<a href="./references#CD001090-bbs2-0016" title="ErdemG , YurdakökM , TekinalpG , ErsoyF . The use of IgM‐enriched intravenous immunoglobulin for the treatment of neonatal sepsis in preterm infants. The Turkish Journal of Pediatrics1993;35:277‐81. [PUBMED: 8160279] ">Erdem 1993</a>; <a href="./references#CD001090-bbs2-0035" title="SamathaS , JalaluMP , HegdeRK , VishwanathD , MaiyaPP . Role of IgM‐enriched intravenous immunoglobulin as an adjuvant to antibiotics in neonatal sepsis. Karnataka Pediatric Journal1997;11:1‐6. ">Samatha 1997</a>). </p> <p>For adults, the dose of polyclonal IVIG varied depending on the type of IVIG, from 250 mg/kg over two days (Intraglobin) to 400 mg/kg/day for three days (Sandoglobin), and 1 g/kg on the first day then 500 mg/kg on days two and three (Endobulin). For Ig‐M enriched IVIG (Pentaglobin) the dose used was 1300 ml infused within 72 hours (<a href="./references#CD001090-bbs2-0005" title="BehreG , OstermannH , SchedelI , HelmerkingM , SchielX , RothenburgerM , et al. Endotoxin concentrations and therapy with polyclonal IgM‐enriched immunoglobulins in neutropenic cancer patients with sepsis syndrome: Pilot study and interim analysis of a randomized trial. Antiinfective Drugs and Chemotherapy1995;13:129‐34. [CENTRAL: CN‐00168897; EMBASE: 1996075665] ">Behre 1995</a>; <a href="./references#CD001090-bbs2-0023" title="HentrichM , FehnleK , OstermannH , KlenastJ , CornelyO , SalatC , et al. IgMA‐enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple‐center trial. Critical Care Medicine2006;34:1319‐25. [PUBMED: 16540956] ">Hentrich 2006</a>). </p> </section> <section id="CD001090-sec-0057"> <h5 class="title">Outcomes</h5> <p>All polyclonal and monoclonal trials reported on all‐cause mortality as a main outcome except for one polyclonal study on neonates (<a href="./references#CD001090-bbs2-0016" title="ErdemG , YurdakökM , TekinalpG , ErsoyF . The use of IgM‐enriched intravenous immunoglobulin for the treatment of neonatal sepsis in preterm infants. The Turkish Journal of Pediatrics1993;35:277‐81. [PUBMED: 8160279] ">Erdem 1993</a>), which reported mortality from sepsis only. One polyclonal study on adults did not report mortality but data were obtained through communication with the authors (<a href="./references#CD001090-bbs2-0029" title="MasaokaT , HasegawaH , TakakuF , MizoguchiH , AsanoS , IkedaY , et al. The efficacy of intravenous immunoglobulin in combination therapy with antibiotics for severe infections. Japanese Journal of Chemotherapy2000;48:199‐217. [CENTRAL: CN‐00418781; EMBASE: 2000159529] ">Masaoka 2000</a>). </p> <p>The polyclonal IVIG trials on neonates did not specify the cut‐off and follow‐up periods for mortality except for one trial which had weekly follow ups for six weeks after discharge (<a href="./references#CD001090-bbs2-0009" title="ChenJY . Intravenous immunoglobulin in the treatment of full term and premature newborns with sepsis. Journal of the Formosan Medical Association: Taiwan Yi Zhi1996;11:839‐44. [PUBMED: 8990771] ">Chen 1996</a>) and another which reported mortality at 56 days (<a href="./references#CD001090-bbs2-0039" title="WeismanLE , StollBJ , KueserTJ , RubioTT , FrankCG , HeimanHS , et al. Intravenous immune globulin therapy for early onset sepsis in premature neonates. Journal of Pediatrics1992;121:434‐43. [PUBMED: 1517923 ] ">Weisman 1992</a>). The large multi‐centre trial (<a href="./references#CD001090-bbs2-0007" title="The INIS Collaborative Group. Treatment of neonatal sepsis with intravenous immune globulin. The New England Journal of Medicine2011;365:1201‐11. The INIS Study Collaborative Group. The INIS Study. International Neonatal Immunotherapy Study: Non‐specific intravenous immunoglobulin therapy for suspected or proven neonatal sepsis: an international, placebo‐controlled, multicentre randomised trial. BMC Pregnancy and Childbirth2008;8:1‐13. ">Brocklehurst 2011</a>) reported death or major disability at two years as the primary outcome and death in hospital as a secondary outcome. </p> <p>Only two polyclonal trials in adults reported long‐term mortality, at 60 days (<a href="./references#CD001090-bbs2-0023" title="HentrichM , FehnleK , OstermannH , KlenastJ , CornelyO , SalatC , et al. IgMA‐enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple‐center trial. Critical Care Medicine2006;34:1319‐25. [PUBMED: 16540956] ">Hentrich 2006</a>) and 180 days ( <a href="./references#CD001090-bbs2-0011" title="DarenbergJ , IhendyaneN , SjölinJ , AufwerberE , HaidlS , FollinP , et al. StreptIg Study Group. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double‐blind placebo‐controlled trial. Clinical Infectious Diseases2003;37:333‐40. [PUBMED: 12884156 ] ">Darenberg 2003</a>). The rest of the trials either reported short‐term mortality, at 28 days (<a href="./references#CD001090-bbs2-0005" title="BehreG , OstermannH , SchedelI , HelmerkingM , SchielX , RothenburgerM , et al. Endotoxin concentrations and therapy with polyclonal IgM‐enriched immunoglobulins in neutropenic cancer patients with sepsis syndrome: Pilot study and interim analysis of a randomized trial. Antiinfective Drugs and Chemotherapy1995;13:129‐34. [CENTRAL: CN‐00168897; EMBASE: 1996075665] ">Behre 1995</a>; <a href="./references#CD001090-bbs2-0011" title="DarenbergJ , IhendyaneN , SjölinJ , AufwerberE , HaidlS , FollinP , et al. StreptIg Study Group. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double‐blind placebo‐controlled trial. Clinical Infectious Diseases2003;37:333‐40. [PUBMED: 12884156 ] ">Darenberg 2003</a>; <a href="./references#CD001090-bbs2-0025" title="KaratzasS , BoutzoukaE , VenetsanouK , MyrianthefsP , FildisisG , BaltopoulosG . The effects of IgM‐enriched immunoglobulin preparations in patients with severe sepsis: another point of view. Critical Care2002;6:543‐4. [PUBMED: 12512504] ">Karatzas 2002</a>; <a href="./references#CD001090-bbs2-0038" title="TugrulS , OzcanPE , AkinciO , SeyhunY , CagatayA , CakarN , et al. The effects of IgM‐enriched immunoglobulin preparations in patients with severe sepsis [ISRCTN28863830]. Critical Care2002;6:357‐62. [PUBMED: 12225613] ">Tugrul 2002</a>; <a href="./references#CD001090-bbs2-0040" title="WerdanK , PilzG , BujdosoO , FraubergerP , NeeserG , SchmeiderRE , et al. Score‐based immunoglobulin G therapy of patients with sepsis: The SBITS study. Critical Care Medicine2007;35:2693‐701. [PUBMED: 18074471] ">Werdan 2007</a>) or 30 days (<a href="./references#CD001090-bbs2-0034" title="RodriguezA , RelloJ , NeiraJ , MaskinB , CerasoD , VastaL , et al. Effects of high‐dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery. Shock2005;23:298‐304. [PUBMED: 15803051 ] ">Rodriguez 2005</a>), or did not specify the cut‐off and follow‐up periods. One trial in which the primary outcome was an increase in platelet count had a nine‐day follow up (<a href="./references#CD001090-bbs2-0008" title="BurnsER , LeeV , RubinsteinA . Treatment of septic thrombocytopenia with immune globulin. Journal of Clinical Immunology1991;11:363‐8. [PUBMED: 1761642] ">Burns 1991</a>) while another trial where the main outcome was defervescence and eradication of symptoms had a seven‐day follow up only (<a href="./references#CD001090-bbs2-0029" title="MasaokaT , HasegawaH , TakakuF , MizoguchiH , AsanoS , IkedaY , et al. The efficacy of intravenous immunoglobulin in combination therapy with antibiotics for severe infections. Japanese Journal of Chemotherapy2000;48:199‐217. [CENTRAL: CN‐00418781; EMBASE: 2000159529] ">Masaoka 2000</a>). </p> <p>Monoclonal trials reported short‐term all‐cause mortality at 28 days except for trials which reported on 14‐day (<a href="./references#CD001090-bbs2-0030" title="MacCloskeyRV , StraubeRC , SandersC , SmithSM , SmithCR . Treatment of septic shock with human monoclonal antibody HA‐1A. A randomized, double‐blind, placebo‐controlled trial. CHESS Trial Study Group. Annals of Internal Medicine1994;121:1‐5. [PUBMED: 8198341] ">McCloskey 1994</a>), 21‐day (<a href="./references#CD001090-bbs2-0019" title="GreenbergRN , WilsonKM , KunzAY , WedelNI , GorelickKJ . Observations using antiendotoxin antibody (E5) as adjuvant therapy in humans with suspected with suspected serious, gram‐negative sepsis. Critical Care Medicine1992;20:730‐5. [PUBMED: 1597023] ">Greenberg 1992</a>), and 30‐day (<a href="./references#CD001090-bbs2-0006" title="BoneRC , BalkRA , FeinAM , PerlTM , WenzelRP , ReinesHD , et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized controlled trial. The E5 Sepsis Study Group. Critical Care Medicine1995;23:994‐1005. [PUBMED: 7774238] ">Bone 1995</a>; <a href="./references#CD001090-bbs2-0020" title="GreenmanRL , ScheinRM , MartinMA , WenzelRP , MacIntyreNR , EmmanuelG , et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram‐negative sepsis. The XOMA Sepsis Study Group. JAMA1991;266:1097‐102. [PUBMED: 1865542] ">Greenman 1991</a>) mortality. Only one monoclonal HA‐1A trial (<a href="./references#CD001090-bbs2-0012" title="DerkxB , WittesJ , McCloskeyR . Randomized, placebo‐controlled trial of HA‐1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group. Clinical Infectious Diseases1999;28:770‐7. [PUBMED: 10825037] ">Derkx 1999</a>) reported on long‐term mortality, at 56 days. </p> </section> <section id="CD001090-sec-0058"> <h5 class="title">Sample size</h5> <p>Of the eight polyclonal IVIG studies on neonates, one was a large multi‐centre, multi‐country trial (<a href="./references#CD001090-bbs2-0007" title="The INIS Collaborative Group. Treatment of neonatal sepsis with intravenous immune globulin. The New England Journal of Medicine2011;365:1201‐11. The INIS Study Collaborative Group. The INIS Study. International Neonatal Immunotherapy Study: Non‐specific intravenous immunoglobulin therapy for suspected or proven neonatal sepsis: an international, placebo‐controlled, multicentre randomised trial. BMC Pregnancy and Childbirth2008;8:1‐13. ">Brocklehurst 2011</a>) and seven were small studies, mainly single centre, with a sample size of &lt; 100 (range 31 to 60) participants. The polyclonal IVIG studies on adults were also small, with the exception of three standard IVIG trials (<a href="./references#CD001090-bbs2-0015" title="DominioniL , BianchiV , ImperatoriA , MinoiaG , DionigiR . High‐dose intravenous IgG for treatment of severe surgical infections. Digestive Surgery1996;13:430‐4. [CENTRAL: CN‐00169903; PUBMED: 1996308558] ">Dominioni 1996</a>; <a href="./references#CD001090-bbs2-0029" title="MasaokaT , HasegawaH , TakakuF , MizoguchiH , AsanoS , IkedaY , et al. The efficacy of intravenous immunoglobulin in combination therapy with antibiotics for severe infections. Japanese Journal of Chemotherapy2000;48:199‐217. [CENTRAL: CN‐00418781; EMBASE: 2000159529] ">Masaoka 2000</a>; <a href="./references#CD001090-bbs2-0040" title="WerdanK , PilzG , BujdosoO , FraubergerP , NeeserG , SchmeiderRE , et al. Score‐based immunoglobulin G therapy of patients with sepsis: The SBITS study. Critical Care Medicine2007;35:2693‐701. [PUBMED: 18074471] ">Werdan 2007</a>) and one IgM‐enriched immunoglobulin trial (<a href="./references#CD001090-bbs2-0023" title="HentrichM , FehnleK , OstermannH , KlenastJ , CornelyO , SalatC , et al. IgMA‐enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple‐center trial. Critical Care Medicine2006;34:1319‐25. [PUBMED: 16540956] ">Hentrich 2006</a>) that had a sample size &gt; 100 participants. </p> <p>Most of the monoclonal trials were relatively large multi‐centre studies, except for two anti‐endotoxin trials (<a href="./references#CD001090-bbs2-0019" title="GreenbergRN , WilsonKM , KunzAY , WedelNI , GorelickKJ . Observations using antiendotoxin antibody (E5) as adjuvant therapy in humans with suspected with suspected serious, gram‐negative sepsis. Critical Care Medicine1992;20:730‐5. [PUBMED: 1597023] ">Greenberg 1992</a>; <a href="./references#CD001090-bbs2-0026" title="LachmanE , PitsoeSB , GaffinSL . Anti‐lipopolysaccharide immunotherapy in management of septic shock of obstetric and gynecological origin. Lancet1984;1:981‐3. [PUBMED: 6143965] ">Lachman 1984</a>) and one anti‐cytokine trial (<a href="./references#CD001090-bbs2-0014" title="DhainautJF , VincentJL , RichardC , LejeuneP , MartinC , FierobeL , et al. CDP 571, a humanized antibody to human tumor necrosis factor alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group. Critical Care Medicine1995;23:1461‐9. [PUBMED: 7664546 ] ">Dhainaut 1995</a>) that had a sample size of &lt; 100 participants. </p> </section> </section> <section id="CD001090-sec-0059"> <h4 class="title">Excluded studies</h4> <p>We excluded 44 studies for the following reasons:</p> <p> <ol id="CD001090-list-0011"> <li> <p>the primary outcome measure was not mortality, in six studies (<a href="./references#CD001090-bbs2-0048" title="ChristensenRD , BrownMS , HallDC , LassiterHA , HillHR . Effect on neutrophil kinetics and serum opsonic capacity of intravenous administration of immune globulin to neonates with clinical signs of early‐onset sepsis. The Journal of Pediatrics1991;118:606‐14. [PUBMED: 1901083] ">Christensen 1991</a>; <a href="./references#CD001090-bbs2-0049" title="deGrooteMA , MartinMA , DensenP , PfallerMA , WenzelRP . Plasma tumor necrosis factor levels in patients with presumed sepsis. Results in those treated with antilipid A antibody vs. placebo. JAMA1989;262:249‐51. [PUBMED: 2739019] ">De Groote 1989</a>; <a href="./references#CD001090-bbs2-0059" title="HomanSE , HallRT , HallSL , MeadeVM , KurthCG . Safety of intravenous immunoglobulin in neonates at risk for sepsis. American Journal of Perinatology1990;7:267‐72. [PUBMED: 2121151] ">Homan 1990</a>; <a href="./references#CD001090-bbs2-0063" title="JonesEB . Prophylactic anti‐lipopolysaccharide freeze‐dried plasma in major burns: a double blind controlled trial. Burns1995;21:267‐72. [PUBMED: 7662126] ">Jones 1995</a>; <a href="./references#CD001090-bbs2-0066" title="KettDH , QuartinAA , SprungCL , FisherCJJr , PeñaMA , HeardSO , et al. An evaluation of the hemodynamic effects of HA‐1A human monoclonal antibody. Critical Care Medicine1994;22:1227‐34. [PUBMED: 8045141] ">Kett 1994</a>; <a href="./references#CD001090-bbs2-0082" title="WangY , DouL , ZhangH , ZhaoB , WangD , CaoS . Treatment of septic thrombocytopenia with immunoglobulin. Chinese Journal of Emergency Medicine2006;15:905‐8. [CENTRAL: CN‐00613262; EMBASE: 2006513788] ">Wang 2006</a>); </p> </li> <li> <p>the study was on an animal model (<a href="./references#CD001090-bbs2-0052" title="FischerGW , HunterKW , HemmingVG , WilsonSR . Functional antibacterial activity of a human intravenous immunoglobulin preparation: in vitro and in vivo studies. Vox Sanguinis1983;44:296‐9. [PUBMED: 6344430] ">Fischer 1983</a>); </p> </li> <li> <p>the study design was not an RCT (<a href="./references#CD001090-bbs2-0045" title="BojicI , BegovicV , TrnjakZ , DokikM . The significance of immunoglobulins in the treatment of patients with sepsis and septic shock. Vojnosanitetski Pregled. Military‐medical and Pharmaceutical Review1998;55 (2 Suppl):75‐8. [PUBMED: 9623363 ] ">Bojic 1998</a>; <a href="./references#CD001090-bbs2-0053" title="FisherCJJr , OpalSM , DhainautJF , StephensS , ZimmermanJL , NightingaleP , et al. Influence of an anti‐tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Critical Care Medicine1993;21:318‐27. [PUBMED: 8440099 ] ">Fisher 1993</a>; <a href="./references#CD001090-bbs2-0055" title="FreemanBD , EichackerPQ , NatansonC . The role of inflammation in sepsis and septic shock: a meta‐analysis of both clinical and pre‐clinical trials of anti‐inflammatory therapies. In: GallinJI , SnydermanR editor(s). Inflammation: Basic Principles and Clinical Correlates. 3rd Edition. Philadelphia: Lippincott Williams &amp; Williams, 1999:965‐76. ">Freeman 1999</a>; <a href="./references#CD001090-bbs2-0057" title="GunesT , KokluE , BuyukkayhanD , KurtogluS , KarakukcuM , PatirogluT . Exchange transfusion or intravenous immunoglobulin therapy as an adjunct to antibiotics for neonatal sepsis in developing countries: a pilot study. Annals of Tropical Paediatrics2006;26:39‐42. [PUBMED: 16494703 ] ">Gunes 2006</a>; <a href="./references#CD001090-bbs2-0064" title="KaulR , McGeerA , Norrby‐TeglundA , KotbM , SchwartzB , O'RourkeK , et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome‐‐a comparative observational study. Clinical Infectious Diseases1999;28:800‐7. [PUBMED: 10825042] ">Kaul 1999</a>; <a href="./references#CD001090-bbs2-0072" title="OkamotoY , MaeharaK , MaseK , IidaY , YasunagaK , OkuboH , et al. Clinical studies on the effectiveness of SM‐4300, a new non‐modified gamma globulin preparation suitable for intravenous use, in refractory infections. The Japanese Journal of Antibiotics1985;38:2515‐25. [PUBMED: 4079018] ">Okimoto 1985</a>; <a href="./references#CD001090-bbs2-0073" title="PankoGF . Use of staphylococcal plasma and antistaphylococcal immunoglobulin in treatment of staphylococcal sepsis. Khirurgiia1976;9:95‐8. [PUBMED: 979012 ] ">Panko 1976</a>; <a href="./references#CD001090-bbs2-0079" title="TomiiM , KobayashiY , FujimoriI . Clinical study of SM‐4300 in the field of medicine. The Japanese Journal of Antibiotics1985;38:2503‐8. [PUBMED: 3935825] ">Tomii 1985</a>; <a href="./references#CD001090-bbs2-0081" title="UedaT , FujimotoM , SakaiK , SasakiT , MorimotoY , MitsuyoshiH , et al. A clinical trial of SM‐4300 against severe infections in surgery. The Japanese Journal of Antibiotics1985;38:2647‐59. [PUBMED: 3908740] ">Ueda 1985</a>; <a href="./references#CD001090-bbs2-0085" title="YavuzL , AynaliG , AynaliA , AlacalaA , KutukS , CeylanBG . The effects of adjuvant immunoglobulin M‐enriched immunoglobulin therapy on mortality rate and renal function in sepsis‐induced multiple organ dysfunction syndrome: retrospective analysis of intensive care unit patients. The Journal of International Medical Research2012;40:1166‐74. ">Yavuz 2012</a>; <a href="./references#CD001090-bbs2-0086" title="ZeniF , FreemanBD , NatansonC . Anti‐inflammatory therapies to treat sepsis and septic shock: a reassessment. Critical Care Medicine1997;25:1095‐100. [PUBMED: 9233726 ] ">Zeni 1997</a>); </p> </li> <li> <p>the studies were either reviews or meta‐analyses (<a href="./references#CD001090-bbs2-0061" title="JensonHB , PollockBH . Meta‐analyses of intravenous immune globulin for prevention and treatment of neonatal sepsis. Pediatrics1997;99(2):E2. [PUBMED: 9099759 ] ">Jenson 1997</a>; <a href="./references#CD001090-bbs2-0068" title="KreymannKG , deHeerG , NierhausA , KlugeS . Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Critical Care Medicine2007;35:2677‐85. [PUBMED: 18074464] ">Kreymann 2007</a>; <a href="./references#CD001090-bbs2-0069" title="LacyJB , OhlssonA . Administration of intravenous immunoglobulins for prophylaxis or treatment of infection in preterm infants: meta‐analyses. Archives of Disease in Childhood. Fetal and Neonatal Edition1995;72:F151‐5. [PUBMED: 7796228 ] ">Lacy 1995</a>; <a href="./references#CD001090-bbs2-0070" title="LauplandKB , KirkpatrickAW , DelaneyA . Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta‐analysis. Critical Care Medicine2007;35:2686‐92. [PUBMED: 18074465 ] ">Laupland 2007</a>; <a href="./references#CD001090-bbs2-0102" title="OhlssonA , LacyJB . Intravenous immunoglobulin for suspected or proven infection in neonates. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD001239.pub4] ">Ohlsson 2013</a>; <a href="./references#CD001090-bbs2-0109" title="SoaresMO , WeltonNJ , HarrisonDA , PeuraP , Shankar‐HariM , HarveySE , et al. An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review,meta‐analysis and value of information analysis. Health Technology Assessment2012;16(7):1‐186. [DOI: 22361003] ">Soares 2012</a>; <a href="./references#CD001090-bbs2-0080" title="TurgeonAF , HuttonB , FergussonDA , McIntyreL , TinmouthAA , CameronDW , et al. Meta‐analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Annals of Internal Medicine2007;146:193‐203. [PUBMED: 17283351 ] ">Turgeon 2007</a>; <a href="./references#CD001090-bbs2-0083" title="WerdanK , PilzG . Supplemental immune globulins in sepsis: a critical appraisal. Clinical and Experimental Immunology1996;104 Suppl 1:83‐90. [PUBMED: 8625550] ">Werdan 1996</a>); </p> </li> <li> <p>alternate allocation to treatment and control arms was used (<a href="./references#CD001090-bbs2-0051" title="El‐NawawyA , El‐KinanyH , Hamdy El‐SayedM , BoshraN . Intravenous polyclonal immunoglobulin administration to sepsis syndrome patients: a prospective study in a pediatric intensive care unit. Journal of Tropical Pediatrics2005;51:271‐8. [PUBMED: 15917261 ] ">El Nawawy 2005</a>; <a href="./references#CD001090-bbs2-0056" title="GökalpAS , ToksoyHB , TürkayS , BakiciMZ , KayaR . Intravenous immunoglobulin in the treatment of Salmonella typhimurium infections in preterm neonates. Clinical Pediatrics1994;33:349‐52. [PUBMED: 8200169 ] ">Gokalp 1994</a>; <a href="./references#CD001090-bbs2-0071" title="MarenovicT , FilipovicD , LukicZ , DokicG . High doses of immunoglobulins decrease mortality rate of surgical patients with severe intraabdominal infections and sepsis. Vojnosanitetski Pregled. Military‐medical and Pharmaceutical Review1998;55 (2 Suppl):71‐4. [PUBMED: 9623362 ] ">Marenovic 1998</a>; <a href="./references#CD001090-bbs2-0077" title="SidiropolousD , BohmeU , vonMuraltG , MorellA , BarandunS . Immunoglobulin substitution in the treatment of neonatal septicemia. Schweizerische Medizinische Wochenschrift1981;111:1649‐55. [PUBMED: 7302548] ">Sidiropolous 1981</a>); </p> </li> <li> <p>lVIG was the control drug rather than the experimental drug (<a href="./references#CD001090-bbs2-0046" title="CairoMS , WorcesterCC , RuckerRW , HantenS , AmlieRN , SenderL , et al. Randomized trial of granulocyte transfusions versus intravenous immune globulin therapy for neonatal neutropenia and sepsis. Journal of Pediatrics1992;120:281‐5. [PUBMED: 1735830 ] ">Cairo 1992</a>; <a href="./references#CD001090-bbs2-0047" title="CalandraT , GlauserMP , SchellekensJ , VerhoefJ . Treatment of gram‐negative septic shock with human IgG antibody to Escherichia coli J5: a prospective double‐blind, randomized trial. Journal of Infectious Diseases1988;158:312‐9. [PUBMED: 3136210] ">Calandra 1988</a>; <a href="./references#CD001090-bbs2-0058" title="HaqueKN , RemoC , BahakimH . Comparison of two types of intravenous immunoglobulins in the treatment of neonatal sepsis. Clinical and Experimental Immunology1995;101:328‐33. [PUBMED: 7648717] ">Haque 1995</a>; <a href="./references#CD001090-bbs2-0074" title="PilzG , AppelR , KreuzerE , WerdanK . Comparison of early IgM‐enriched immunoglobulin vs. polyvalent IgG administration in score‐identified postcardiac surgical patients at high risk for sepsis. Chest1997;111:419‐26. [PUBMED: 9041991] ">Pilz 1997</a>); </p> </li> <li> <p>the immunoglobulin was administered by the intramuscular route (<a href="./references#CD001090-bbs2-0044" title="AitchisonJM , ArbuckleDD . Anti‐endotoxin in the treatment of surgical septic shock. Results of a randomized double‐blind trial. South African Medical Journal1985;68:787‐9. [PUBMED: 3906941 ] ">Aitchison 1985</a>); </p> </li> <li> <p>the study population described was a subgroup of a larger published study (<a href="./references#CD001090-bbs2-0067" title="KornelisseRF , HazelzetJA , HopWC , SpanjaardL , SuurMH , van derVoortE , et al. Meningococcal septic shock in children: clinical and laboratory features, outcome and development of a prognostic score. Clinical Infectious Diseases1997;25:640‐6. [PUBMED: 9314453 ] ">Kornelisse 1997</a>; <a href="./references#CD001090-bbs2-0084" title="WortelCH , von derMöhlenMA , vanDeventerSJ , SprungCL , JastremskiM , LubbersMJ , et al. Effectiveness of a human monoclonal anti‐endotoxin antibody (HA‐1A) in gram‐negative sepsis: relationship to endotoxin and cytokine levels. The Journal of Infectious Diseases1992;166:1367‐74. [PUBMED: 1431255] ">Wortel 1992</a>); </p> </li> <li> <p>the study participants were patients with specific infections not necessarily sepsis (<a href="./references#CD001090-bbs2-0062" title="JesdinskyHJ , TempelG , CastrupHJ , SeifertJ . Cooperative group of additional immunoglobulin therapy in severe bacterial infections: results of a multicenter randomized controlled trial in cases of diffuse fibrinopurulent peritonitis. Klinische Wochenschrift1987;65:1132‐8. [PUBMED: 3323648] ">Jesdinsky 1987</a>); </p> </li> <li> <p>the experimental treatment was a tumour necrosis factor, Fc fusion protein (<a href="./references#CD001090-bbs2-0054" title="FisherCJ , AgostiJM , OpalSM , LowrySF , BalkRA , SadoffJC , et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. The New England Journal of Medicine1996;334:1697‐702. [CENTRAL: CN‐00125377; PUBMED: 8637514] ">Fisher 1996</a>; <a href="./references#CD001090-bbs2-0075" title="PittetD , HarbarthS , SuterPM , ReinhartK , LeightonK , BarkerC , et al. Impact of immunomodulating therapy on morbidity in patients with severe sepsis. American Journal of Respiratory and Critical Care Medicine1999;160:852‐7. [PUBMED: 10471608] ">Pittet 1999</a>); </p> </li> <li> <p>the study was an interim analysis (<a href="./references#CD001090-bbs2-0050" title="DominioniL , DionigiR , ZanelloM , ChiarandaM , DionigiR , AcquaroloA , et al. Effects of high‐dose IgG on survival of surgical patients with sepsis scores of 20 or greater. Archives of Surgery1991;126:236‐40. [PUBMED: 1992998] ">Dominioni 1991</a>) of a clinical trial which we have included in our review (<a href="./references#CD001090-bbs2-0015" title="DominioniL , BianchiV , ImperatoriA , MinoiaG , DionigiR . High‐dose intravenous IgG for treatment of severe surgical infections. Digestive Surgery1996;13:430‐4. [CENTRAL: CN‐00169903; PUBMED: 1996308558] ">Dominioni 1996</a>); and </p> </li> <li> <p>duplicate publication (<a href="./references#CD001090-bbs2-0076" title="SchedelI , DreichhausenU . [Therapy of gram‐negative septicotoxic diseases with pentaglobin ‐ immunoglobulin with increased IgM content: a prospective randomized clinical study]. Anesteziologiia i Reanimatologiia1996;199:4‐9. [CENTRAL: CN‐00129822; PUBMED: 8967617] ">Schedel 1996</a>; <a href="./references#CD001090-bbs2-0078" title="SidiropoulosD , BoehmeU , VonMuraltG , MorellA , BarandunS . Immunoglobulin supplementation in prevention or treatment of neonatal sepsis. Pediatric Infectious Disease1986;5:S193‐94. [PUBMED: 3714523] ">Sidiropoulos 1986</a>). </p> </li> </ol> </p> </section> </section> <section id="CD001090-sec-0060"> <h3 class="title">Risk of bias in included studies</h3> <p>The assessment of the quality of the individual studies is shown in the table <a href="./references#CD001090-sec-0115" title="">Characteristics of included studies</a> and summarized in <a href="#CD001090-fig-0002">Figure 2</a> and <a href="#CD001090-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD001090-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgments about each methodological quality item for each included study." data-id="CD001090-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgments about each methodological quality item for each included study. </p> </div> </div> </div> <div class="figure" id="CD001090-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD001090-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD001090-sec-0061"> <h4 class="title">Polyclonal IVIG trials</h4> <p>Eight trials were assessed as having low risk of bias. That is, they had adequate allocation concealment and blinding with an intention‐to‐treat analysis. Three of these trials were on polyclonal IVIG in neonates (<a href="./references#CD001090-bbs2-0007" title="The INIS Collaborative Group. Treatment of neonatal sepsis with intravenous immune globulin. The New England Journal of Medicine2011;365:1201‐11. The INIS Study Collaborative Group. The INIS Study. International Neonatal Immunotherapy Study: Non‐specific intravenous immunoglobulin therapy for suspected or proven neonatal sepsis: an international, placebo‐controlled, multicentre randomised trial. BMC Pregnancy and Childbirth2008;8:1‐13. ">Brocklehurst 2011</a>; <a href="./references#CD001090-bbs2-0028" title="Mancilla‐RamírezJ , González‐YunesR , Castellanos‐CruzC , García‐RocaP , Santos‐PreciadoJI . Intravenous immunoglobulin in the treatment of neonatal septicemia [Inmunoglobulina intravenosa en el tratamiento de septicemia neonatal.]. Boletín Médico del Hospital Infantil de México1992;49:4‐11. [PUBMED: 1304766] ">Mancilla‐Ramirez 1992</a>; <a href="./references#CD001090-bbs2-0039" title="WeismanLE , StollBJ , KueserTJ , RubioTT , FrankCG , HeimanHS , et al. Intravenous immune globulin therapy for early onset sepsis in premature neonates. Journal of Pediatrics1992;121:434‐43. [PUBMED: 1517923 ] ">Weisman 1992</a>) and five were in adults (<a href="./references#CD001090-bbs2-0008" title="BurnsER , LeeV , RubinsteinA . Treatment of septic thrombocytopenia with immune globulin. Journal of Clinical Immunology1991;11:363‐8. [PUBMED: 1761642] ">Burns 1991</a>; <a href="./references#CD001090-bbs2-0011" title="DarenbergJ , IhendyaneN , SjölinJ , AufwerberE , HaidlS , FollinP , et al. StreptIg Study Group. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double‐blind placebo‐controlled trial. Clinical Infectious Diseases2003;37:333‐40. [PUBMED: 12884156 ] ">Darenberg 2003</a>; <a href="./references#CD001090-bbs2-0023" title="HentrichM , FehnleK , OstermannH , KlenastJ , CornelyO , SalatC , et al. IgMA‐enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple‐center trial. Critical Care Medicine2006;34:1319‐25. [PUBMED: 16540956] ">Hentrich 2006</a>; <a href="./references#CD001090-bbs2-0034" title="RodriguezA , RelloJ , NeiraJ , MaskinB , CerasoD , VastaL , et al. Effects of high‐dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery. Shock2005;23:298‐304. [PUBMED: 15803051 ] ">Rodriguez 2005</a>; <a href="./references#CD001090-bbs2-0040" title="WerdanK , PilzG , BujdosoO , FraubergerP , NeeserG , SchmeiderRE , et al. Score‐based immunoglobulin G therapy of patients with sepsis: The SBITS study. Critical Care Medicine2007;35:2693‐701. [PUBMED: 18074471] ">Werdan 2007</a>). Of the five trials on adults, three were on medical patients (<a href="./references#CD001090-bbs2-0008" title="BurnsER , LeeV , RubinsteinA . Treatment of septic thrombocytopenia with immune globulin. Journal of Clinical Immunology1991;11:363‐8. [PUBMED: 1761642] ">Burns 1991</a>; <a href="./references#CD001090-bbs2-0011" title="DarenbergJ , IhendyaneN , SjölinJ , AufwerberE , HaidlS , FollinP , et al. StreptIg Study Group. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double‐blind placebo‐controlled trial. Clinical Infectious Diseases2003;37:333‐40. [PUBMED: 12884156 ] ">Darenberg 2003</a>; <a href="./references#CD001090-bbs2-0023" title="HentrichM , FehnleK , OstermannH , KlenastJ , CornelyO , SalatC , et al. IgMA‐enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple‐center trial. Critical Care Medicine2006;34:1319‐25. [PUBMED: 16540956] ">Hentrich 2006</a>), one on surgical patients (<a href="./references#CD001090-bbs2-0034" title="RodriguezA , RelloJ , NeiraJ , MaskinB , CerasoD , VastaL , et al. Effects of high‐dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery. Shock2005;23:298‐304. [PUBMED: 15803051 ] ">Rodriguez 2005</a>), and one on mixed medical‐surgical patients (<a href="./references#CD001090-bbs2-0040" title="WerdanK , PilzG , BujdosoO , FraubergerP , NeeserG , SchmeiderRE , et al. Score‐based immunoglobulin G therapy of patients with sepsis: The SBITS study. Critical Care Medicine2007;35:2693‐701. [PUBMED: 18074471] ">Werdan 2007</a>). </p> </section> <section id="CD001090-sec-0062"> <h4 class="title">Monoclonal trials</h4> <p>Four studies were assessed to have low risk of bias; that is, they had adequate allocation concealment and blinding, with an intention‐to‐treat analysis. Three were on the anti‐cytokines anti‐TNF alpha (<a href="./references#CD001090-bbs2-0002" title="AbrahamE , AnzuetoA , GutierrezG , TesslerS , San PedroG , WunderinkR , et al. Double‐blind randomized controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock.NORASEPT II Study Group. Lancet1998;351:929‐33. [PUBMED: 9734938] ">Abraham 1998</a>; <a href="./references#CD001090-bbs2-0010" title="CohenJ , CarletJ . INTERSEPT: an international, multicenter, placebo‐controlled‐trial of monoclonal antibody to human tumor necrosis factor‐alpha in patients with sepsis. International Sepsis Trial Study Group. Critical Care Medicine1996;24:1431‐40. [PUBMED: 8797612 ] ">Cohen 1996</a>) and anti‐TNF antibody fragment afelimomab (<a href="./references#CD001090-bbs2-0032" title="PanacekEA , MarshallJC , AlbertsonTE , JohnsonDH , JohnsonS , MacArthurRD , et al. Monoclonal Anti‐TNF: Randomized Controlled Sepsis Study Investigators. Efficacy and safety of the monoclonal anti‐‐tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin‐6 levels. Critical Care Medicine2004;32:2173‐82. [PUBMED: 15640628 ] ">Panacek 2004</a>); and one was an anti‐endotoxin trial, specifically HA‐1a (<a href="./references#CD001090-bbs2-0012" title="DerkxB , WittesJ , McCloskeyR . Randomized, placebo‐controlled trial of HA‐1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group. Clinical Infectious Diseases1999;28:770‐7. [PUBMED: 10825037] ">Derkx 1999</a>). </p> </section> <section id="CD001090-sec-0063"> <h4 class="title">Allocation</h4> <p>Of the 17 polyclonal IVIG trials on adults, nine had adequate allocation concealment (<a href="./references#CD001090-bbs2-0008" title="BurnsER , LeeV , RubinsteinA . Treatment of septic thrombocytopenia with immune globulin. Journal of Clinical Immunology1991;11:363‐8. [PUBMED: 1761642] ">Burns 1991</a>; <a href="./references#CD001090-bbs2-0011" title="DarenbergJ , IhendyaneN , SjölinJ , AufwerberE , HaidlS , FollinP , et al. StreptIg Study Group. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double‐blind placebo‐controlled trial. Clinical Infectious Diseases2003;37:333‐40. [PUBMED: 12884156 ] ">Darenberg 2003</a>; <a href="./references#CD001090-bbs2-0023" title="HentrichM , FehnleK , OstermannH , KlenastJ , CornelyO , SalatC , et al. IgMA‐enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple‐center trial. Critical Care Medicine2006;34:1319‐25. [PUBMED: 16540956] ">Hentrich 2006</a>; <a href="./references#CD001090-bbs2-0025" title="KaratzasS , BoutzoukaE , VenetsanouK , MyrianthefsP , FildisisG , BaltopoulosG . The effects of IgM‐enriched immunoglobulin preparations in patients with severe sepsis: another point of view. Critical Care2002;6:543‐4. [PUBMED: 12512504] ">Karatzas 2002</a>; <a href="./references#CD001090-bbs2-0027" title="LindquistL , LundberghP , MaasingR . Pepsin‐treated human gamma globulin in bacterial infections. A randomized study in patients with septicemia and pneumonia. Vox Sanguinis1981;40:329‐37. [PUBMED: 6166128 ] ">Lindquist 1981</a>; <a href="./references#CD001090-bbs2-0029" title="MasaokaT , HasegawaH , TakakuF , MizoguchiH , AsanoS , IkedaY , et al. The efficacy of intravenous immunoglobulin in combination therapy with antibiotics for severe infections. Japanese Journal of Chemotherapy2000;48:199‐217. [CENTRAL: CN‐00418781; EMBASE: 2000159529] ">Masaoka 2000</a>; <a href="./references#CD001090-bbs2-0034" title="RodriguezA , RelloJ , NeiraJ , MaskinB , CerasoD , VastaL , et al. Effects of high‐dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery. Shock2005;23:298‐304. [PUBMED: 15803051 ] ">Rodriguez 2005</a>; <a href="./references#CD001090-bbs2-0036" title="SchedelI , DreikhausenU , NentwigB , HöckenschniederM , RauthmannD , BalikciogluS , et al. Treatment of Gram‐negative septic shock and an immunoglobulin preparation: A prospective randomized clinical trial. Critical Care Medicine1991;10:1104‐13. [PUBMED: 1884609] ">Schedel 1991</a>; <a href="./references#CD001090-bbs2-0040" title="WerdanK , PilzG , BujdosoO , FraubergerP , NeeserG , SchmeiderRE , et al. Score‐based immunoglobulin G therapy of patients with sepsis: The SBITS study. Critical Care Medicine2007;35:2693‐701. [PUBMED: 18074471] ">Werdan 2007</a>); two trials had inadequate allocation concealment (<a href="./references#CD001090-bbs2-0038" title="TugrulS , OzcanPE , AkinciO , SeyhunY , CagatayA , CakarN , et al. The effects of IgM‐enriched immunoglobulin preparations in patients with severe sepsis [ISRCTN28863830]. Critical Care2002;6:357‐62. [PUBMED: 12225613] ">Tugrul 2002</a>; <a href="./references#CD001090-bbs2-0041" title="WesolyC , KippingN , GrundmannR . Immunoglobulin therapy of postoperative sepsis [Immunglobulintherapie der postoperativen Sepsis]. Zeitschrift für experimentelle Chirurgie, Transplantation, und künstliche Organe: Organ der Sektion Experimentelle Chirurgie der Gesellschaft für Chirurgie der DDR1990;23:213‐6. [CENTRAL: CN‐00075746; PUBMED: 2095647] ">Wesoly 1990</a>); and six had unclear allocation concealment (<a href="./references#CD001090-bbs2-0005" title="BehreG , OstermannH , SchedelI , HelmerkingM , SchielX , RothenburgerM , et al. Endotoxin concentrations and therapy with polyclonal IgM‐enriched immunoglobulins in neutropenic cancer patients with sepsis syndrome: Pilot study and interim analysis of a randomized trial. Antiinfective Drugs and Chemotherapy1995;13:129‐34. [CENTRAL: CN‐00168897; EMBASE: 1996075665] ">Behre 1995</a>; <a href="./references#CD001090-bbs2-0013" title="DeSimoneC , DeloguG , CorbettaG . Intravenous immunoglobulins in association with antibiotics: a therapeutic trial in septic intensive care unit patients. Critical Care Medicine1988;16:23‐6. [PUBMED: 3276446] ">De Simone 1988</a>; <a href="./references#CD001090-bbs2-0015" title="DominioniL , BianchiV , ImperatoriA , MinoiaG , DionigiR . High‐dose intravenous IgG for treatment of severe surgical infections. Digestive Surgery1996;13:430‐4. [CENTRAL: CN‐00169903; PUBMED: 1996308558] ">Dominioni 1996</a>; <a href="./references#CD001090-bbs2-0021" title="GrundmannR , HornungM . Immunoglobulin therapy in patients with endotoxemia and postoperative sepsis ‐ a prospective randomized study. Progress in Clinical and Biological Research1988;272:339‐49. [PUBMED: 3293080] ">Grundmann 1988</a>; <a href="./references#CD001090-bbs2-0024" title="JustHM , MetzgerM , VogelW , PelkaRB . Effect of adjuvant immunoglobulin therapy in patients in a surgical intensive care unit. Results of a randomized controlled study [Einfluss einer adjuvanten Immunglobulintherapie auf Infektionen bei Patienten einer operativen Intensiv‐Therapie‐Station.]. Klinische Wochenschrift1986;64:245‐56. [PUBMED: 3713101] ">Just 1986</a>; <a href="./references#CD001090-bbs2-0042" title="YakutM , CetinerS , AkinA , TanA , KaymakciogluN , SimsekA , et al. Effects of immunoglobulin G on surgical sepsis and septic shock [Sepsisdeki hastalarda immunoglobulin G (IGG) kulianiminin mortalite oranina etkisi]. Bulletin of Gulhane Military Medical Academy1998;40:76‐81. [CENTRAL: CN‐00200598] ">Yakut 1998</a>). </p> <p>Of the eight polyclonal IVIG trials on neonates, four had adequate allocation concealment (<a href="./references#CD001090-bbs2-0007" title="The INIS Collaborative Group. Treatment of neonatal sepsis with intravenous immune globulin. The New England Journal of Medicine2011;365:1201‐11. The INIS Study Collaborative Group. The INIS Study. International Neonatal Immunotherapy Study: Non‐specific intravenous immunoglobulin therapy for suspected or proven neonatal sepsis: an international, placebo‐controlled, multicentre randomised trial. BMC Pregnancy and Childbirth2008;8:1‐13. ">Brocklehurst 2011</a>; <a href="./references#CD001090-bbs2-0028" title="Mancilla‐RamírezJ , González‐YunesR , Castellanos‐CruzC , García‐RocaP , Santos‐PreciadoJI . Intravenous immunoglobulin in the treatment of neonatal septicemia [Inmunoglobulina intravenosa en el tratamiento de septicemia neonatal.]. Boletín Médico del Hospital Infantil de México1992;49:4‐11. [PUBMED: 1304766] ">Mancilla‐Ramirez 1992</a>; <a href="./references#CD001090-bbs2-0037" title="ShenoiA , NageshNK , MaiyaPP , BhatSR , Subba RaoSD . Multicenter randomized placebo controlled trial of therapy with intravenous immunoglobulin in decreasing mortality due to neonatal sepsis. Indian Pediatrics1999;36:1113‐8. [PUBMED: 10745332] ">Shenoi 1999</a>; <a href="./references#CD001090-bbs2-0039" title="WeismanLE , StollBJ , KueserTJ , RubioTT , FrankCG , HeimanHS , et al. Intravenous immune globulin therapy for early onset sepsis in premature neonates. Journal of Pediatrics1992;121:434‐43. [PUBMED: 1517923 ] ">Weisman 1992</a>); one trial had a high risk for bias due to inadequate allocation concealment (<a href="./references#CD001090-bbs2-0016" title="ErdemG , YurdakökM , TekinalpG , ErsoyF . The use of IgM‐enriched intravenous immunoglobulin for the treatment of neonatal sepsis in preterm infants. The Turkish Journal of Pediatrics1993;35:277‐81. [PUBMED: 8160279] ">Erdem 1993</a>); and three had unclear allocation concealment (<a href="./references#CD001090-bbs2-0009" title="ChenJY . Intravenous immunoglobulin in the treatment of full term and premature newborns with sepsis. Journal of the Formosan Medical Association: Taiwan Yi Zhi1996;11:839‐44. [PUBMED: 8990771] ">Chen 1996</a>; <a href="./references#CD001090-bbs2-0022" title="HaqueKN , ZaidiMH , BahakimH . IgM‐enriched intravenous immunoglobulin therapy in neonatal sepsis. American Journal of Diseases of Childhood1988;142:1293‐6. [PUBMED: 3195529] ">Haque 1988</a>; <a href="./references#CD001090-bbs2-0035" title="SamathaS , JalaluMP , HegdeRK , VishwanathD , MaiyaPP . Role of IgM‐enriched intravenous immunoglobulin as an adjuvant to antibiotics in neonatal sepsis. Karnataka Pediatric Journal1997;11:1‐6. ">Samatha 1997</a>). </p> <p>Seven monoclonal trials had unclear allocation concealment (<a href="./references#CD001090-bbs2-0001" title="AbrahamE , WunderinkR , SilvermanH , PerlTM , NasrawayS , LevyH , et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled double‐blind, multicenter clinical trial. TNF‐alpha MAb Sepsis Study group. JAMA1995;273:934‐41. [PUBMED: 7884952] ">Abraham 1995</a>; <a href="./references#CD001090-bbs2-0003" title="AlbertsonTE , PanacekEA , MacArthurRD , JohnsonSB , BenjaminE , MatsuchakG , et al. Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram‐negative sepsis. Critical Care Medicine2003;31:419‐27. [PUBMED: 12576946 ] ">Albertson 2003</a>; <a href="./references#CD001090-bbs2-0006" title="BoneRC , BalkRA , FeinAM , PerlTM , WenzelRP , ReinesHD , et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized controlled trial. The E5 Sepsis Study Group. Critical Care Medicine1995;23:994‐1005. [PUBMED: 7774238] ">Bone 1995</a>; <a href="./references#CD001090-bbs2-0014" title="DhainautJF , VincentJL , RichardC , LejeuneP , MartinC , FierobeL , et al. CDP 571, a humanized antibody to human tumor necrosis factor alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group. Critical Care Medicine1995;23:1461‐9. [PUBMED: 7664546 ] ">Dhainaut 1995</a>; <a href="./references#CD001090-bbs2-0019" title="GreenbergRN , WilsonKM , KunzAY , WedelNI , GorelickKJ . Observations using antiendotoxin antibody (E5) as adjuvant therapy in humans with suspected with suspected serious, gram‐negative sepsis. Critical Care Medicine1992;20:730‐5. [PUBMED: 1597023] ">Greenberg 1992</a>; <a href="./references#CD001090-bbs2-0026" title="LachmanE , PitsoeSB , GaffinSL . Anti‐lipopolysaccharide immunotherapy in management of septic shock of obstetric and gynecological origin. Lancet1984;1:981‐3. [PUBMED: 6143965] ">Lachman 1984</a>; <a href="./references#CD001090-bbs2-0033" title="ReinhartK , Wiegand‐LöhnertC , GrimmingerF , KaulM , WithingtonS , TreacherD , et al. Assessment of the safety and efficacy of the monoclonal anti‐tumor necrosis factor antibody‐fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo‐controlled, dose ranging study. Critical Care Medicine1996;24:733‐42. [PUBMED: 8706447] ">Reinhart 1996</a>). </p> </section> <section id="CD001090-sec-0064"> <h4 class="title">Blinding</h4> <p>Nine polyclonal IVIG trials on adults (<a href="./references#CD001090-bbs2-0013" title="DeSimoneC , DeloguG , CorbettaG . Intravenous immunoglobulins in association with antibiotics: a therapeutic trial in septic intensive care unit patients. Critical Care Medicine1988;16:23‐6. [PUBMED: 3276446] ">De Simone 1988</a>; <a href="./references#CD001090-bbs2-0021" title="GrundmannR , HornungM . Immunoglobulin therapy in patients with endotoxemia and postoperative sepsis ‐ a prospective randomized study. Progress in Clinical and Biological Research1988;272:339‐49. [PUBMED: 3293080] ">Grundmann 1988</a>; <a href="./references#CD001090-bbs2-0024" title="JustHM , MetzgerM , VogelW , PelkaRB . Effect of adjuvant immunoglobulin therapy in patients in a surgical intensive care unit. Results of a randomized controlled study [Einfluss einer adjuvanten Immunglobulintherapie auf Infektionen bei Patienten einer operativen Intensiv‐Therapie‐Station.]. Klinische Wochenschrift1986;64:245‐56. [PUBMED: 3713101] ">Just 1986</a>; <a href="./references#CD001090-bbs2-0025" title="KaratzasS , BoutzoukaE , VenetsanouK , MyrianthefsP , FildisisG , BaltopoulosG . The effects of IgM‐enriched immunoglobulin preparations in patients with severe sepsis: another point of view. Critical Care2002;6:543‐4. [PUBMED: 12512504] ">Karatzas 2002</a>; <a href="./references#CD001090-bbs2-0027" title="LindquistL , LundberghP , MaasingR . Pepsin‐treated human gamma globulin in bacterial infections. A randomized study in patients with septicemia and pneumonia. Vox Sanguinis1981;40:329‐37. [PUBMED: 6166128 ] ">Lindquist 1981</a>; <a href="./references#CD001090-bbs2-0029" title="MasaokaT , HasegawaH , TakakuF , MizoguchiH , AsanoS , IkedaY , et al. The efficacy of intravenous immunoglobulin in combination therapy with antibiotics for severe infections. Japanese Journal of Chemotherapy2000;48:199‐217. [CENTRAL: CN‐00418781; EMBASE: 2000159529] ">Masaoka 2000</a>; <a href="./references#CD001090-bbs2-0036" title="SchedelI , DreikhausenU , NentwigB , HöckenschniederM , RauthmannD , BalikciogluS , et al. Treatment of Gram‐negative septic shock and an immunoglobulin preparation: A prospective randomized clinical trial. Critical Care Medicine1991;10:1104‐13. [PUBMED: 1884609] ">Schedel 1991</a>; <a href="./references#CD001090-bbs2-0038" title="TugrulS , OzcanPE , AkinciO , SeyhunY , CagatayA , CakarN , et al. The effects of IgM‐enriched immunoglobulin preparations in patients with severe sepsis [ISRCTN28863830]. Critical Care2002;6:357‐62. [PUBMED: 12225613] ">Tugrul 2002</a>; <a href="./references#CD001090-bbs2-0041" title="WesolyC , KippingN , GrundmannR . Immunoglobulin therapy of postoperative sepsis [Immunglobulintherapie der postoperativen Sepsis]. Zeitschrift für experimentelle Chirurgie, Transplantation, und künstliche Organe: Organ der Sektion Experimentelle Chirurgie der Gesellschaft für Chirurgie der DDR1990;23:213‐6. [CENTRAL: CN‐00075746; PUBMED: 2095647] ">Wesoly 1990</a>) and three trials on neonates (<a href="./references#CD001090-bbs2-0016" title="ErdemG , YurdakökM , TekinalpG , ErsoyF . The use of IgM‐enriched intravenous immunoglobulin for the treatment of neonatal sepsis in preterm infants. The Turkish Journal of Pediatrics1993;35:277‐81. [PUBMED: 8160279] ">Erdem 1993</a>; <a href="./references#CD001090-bbs2-0035" title="SamathaS , JalaluMP , HegdeRK , VishwanathD , MaiyaPP . Role of IgM‐enriched intravenous immunoglobulin as an adjuvant to antibiotics in neonatal sepsis. Karnataka Pediatric Journal1997;11:1‐6. ">Samatha 1997</a>; <a href="./references#CD001090-bbs2-0037" title="ShenoiA , NageshNK , MaiyaPP , BhatSR , Subba RaoSD . Multicenter randomized placebo controlled trial of therapy with intravenous immunoglobulin in decreasing mortality due to neonatal sepsis. Indian Pediatrics1999;36:1113‐8. [PUBMED: 10745332] ">Shenoi 1999</a>) did not have a placebo in the control group, which precluded blinding. </p> <p>Two monoclonal trials lacked blinding manoeuvres (<a href="./references#CD001090-bbs2-0026" title="LachmanE , PitsoeSB , GaffinSL . Anti‐lipopolysaccharide immunotherapy in management of septic shock of obstetric and gynecological origin. Lancet1984;1:981‐3. [PUBMED: 6143965] ">Lachman 1984</a>; <a href="./references#CD001090-bbs2-0033" title="ReinhartK , Wiegand‐LöhnertC , GrimmingerF , KaulM , WithingtonS , TreacherD , et al. Assessment of the safety and efficacy of the monoclonal anti‐tumor necrosis factor antibody‐fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo‐controlled, dose ranging study. Critical Care Medicine1996;24:733‐42. [PUBMED: 8706447] ">Reinhart 1996</a>). </p> </section> <section id="CD001090-sec-0065"> <h4 class="title">Incomplete outcome data</h4> <p>Intention‐to‐treat analysis was not done in six polyclonal IVIG trials on adults (<a href="./references#CD001090-bbs2-0005" title="BehreG , OstermannH , SchedelI , HelmerkingM , SchielX , RothenburgerM , et al. Endotoxin concentrations and therapy with polyclonal IgM‐enriched immunoglobulins in neutropenic cancer patients with sepsis syndrome: Pilot study and interim analysis of a randomized trial. Antiinfective Drugs and Chemotherapy1995;13:129‐34. [CENTRAL: CN‐00168897; EMBASE: 1996075665] ">Behre 1995</a>; <a href="./references#CD001090-bbs2-0015" title="DominioniL , BianchiV , ImperatoriA , MinoiaG , DionigiR . High‐dose intravenous IgG for treatment of severe surgical infections. Digestive Surgery1996;13:430‐4. [CENTRAL: CN‐00169903; PUBMED: 1996308558] ">Dominioni 1996</a>; <a href="./references#CD001090-bbs2-0024" title="JustHM , MetzgerM , VogelW , PelkaRB . Effect of adjuvant immunoglobulin therapy in patients in a surgical intensive care unit. Results of a randomized controlled study [Einfluss einer adjuvanten Immunglobulintherapie auf Infektionen bei Patienten einer operativen Intensiv‐Therapie‐Station.]. Klinische Wochenschrift1986;64:245‐56. [PUBMED: 3713101] ">Just 1986</a>; <a href="./references#CD001090-bbs2-0027" title="LindquistL , LundberghP , MaasingR . Pepsin‐treated human gamma globulin in bacterial infections. A randomized study in patients with septicemia and pneumonia. Vox Sanguinis1981;40:329‐37. [PUBMED: 6166128 ] ">Lindquist 1981</a>; <a href="./references#CD001090-bbs2-0029" title="MasaokaT , HasegawaH , TakakuF , MizoguchiH , AsanoS , IkedaY , et al. The efficacy of intravenous immunoglobulin in combination therapy with antibiotics for severe infections. Japanese Journal of Chemotherapy2000;48:199‐217. [CENTRAL: CN‐00418781; EMBASE: 2000159529] ">Masaoka 2000</a>; <a href="./references#CD001090-bbs2-0036" title="SchedelI , DreikhausenU , NentwigB , HöckenschniederM , RauthmannD , BalikciogluS , et al. Treatment of Gram‐negative septic shock and an immunoglobulin preparation: A prospective randomized clinical trial. Critical Care Medicine1991;10:1104‐13. [PUBMED: 1884609] ">Schedel 1991</a>) and one trial on neonates (<a href="./references#CD001090-bbs2-0037" title="ShenoiA , NageshNK , MaiyaPP , BhatSR , Subba RaoSD . Multicenter randomized placebo controlled trial of therapy with intravenous immunoglobulin in decreasing mortality due to neonatal sepsis. Indian Pediatrics1999;36:1113‐8. [PUBMED: 10745332] ">Shenoi 1999</a>). </p> <p>Intention‐to‐treat analysis was not performed in seven monoclonal trials (<a href="./references#CD001090-bbs2-0001" title="AbrahamE , WunderinkR , SilvermanH , PerlTM , NasrawayS , LevyH , et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled double‐blind, multicenter clinical trial. TNF‐alpha MAb Sepsis Study group. JAMA1995;273:934‐41. [PUBMED: 7884952] ">Abraham 1995</a>; <a href="./references#CD001090-bbs2-0004" title="AngusDC , BirminghamMC , BalkRA , ScannonPJ , CollinsD , KruseJA , et al. E5 murine monoclonal antiendotoxin antibody in gram‐negative sepsis: a randomized controlled trial. E5 Study Investigators. JAMA2000;283:1723‐30. [PUBMED: 10755499] ">Angus 2000</a>; <a href="./references#CD001090-bbs2-0006" title="BoneRC , BalkRA , FeinAM , PerlTM , WenzelRP , ReinesHD , et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized controlled trial. The E5 Sepsis Study Group. Critical Care Medicine1995;23:994‐1005. [PUBMED: 7774238] ">Bone 1995</a>; <a href="./references#CD001090-bbs2-0018" title="FisherCJJr , DhainautJF , OpalSM , PribbleJP , BalkRA , SlotmanGJ , et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: Results from a randomized double‐blind, placebo‐controlled trial. Phase III rhIL‐1ra Sepsis Syndrome Study Group. JAMA1994;271:1836‐43. ">Fisher 1994b</a>; <a href="./references#CD001090-bbs2-0020" title="GreenmanRL , ScheinRM , MartinMA , WenzelRP , MacIntyreNR , EmmanuelG , et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram‐negative sepsis. The XOMA Sepsis Study Group. JAMA1991;266:1097‐102. [PUBMED: 1865542] ">Greenman 1991</a>; <a href="./references#CD001090-bbs2-0031" title="OpalSM , FisherCJ , DhainautJF , VincentJL , BraseR , LowrySF , et al. Confirmatory interleukin‐1 receptor antagonist trial in severe sepsis: A phase III, randomized, double‐blind, placebo‐controlled, multicenter trial. The Interleukin‐1 Receptor Antagonist Sepsis Investigator Group. Critical Care Medicine1997;25:1115‐24. [PUBMED: 9233735] ">Opal 1997</a>; <a href="./references#CD001090-bbs2-0043" title="ZieglerEJ , FisherCJ , SprungCL , StraubeRC , SadoffJC , FoulkeGE , et al. Treatment of gram‐negative bacteremia and septic shock with HA‐1A human monoclonal antibody against endotoxin. A randomized, double‐blind, placebo‐controlled trial. The HA‐1A Sepsis Study Group.l. The New England Journal of Medicine1991;324:429‐36. [PUBMED: 1988827] ">Ziegler 1991</a>). </p> </section> <section id="CD001090-sec-0066"> <h4 class="title">Selective reporting</h4> <p>Only seven (<a href="./references#CD001090-bbs2-0011" title="DarenbergJ , IhendyaneN , SjölinJ , AufwerberE , HaidlS , FollinP , et al. StreptIg Study Group. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double‐blind placebo‐controlled trial. Clinical Infectious Diseases2003;37:333‐40. [PUBMED: 12884156 ] ">Darenberg 2003</a>; <a href="./references#CD001090-bbs2-0015" title="DominioniL , BianchiV , ImperatoriA , MinoiaG , DionigiR . High‐dose intravenous IgG for treatment of severe surgical infections. Digestive Surgery1996;13:430‐4. [CENTRAL: CN‐00169903; PUBMED: 1996308558] ">Dominioni 1996</a>; <a href="./references#CD001090-bbs2-0023" title="HentrichM , FehnleK , OstermannH , KlenastJ , CornelyO , SalatC , et al. IgMA‐enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple‐center trial. Critical Care Medicine2006;34:1319‐25. [PUBMED: 16540956] ">Hentrich 2006</a>; <a href="./references#CD001090-bbs2-0027" title="LindquistL , LundberghP , MaasingR . Pepsin‐treated human gamma globulin in bacterial infections. A randomized study in patients with septicemia and pneumonia. Vox Sanguinis1981;40:329‐37. [PUBMED: 6166128 ] ">Lindquist 1981</a>; <a href="./references#CD001090-bbs2-0029" title="MasaokaT , HasegawaH , TakakuF , MizoguchiH , AsanoS , IkedaY , et al. The efficacy of intravenous immunoglobulin in combination therapy with antibiotics for severe infections. Japanese Journal of Chemotherapy2000;48:199‐217. [CENTRAL: CN‐00418781; EMBASE: 2000159529] ">Masaoka 2000</a>; <a href="./references#CD001090-bbs2-0036" title="SchedelI , DreikhausenU , NentwigB , HöckenschniederM , RauthmannD , BalikciogluS , et al. Treatment of Gram‐negative septic shock and an immunoglobulin preparation: A prospective randomized clinical trial. Critical Care Medicine1991;10:1104‐13. [PUBMED: 1884609] ">Schedel 1991</a>; <a href="./references#CD001090-bbs2-0040" title="WerdanK , PilzG , BujdosoO , FraubergerP , NeeserG , SchmeiderRE , et al. Score‐based immunoglobulin G therapy of patients with sepsis: The SBITS study. Critical Care Medicine2007;35:2693‐701. [PUBMED: 18074471] ">Werdan 2007</a>) of the 17 polyclonal IVIG trials in adults and four (<a href="./references#CD001090-bbs2-0007" title="The INIS Collaborative Group. Treatment of neonatal sepsis with intravenous immune globulin. The New England Journal of Medicine2011;365:1201‐11. The INIS Study Collaborative Group. The INIS Study. International Neonatal Immunotherapy Study: Non‐specific intravenous immunoglobulin therapy for suspected or proven neonatal sepsis: an international, placebo‐controlled, multicentre randomised trial. BMC Pregnancy and Childbirth2008;8:1‐13. ">Brocklehurst 2011</a>; <a href="./references#CD001090-bbs2-0035" title="SamathaS , JalaluMP , HegdeRK , VishwanathD , MaiyaPP . Role of IgM‐enriched intravenous immunoglobulin as an adjuvant to antibiotics in neonatal sepsis. Karnataka Pediatric Journal1997;11:1‐6. ">Samatha 1997</a>; <a href="./references#CD001090-bbs2-0037" title="ShenoiA , NageshNK , MaiyaPP , BhatSR , Subba RaoSD . Multicenter randomized placebo controlled trial of therapy with intravenous immunoglobulin in decreasing mortality due to neonatal sepsis. Indian Pediatrics1999;36:1113‐8. [PUBMED: 10745332] ">Shenoi 1999</a>; <a href="./references#CD001090-bbs2-0039" title="WeismanLE , StollBJ , KueserTJ , RubioTT , FrankCG , HeimanHS , et al. Intravenous immune globulin therapy for early onset sepsis in premature neonates. Journal of Pediatrics1992;121:434‐43. [PUBMED: 1517923 ] ">Weisman 1992</a>) of eight trials in neonates included adverse events in their reports. </p> </section> <section id="CD001090-sec-0067"> <h4 class="title">Other potential sources of bias</h4> <p>Two polyclonal IVIG trials in adults (<a href="./references#CD001090-bbs2-0024" title="JustHM , MetzgerM , VogelW , PelkaRB . Effect of adjuvant immunoglobulin therapy in patients in a surgical intensive care unit. Results of a randomized controlled study [Einfluss einer adjuvanten Immunglobulintherapie auf Infektionen bei Patienten einer operativen Intensiv‐Therapie‐Station.]. Klinische Wochenschrift1986;64:245‐56. [PUBMED: 3713101] ">Just 1986</a>; <a href="./references#CD001090-bbs2-0041" title="WesolyC , KippingN , GrundmannR . Immunoglobulin therapy of postoperative sepsis [Immunglobulintherapie der postoperativen Sepsis]. Zeitschrift für experimentelle Chirurgie, Transplantation, und künstliche Organe: Organ der Sektion Experimentelle Chirurgie der Gesellschaft für Chirurgie der DDR1990;23:213‐6. [CENTRAL: CN‐00075746; PUBMED: 2095647] ">Wesoly 1990</a>) and one in neonates (<a href="./references#CD001090-bbs2-0037" title="ShenoiA , NageshNK , MaiyaPP , BhatSR , Subba RaoSD . Multicenter randomized placebo controlled trial of therapy with intravenous immunoglobulin in decreasing mortality due to neonatal sepsis. Indian Pediatrics1999;36:1113‐8. [PUBMED: 10745332] ">Shenoi 1999</a>) had significant differences in the baseline characteristics of the treatment and control groups, which could have influenced the outcome. </p> <p>Three monoclonal studies were assessed as having a high risk of bias in terms of significant differences in the baseline characteristics of the treatment and control groups that could have influenced the outcome: monoclonal antibody to Enterobacteriaceae (<a href="./references#CD001090-bbs2-0003" title="AlbertsonTE , PanacekEA , MacArthurRD , JohnsonSB , BenjaminE , MatsuchakG , et al. Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram‐negative sepsis. Critical Care Medicine2003;31:419‐27. [PUBMED: 12576946 ] ">Albertson 2003</a>); anti‐TNF alpha (<a href="./references#CD001090-bbs2-0014" title="DhainautJF , VincentJL , RichardC , LejeuneP , MartinC , FierobeL , et al. CDP 571, a humanized antibody to human tumor necrosis factor alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group. Critical Care Medicine1995;23:1461‐9. [PUBMED: 7664546 ] ">Dhainaut 1995</a>); and anti‐LPS (<a href="./references#CD001090-bbs2-0026" title="LachmanE , PitsoeSB , GaffinSL . Anti‐lipopolysaccharide immunotherapy in management of septic shock of obstetric and gynecological origin. Lancet1984;1:981‐3. [PUBMED: 6143965] ">Lachman 1984</a>). </p> </section> </section> <section id="CD001090-sec-0068"> <h3 class="title" id="CD001090-sec-0068">Effects of interventions</h3> <p>See: <a href="./full#CD001090-tbl-0001"><b>Summary of findings for the main comparison</b> Polyclonal intravenous immunoglobulin (IVIG) versus placebo or no intervention for sepsis, severe sepsis and septic shock</a>; <a href="./full#CD001090-tbl-0002"><b>Summary of findings 2</b> Polyclonal intravenous immunoglobulin (IVIG) versus placebo or no intervention for sepsis, severe sepsis and septic shock</a>; <a href="./full#CD001090-tbl-0003"><b>Summary of findings 3</b> Monoclonal antibodies compared to placebo for sepsis, severe sepsis, septic shock</a>; <a href="./full#CD001090-tbl-0004"><b>Summary of findings 4</b> Monoclonal antibodies compared to placebo for sepsis, severe sepsis, septic shock</a> </p> <section id="CD001090-sec-0069"> <h4 class="title">All‐cause mortality across all IVIG preparations</h4> <p>Forty‐three trials fulfilled the inclusion criteria. A pooled analysis of all the IVIG preparations was not done because of clinical heterogeneity. </p> <p>The outcomes were analysed according to the type of IVIG preparation because of the structural differences and the varying mechanisms of action of polyclonal and monoclonal IVIGs, as planned in the protocol. </p> </section> <section id="CD001090-sec-0070"> <h4 class="title">All‐cause mortality by type of immunoglobulin and age group</h4> <section id="CD001090-sec-0071"> <h5 class="title">Polyclonal IVIG in adults</h5> <p>Subgroup analysis of 17 polyclonal IVIG trials in adults with sepsis (n = 1958) demonstrated that polyclonal IVIG significantly reduced short‐term mortality (RR 0.77; 95% CI 0.68 to 0.87) but with some degree of heterogeneity across the trials (P = 0.07, I<sup>2</sup> = 36%) (<a href="./references#CD001090-fig-0009" title="">Analysis 2.1</a>). Further subgroup analysis according to type of polyclonal IVIG likewise showed significant reductions in mortality for those participants given standard polyclonal IVIG (RR 0.81; 95% CI 0.70 to 0.93; 10 trials, n = 1430) or IgM‐enriched polyclonal IVIG (RR 0.66; 95% CI 0.51 to 0.85; 7 trials, n = 528). The trials of standard polyclonal IVIG had some degree of heterogeneity (P = 0.04, I<sup>2</sup> = 48%) while the trials of IgM‐enriched polyclonal IVIG were not heterogenous (P = 0.47, I<sup>2</sup> = 0%). However, sensitivity analysis using the five trials with low risk of bias, three using standard polyclonal IVIG in adults (<a href="./references#CD001090-bbs2-0008" title="BurnsER , LeeV , RubinsteinA . Treatment of septic thrombocytopenia with immune globulin. Journal of Clinical Immunology1991;11:363‐8. [PUBMED: 1761642] ">Burns 1991</a>; <a href="./references#CD001090-bbs2-0011" title="DarenbergJ , IhendyaneN , SjölinJ , AufwerberE , HaidlS , FollinP , et al. StreptIg Study Group. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double‐blind placebo‐controlled trial. Clinical Infectious Diseases2003;37:333‐40. [PUBMED: 12884156 ] ">Darenberg 2003</a>; <a href="./references#CD001090-bbs2-0040" title="WerdanK , PilzG , BujdosoO , FraubergerP , NeeserG , SchmeiderRE , et al. Score‐based immunoglobulin G therapy of patients with sepsis: The SBITS study. Critical Care Medicine2007;35:2693‐701. [PUBMED: 18074471] ">Werdan 2007</a>) and two of IgM‐enriched IVIG in adults (<a href="./references#CD001090-bbs2-0023" title="HentrichM , FehnleK , OstermannH , KlenastJ , CornelyO , SalatC , et al. IgMA‐enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple‐center trial. Critical Care Medicine2006;34:1319‐25. [PUBMED: 16540956] ">Hentrich 2006</a>; <a href="./references#CD001090-bbs2-0034" title="RodriguezA , RelloJ , NeiraJ , MaskinB , CerasoD , VastaL , et al. Effects of high‐dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery. Shock2005;23:298‐304. [PUBMED: 15803051 ] ">Rodriguez 2005)</a>, did not show a significant reduction in mortality (RR 0.97; 95% CI 0.81 to 1.15; n = 945) (<a href="#CD001090-fig-0004">Figure 4</a>; <a href="./references#CD001090-fig-0010" title="">Analysis 2.2</a>). The test for heterogeneity was not significant (P = 0.34, I<sup>2</sup> = 12%). </p> <div class="figure" id="CD001090-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Polyclonal IVIG versus placebo or no intervention, outcome: all‐cause mortality by type of polyclonal IVIG, sensitivity analysis, low risk of bias trials." data-id="CD001090-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Polyclonal IVIG versus placebo or no intervention, outcome: all‐cause mortality by type of polyclonal IVIG, sensitivity analysis, low risk of bias trials. </p> </div> </div> </div> <p>The trials that reported long‐term mortality, at 60 days (<a href="./references#CD001090-bbs2-0023" title="HentrichM , FehnleK , OstermannH , KlenastJ , CornelyO , SalatC , et al. IgMA‐enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple‐center trial. Critical Care Medicine2006;34:1319‐25. [PUBMED: 16540956] ">Hentrich 2006</a>) and 180 days (<a href="./references#CD001090-bbs2-0011" title="DarenbergJ , IhendyaneN , SjölinJ , AufwerberE , HaidlS , FollinP , et al. StreptIg Study Group. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double‐blind placebo‐controlled trial. Clinical Infectious Diseases2003;37:333‐40. [PUBMED: 12884156 ] ">Darenberg 2003</a>), likewise showed no significant reduction in mortality (29.6% versus 34.7%, P = 0.50; 2/10 versus 4/36, respectively). </p> <p>Meta‐analysis using a random‐effects model showed significant reduction in mortality (RR 0.70; 95% CI 0.58 to 0.84) (<a href="./references#CD001090-fig-0007" title="">Analysis 1.1</a>) but this reduction was not seen when only trials with low risk of bias were analysed (RR 0.94; 95% CI 0.74 to 1.18) (<a href="./references#CD001090-fig-0008" title="">Analysis 1.2</a>). </p> </section> <section id="CD001090-sec-0072"> <h5 class="title">Polyclonal IVIG in neonates</h5> <p>Post hoc subanalysis of eight polyclonal IVIG trials in neonates with sepsis showed that polyclonal IVIG did not reduce mortality (RR 0.98; 95% CI 0.91 to 1.07); there was no significant heterogeneity (P = 0.71, I<sup>2</sup> = 0%). Likewise, no significant reduction in mortality was observed with standard polyclonal IVIG (RR 1.00; 95% CI 0.92 to 1.08; n = 3667) or IgM‐enriched polyclonal IVIG (RR 0.57; 95% CI 0.31 to 1.04; n = 164) (<a href="./references#CD001090-fig-0011" title="">Analysis 2.3</a>). Sensitivity analysis of three trials on standard IVIG with low risk of bias (<a href="./references#CD001090-bbs2-0007" title="The INIS Collaborative Group. Treatment of neonatal sepsis with intravenous immune globulin. The New England Journal of Medicine2011;365:1201‐11. The INIS Study Collaborative Group. The INIS Study. International Neonatal Immunotherapy Study: Non‐specific intravenous immunoglobulin therapy for suspected or proven neonatal sepsis: an international, placebo‐controlled, multicentre randomised trial. BMC Pregnancy and Childbirth2008;8:1‐13. ">Brocklehurst 2011</a>; <a href="./references#CD001090-bbs2-0028" title="Mancilla‐RamírezJ , González‐YunesR , Castellanos‐CruzC , García‐RocaP , Santos‐PreciadoJI . Intravenous immunoglobulin in the treatment of neonatal septicemia [Inmunoglobulina intravenosa en el tratamiento de septicemia neonatal.]. Boletín Médico del Hospital Infantil de México1992;49:4‐11. [PUBMED: 1304766] ">Mancilla‐Ramirez 1992</a>; <a href="./references#CD001090-bbs2-0039" title="WeismanLE , StollBJ , KueserTJ , RubioTT , FrankCG , HeimanHS , et al. Intravenous immune globulin therapy for early onset sepsis in premature neonates. Journal of Pediatrics1992;121:434‐43. [PUBMED: 1517923 ] ">Weisman 1992</a>) also showed no significant reduction in mortality (RR 1.01; 95% CI 0.93 to 1.09; n = 3561) (<a href="#CD001090-fig-0004">Figure 4</a>; <a href="./references#CD001090-fig-0012" title="">Analysis 2.4</a>). Tests for heterogeneity were not significant for both the subgroup and sensitivity analyses. </p> <p>Random‐effects model meta‐analysis likewise showed no significant reduction in mortality both for all eight trials on neonatal sepsis (RR 0.99; 95% CI 0.91 to 1.07) (<a href="./references#CD001090-fig-0007" title="">Analysis 1.1</a>) and when only the trials with low risk of bias were analysed (RR 0.81; 95% CI 0.46 to 1.42) (<a href="./references#CD001090-fig-0008" title="">Analysis 1.2</a>). </p> </section> <section id="CD001090-sec-0073"> <h5 class="title">Monoclonal immunoglobulins ‐ anti‐endotoxins</h5> <p>The eight trials of anti‐endotoxins (four E5 trials, three HA‐1A trials, one anti‐LPS trial) were heterogeneous (P = 0.02, I<sup>2</sup> = 57%), precluding an overall estimate of effect (<a href="./references#CD001090-fig-0018" title="">Analysis 3.1</a>). The apparent source of heterogeneity was the HA‐1A trial (<a href="./references#CD001090-bbs2-0043" title="ZieglerEJ , FisherCJ , SprungCL , StraubeRC , SadoffJC , FoulkeGE , et al. Treatment of gram‐negative bacteremia and septic shock with HA‐1A human monoclonal antibody against endotoxin. A randomized, double‐blind, placebo‐controlled trial. The HA‐1A Sepsis Study Group.l. The New England Journal of Medicine1991;324:429‐36. [PUBMED: 1988827] ">Ziegler 1991</a>). This trial only analysed patients with confirmed gram‐negative bacteraemia and showed a reduction in mortality while the rest of the trials did not show a survival benefit. A sensitivity analysis of one study with low risk of bias (<a href="./references#CD001090-bbs2-0012" title="DerkxB , WittesJ , McCloskeyR . Randomized, placebo‐controlled trial of HA‐1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group. Clinical Infectious Diseases1999;28:770‐7. [PUBMED: 10825037] ">Derkx 1999</a>) and five studies with uncertain risk of bias (<a href="./references#CD001090-bbs2-0004" title="AngusDC , BirminghamMC , BalkRA , ScannonPJ , CollinsD , KruseJA , et al. E5 murine monoclonal antiendotoxin antibody in gram‐negative sepsis: a randomized controlled trial. E5 Study Investigators. JAMA2000;283:1723‐30. [PUBMED: 10755499] ">Angus 2000</a>; <a href="./references#CD001090-bbs2-0006" title="BoneRC , BalkRA , FeinAM , PerlTM , WenzelRP , ReinesHD , et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized controlled trial. The E5 Sepsis Study Group. Critical Care Medicine1995;23:994‐1005. [PUBMED: 7774238] ">Bone 1995</a>; <a href="./references#CD001090-bbs2-0019" title="GreenbergRN , WilsonKM , KunzAY , WedelNI , GorelickKJ . Observations using antiendotoxin antibody (E5) as adjuvant therapy in humans with suspected with suspected serious, gram‐negative sepsis. Critical Care Medicine1992;20:730‐5. [PUBMED: 1597023] ">Greenberg 1992</a>; <a href="./references#CD001090-bbs2-0020" title="GreenmanRL , ScheinRM , MartinMA , WenzelRP , MacIntyreNR , EmmanuelG , et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram‐negative sepsis. The XOMA Sepsis Study Group. JAMA1991;266:1097‐102. [PUBMED: 1865542] ">Greenman 1991</a>; <a href="./references#CD001090-bbs2-0030" title="MacCloskeyRV , StraubeRC , SandersC , SmithSM , SmithCR . Treatment of septic shock with human monoclonal antibody HA‐1A. A randomized, double‐blind, placebo‐controlled trial. CHESS Trial Study Group. Annals of Internal Medicine1994;121:1‐5. [PUBMED: 8198341] ">McCloskey 1994</a>) revealed no significant survival benefit (RR 1.01; 95% CI 0.94 to 1.09; n = 4443) (<a href="./references#CD001090-fig-0019" title="">Analysis 3.2</a>). Likewise, a subanalysis of the four trials on E5 monoclonal antibody (<a href="./references#CD001090-bbs2-0004" title="AngusDC , BirminghamMC , BalkRA , ScannonPJ , CollinsD , KruseJA , et al. E5 murine monoclonal antiendotoxin antibody in gram‐negative sepsis: a randomized controlled trial. E5 Study Investigators. JAMA2000;283:1723‐30. [PUBMED: 10755499] ">Angus 2000</a>; <a href="./references#CD001090-bbs2-0006" title="BoneRC , BalkRA , FeinAM , PerlTM , WenzelRP , ReinesHD , et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized controlled trial. The E5 Sepsis Study Group. Critical Care Medicine1995;23:994‐1005. [PUBMED: 7774238] ">Bone 1995</a>; <a href="./references#CD001090-bbs2-0019" title="GreenbergRN , WilsonKM , KunzAY , WedelNI , GorelickKJ . Observations using antiendotoxin antibody (E5) as adjuvant therapy in humans with suspected with suspected serious, gram‐negative sepsis. Critical Care Medicine1992;20:730‐5. [PUBMED: 1597023] ">Greenberg 1992</a>; <a href="./references#CD001090-bbs2-0020" title="GreenmanRL , ScheinRM , MartinMA , WenzelRP , MacIntyreNR , EmmanuelG , et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram‐negative sepsis. The XOMA Sepsis Study Group. JAMA1991;266:1097‐102. [PUBMED: 1865542] ">Greenman 1991</a>) showed no reduction in mortality (RR 0.98; 95% CI 0.88 to 1.10; n = 1975) (<a href="./references#CD001090-fig-0018" title="">Analysis 3.1</a>). Tests for heterogeneity were not significant for both the sensitivity (P = 0.26, I<sup>2</sup> = 23%) and subgroup (P = 0.64, I<sup>2</sup> = 0%) analyses. The three trials of HA‐1A antibody (<a href="./references#CD001090-bbs2-0012" title="DerkxB , WittesJ , McCloskeyR . Randomized, placebo‐controlled trial of HA‐1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group. Clinical Infectious Diseases1999;28:770‐7. [PUBMED: 10825037] ">Derkx 1999</a>; <a href="./references#CD001090-bbs2-0030" title="MacCloskeyRV , StraubeRC , SandersC , SmithSM , SmithCR . Treatment of septic shock with human monoclonal antibody HA‐1A. A randomized, double‐blind, placebo‐controlled trial. CHESS Trial Study Group. Annals of Internal Medicine1994;121:1‐5. [PUBMED: 8198341] ">McCloskey 1994</a>; <a href="./references#CD001090-bbs2-0043" title="ZieglerEJ , FisherCJ , SprungCL , StraubeRC , SadoffJC , FoulkeGE , et al. Treatment of gram‐negative bacteremia and septic shock with HA‐1A human monoclonal antibody against endotoxin. A randomized, double‐blind, placebo‐controlled trial. The HA‐1A Sepsis Study Group.l. The New England Journal of Medicine1991;324:429‐36. [PUBMED: 1988827] ">Ziegler 1991</a>) were significantly heterogeneous (P = 0.005, I<sup>2</sup> = 81%), which could be due to differences in study population and methodologic quality. The trial of <a href="./references#CD001090-bbs2-0012" title="DerkxB , WittesJ , McCloskeyR . Randomized, placebo‐controlled trial of HA‐1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group. Clinical Infectious Diseases1999;28:770‐7. [PUBMED: 10825037] ">Derkx 1999</a> involved children with a presumptive diagnosis of meningococcal septic shock; <a href="./references#CD001090-bbs2-0030" title="MacCloskeyRV , StraubeRC , SandersC , SmithSM , SmithCR . Treatment of septic shock with human monoclonal antibody HA‐1A. A randomized, double‐blind, placebo‐controlled trial. CHESS Trial Study Group. Annals of Internal Medicine1994;121:1‐5. [PUBMED: 8198341] ">McCloskey 1994</a> included patients with gram‐negative bacteraemia and septic shock; while <a href="./references#CD001090-bbs2-0043" title="ZieglerEJ , FisherCJ , SprungCL , StraubeRC , SadoffJC , FoulkeGE , et al. Treatment of gram‐negative bacteremia and septic shock with HA‐1A human monoclonal antibody against endotoxin. A randomized, double‐blind, placebo‐controlled trial. The HA‐1A Sepsis Study Group.l. The New England Journal of Medicine1991;324:429‐36. [PUBMED: 1988827] ">Ziegler 1991</a> selectively analysed patients with confirmed gram‐negative bacteraemia. </p> </section> <section id="CD001090-sec-0074"> <h5 class="title">Monoclonal immunoglobulins ‐ anti‐cytokines</h5> <p>Pooled analysis of the nine trials on anti‐cytokines (six anti‐TNF alpha trials, three recombinant human IL‐1 receptor antagonist (rh IL‐1ra) trials) (<a href="./references#CD001090-fig-0020" title="">Analysis 3.3</a>) revealed a small but significant reduction in mortality (RR 0.92; 95% CI 0.86 to 0.97; n = 7893) with no significant heterogeneity (P = 0.76, I<sup>2</sup> = 0%). Sensitivity analysis of three trials with low risk of bias (<a href="./references#CD001090-bbs2-0002" title="AbrahamE , AnzuetoA , GutierrezG , TesslerS , San PedroG , WunderinkR , et al. Double‐blind randomized controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock.NORASEPT II Study Group. Lancet1998;351:929‐33. [PUBMED: 9734938] ">Abraham 1998</a>; <a href="./references#CD001090-bbs2-0010" title="CohenJ , CarletJ . INTERSEPT: an international, multicenter, placebo‐controlled‐trial of monoclonal antibody to human tumor necrosis factor‐alpha in patients with sepsis. International Sepsis Trial Study Group. Critical Care Medicine1996;24:1431‐40. [PUBMED: 8797612 ] ">Cohen 1996</a>; <a href="./references#CD001090-bbs2-0032" title="PanacekEA , MarshallJC , AlbertsonTE , JohnsonDH , JohnsonS , MacArthurRD , et al. Monoclonal Anti‐TNF: Randomized Controlled Sepsis Study Investigators. Efficacy and safety of the monoclonal anti‐‐tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin‐6 levels. Critical Care Medicine2004;32:2173‐82. [PUBMED: 15640628 ] ">Panacek 2004</a>) and four studies with uncertain risk of bias (<a href="./references#CD001090-bbs2-0001" title="AbrahamE , WunderinkR , SilvermanH , PerlTM , NasrawayS , LevyH , et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled double‐blind, multicenter clinical trial. TNF‐alpha MAb Sepsis Study group. JAMA1995;273:934‐41. [PUBMED: 7884952] ">Abraham 1995</a>; <a href="./references#CD001090-bbs2-0017" title="FisherCJJr , SlotmanGJ , OpalSM , PribbleJP , BoneRC , EmmanuelG , et al. IL‐1RA Sepsis Syndrome Study Group. Initial evaluation of human recombinant interleukin‐1 receptor antagonist in the treatment of sepsis syndrome: a randomized open‐label, placebo‐controlled multicenter trial. Critical Care Medicine1994;22:12‐21. [PUBMED: 8124953] ">Fisher 1994a</a>; <a href="./references#CD001090-bbs2-0018" title="FisherCJJr , DhainautJF , OpalSM , PribbleJP , BalkRA , SlotmanGJ , et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: Results from a randomized double‐blind, placebo‐controlled trial. Phase III rhIL‐1ra Sepsis Syndrome Study Group. JAMA1994;271:1836‐43. ">Fisher 1994b</a>; <a href="./references#CD001090-bbs2-0031" title="OpalSM , FisherCJ , DhainautJF , VincentJL , BraseR , LowrySF , et al. Confirmatory interleukin‐1 receptor antagonist trial in severe sepsis: A phase III, randomized, double‐blind, placebo‐controlled, multicenter trial. The Interleukin‐1 Receptor Antagonist Sepsis Investigator Group. Critical Care Medicine1997;25:1115‐24. [PUBMED: 9233735] ">Opal 1997</a>) showed a marginal reduction in mortality (RR 0.91; 95% CI 0.86 to 0.97; n = 7648) (<a href="./references#CD001090-fig-0021" title="">Analysis 3.4</a>). Likewise, sensitivity analysis of the three studies with low risk of bias (<a href="./references#CD001090-bbs2-0002" title="AbrahamE , AnzuetoA , GutierrezG , TesslerS , San PedroG , WunderinkR , et al. Double‐blind randomized controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock.NORASEPT II Study Group. Lancet1998;351:929‐33. [PUBMED: 9734938] ">Abraham 1998</a>; <a href="./references#CD001090-bbs2-0010" title="CohenJ , CarletJ . INTERSEPT: an international, multicenter, placebo‐controlled‐trial of monoclonal antibody to human tumor necrosis factor‐alpha in patients with sepsis. International Sepsis Trial Study Group. Critical Care Medicine1996;24:1431‐40. [PUBMED: 8797612 ] ">Cohen 1996</a>; <a href="./references#CD001090-bbs2-0032" title="PanacekEA , MarshallJC , AlbertsonTE , JohnsonDH , JohnsonS , MacArthurRD , et al. Monoclonal Anti‐TNF: Randomized Controlled Sepsis Study Investigators. Efficacy and safety of the monoclonal anti‐‐tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin‐6 levels. Critical Care Medicine2004;32:2173‐82. [PUBMED: 15640628 ] ">Panacek 2004</a>) showed a marginal reduction in mortality (RR 0.92; 95% CI 0.86 to 0.99; n = 5065). Tests of heterogeneity were not significant for both sensitivity analyses. It is important to note that the marginal benefit was contributed mainly by one large study (n = 2634) on anti‐TNF antibody F(ab')<sub>2</sub> fragment afelimomab (<a href="./references#CD001090-bbs2-0032" title="PanacekEA , MarshallJC , AlbertsonTE , JohnsonDH , JohnsonS , MacArthurRD , et al. Monoclonal Anti‐TNF: Randomized Controlled Sepsis Study Investigators. Efficacy and safety of the monoclonal anti‐‐tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin‐6 levels. Critical Care Medicine2004;32:2173‐82. [PUBMED: 15640628 ] ">Panacek 2004</a>), which showed a marginal reduction in the overall mortality and in the subgroup analysis of patients with elevated IL‐6 levels. </p> </section> <section id="CD001090-sec-0075"> <h5 class="title">Monoclonal antibody for Enterobacteriaceae common antigen</h5> <p>We included one trial on a human monoclonal IgM antibody specific for Enterobacteriaceae common antigen (ECA), which is a specific glycophospholipid surface antigen found in organisms belonging to the Enterobacteriaceae family (<a href="./references#CD001090-bbs2-0003" title="AlbertsonTE , PanacekEA , MacArthurRD , JohnsonSB , BenjaminE , MatsuchakG , et al. Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram‐negative sepsis. Critical Care Medicine2003;31:419‐27. [PUBMED: 12576946 ] ">Albertson 2003</a>). This trial did not demonstrate reduced mortality in patients with presumed and proven gram‐negative sepsis (<a href="./references#CD001090-fig-0022" title="">Analysis 3.5</a>). </p> </section> </section> <section id="CD001090-sec-0076"> <h4 class="title">Mortality from sepsis</h4> <p>Mortality from sepsis or septic shock was reported in only six trials. A subanalysis of the four adult trials on polyclonal IVIG (<a href="./references#CD001090-bbs2-0050" title="DominioniL , DionigiR , ZanelloM , ChiarandaM , DionigiR , AcquaroloA , et al. Effects of high‐dose IgG on survival of surgical patients with sepsis scores of 20 or greater. Archives of Surgery1991;126:236‐40. [PUBMED: 1992998] ">Dominioni 1991</a>; <a href="./references#CD001090-bbs2-0023" title="HentrichM , FehnleK , OstermannH , KlenastJ , CornelyO , SalatC , et al. IgMA‐enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple‐center trial. Critical Care Medicine2006;34:1319‐25. [PUBMED: 16540956] ">Hentrich 2006</a>; <a href="./references#CD001090-bbs2-0036" title="SchedelI , DreikhausenU , NentwigB , HöckenschniederM , RauthmannD , BalikciogluS , et al. Treatment of Gram‐negative septic shock and an immunoglobulin preparation: A prospective randomized clinical trial. Critical Care Medicine1991;10:1104‐13. [PUBMED: 1884609] ">Schedel 1991</a>; <a href="./references#CD001090-bbs2-0042" title="YakutM , CetinerS , AkinA , TanA , KaymakciogluN , SimsekA , et al. Effects of immunoglobulin G on surgical sepsis and septic shock [Sepsisdeki hastalarda immunoglobulin G (IGG) kulianiminin mortalite oranina etkisi]. Bulletin of Gulhane Military Medical Academy1998;40:76‐81. [CENTRAL: CN‐00200598] ">Yakut 1998</a>) demonstrated a significant decrease in mortality from septic shock (RR 0.45; 95% CI 0.29 to 0.69) (<a href="./references#CD001090-fig-0013" title="">Analysis 2.5</a>). The trials were significantly heterogeneous (P = 0.03, I<sup>2</sup> = 66%) probably due to differences in study population (<a href="./references#CD001090-fig-0013" title="">Analysis 2.5</a>). The largest trial, with a low risk of bias (<a href="./references#CD001090-bbs2-0023" title="HentrichM , FehnleK , OstermannH , KlenastJ , CornelyO , SalatC , et al. IgMA‐enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple‐center trial. Critical Care Medicine2006;34:1319‐25. [PUBMED: 16540956] ">Hentrich 2006</a>), was conducted on neutropenic patients with haematologic malignancies and did not show any reduction in mortality from sepsis; the small trials on surgical patients (<a href="./references#CD001090-bbs2-0015" title="DominioniL , BianchiV , ImperatoriA , MinoiaG , DionigiR . High‐dose intravenous IgG for treatment of severe surgical infections. Digestive Surgery1996;13:430‐4. [CENTRAL: CN‐00169903; PUBMED: 1996308558] ">Dominioni 1996</a>; <a href="./references#CD001090-bbs2-0042" title="YakutM , CetinerS , AkinA , TanA , KaymakciogluN , SimsekA , et al. Effects of immunoglobulin G on surgical sepsis and septic shock [Sepsisdeki hastalarda immunoglobulin G (IGG) kulianiminin mortalite oranina etkisi]. Bulletin of Gulhane Military Medical Academy1998;40:76‐81. [CENTRAL: CN‐00200598] ">Yakut 1998</a>) and adults with gram‐negative septic shock (<a href="./references#CD001090-bbs2-0036" title="SchedelI , DreikhausenU , NentwigB , HöckenschniederM , RauthmannD , BalikciogluS , et al. Treatment of Gram‐negative septic shock and an immunoglobulin preparation: A prospective randomized clinical trial. Critical Care Medicine1991;10:1104‐13. [PUBMED: 1884609] ">Schedel 1991</a>) showed reductions in mortality. The monoclonal trial of E5 antibody (<a href="./references#CD001090-bbs2-0006" title="BoneRC , BalkRA , FeinAM , PerlTM , WenzelRP , ReinesHD , et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized controlled trial. The E5 Sepsis Study Group. Critical Care Medicine1995;23:994‐1005. [PUBMED: 7774238] ">Bone 1995</a>) and the polyclonal IVIG trial on neonates (<a href="./references#CD001090-bbs2-0016" title="ErdemG , YurdakökM , TekinalpG , ErsoyF . The use of IgM‐enriched intravenous immunoglobulin for the treatment of neonatal sepsis in preterm infants. The Turkish Journal of Pediatrics1993;35:277‐81. [PUBMED: 8160279] ">Erdem 1993</a>) did not reduce mortality from sepsis. </p> </section> <section id="CD001090-sec-0077"> <h4 class="title">Other outcomes</h4> <p>Length of hospital stay among survivors was reported as a secondary outcome measure in 11 polyclonal IVIG trials and one monoclonal IVIG trial (<a href="./references#CD001090-bbs2-0026" title="LachmanE , PitsoeSB , GaffinSL . Anti‐lipopolysaccharide immunotherapy in management of septic shock of obstetric and gynecological origin. Lancet1984;1:981‐3. [PUBMED: 6143965] ">Lachman 1984</a>). A subanalysis of the six polyclonal trials in adults (<a href="./references#CD001090-bbs2-0015" title="DominioniL , BianchiV , ImperatoriA , MinoiaG , DionigiR . High‐dose intravenous IgG for treatment of severe surgical infections. Digestive Surgery1996;13:430‐4. [CENTRAL: CN‐00169903; PUBMED: 1996308558] ">Dominioni 1996</a>; <a href="./references#CD001090-bbs2-0021" title="GrundmannR , HornungM . Immunoglobulin therapy in patients with endotoxemia and postoperative sepsis ‐ a prospective randomized study. Progress in Clinical and Biological Research1988;272:339‐49. [PUBMED: 3293080] ">Grundmann 1988</a>; <a href="./references#CD001090-bbs2-0024" title="JustHM , MetzgerM , VogelW , PelkaRB . Effect of adjuvant immunoglobulin therapy in patients in a surgical intensive care unit. Results of a randomized controlled study [Einfluss einer adjuvanten Immunglobulintherapie auf Infektionen bei Patienten einer operativen Intensiv‐Therapie‐Station.]. Klinische Wochenschrift1986;64:245‐56. [PUBMED: 3713101] ">Just 1986</a>; <a href="./references#CD001090-bbs2-0027" title="LindquistL , LundberghP , MaasingR . Pepsin‐treated human gamma globulin in bacterial infections. A randomized study in patients with septicemia and pneumonia. Vox Sanguinis1981;40:329‐37. [PUBMED: 6166128 ] ">Lindquist 1981</a>; <a href="./references#CD001090-bbs2-0038" title="TugrulS , OzcanPE , AkinciO , SeyhunY , CagatayA , CakarN , et al. The effects of IgM‐enriched immunoglobulin preparations in patients with severe sepsis [ISRCTN28863830]. Critical Care2002;6:357‐62. [PUBMED: 12225613] ">Tugrul 2002</a>; <a href="./references#CD001090-bbs2-0041" title="WesolyC , KippingN , GrundmannR . Immunoglobulin therapy of postoperative sepsis [Immunglobulintherapie der postoperativen Sepsis]. Zeitschrift für experimentelle Chirurgie, Transplantation, und künstliche Organe: Organ der Sektion Experimentelle Chirurgie der Gesellschaft für Chirurgie der DDR1990;23:213‐6. [CENTRAL: CN‐00075746; PUBMED: 2095647] ">Wesoly 1990</a>) showed no significant reduction in the length of hospital stay in the IVIG group (MD ‐3.00; 95% CI ‐6.37 to 0.38) and there was no significant heterogeneity (<a href="./references#CD001090-fig-0014" title="">Analysis 2.6</a>; subgroup1). These six trials were assessed as having uncertain risk of bias. </p> <p>Subanalysis of five polyclonal IVIG trials on neonates demonstrated a significant reduction in mortality in the IVIG group (MD ‐5.84; 95% CI ‐9.72 to ‐1.95) but there was moderate heterogeneity (P = 0.11, I<sup>2</sup> = 55%). Sensitivity analysis of trials with low risk of bias (<a href="./references#CD001090-bbs2-0039" title="WeismanLE , StollBJ , KueserTJ , RubioTT , FrankCG , HeimanHS , et al. Intravenous immune globulin therapy for early onset sepsis in premature neonates. Journal of Pediatrics1992;121:434‐43. [PUBMED: 1517923 ] ">Weisman 1992</a>) and uncertain risk of bias (<a href="./references#CD001090-bbs2-0009" title="ChenJY . Intravenous immunoglobulin in the treatment of full term and premature newborns with sepsis. Journal of the Formosan Medical Association: Taiwan Yi Zhi1996;11:839‐44. [PUBMED: 8990771] ">Chen 1996</a>; <a href="./references#CD001090-bbs2-0035" title="SamathaS , JalaluMP , HegdeRK , VishwanathD , MaiyaPP . Role of IgM‐enriched intravenous immunoglobulin as an adjuvant to antibiotics in neonatal sepsis. Karnataka Pediatric Journal1997;11:1‐6. ">Samatha 1997</a>) did not demonstrate any reduction in the duration of hospital stay (<a href="./references#CD001090-fig-0015" title="">Analysis 2.7</a>). The large multi‐centre trial on polyclonal IVIG (<a href="./references#CD001090-bbs2-0007" title="The INIS Collaborative Group. Treatment of neonatal sepsis with intravenous immune globulin. The New England Journal of Medicine2011;365:1201‐11. The INIS Study Collaborative Group. The INIS Study. International Neonatal Immunotherapy Study: Non‐specific intravenous immunoglobulin therapy for suspected or proven neonatal sepsis: an international, placebo‐controlled, multicentre randomised trial. BMC Pregnancy and Childbirth2008;8:1‐13. ">Brocklehurst 2011</a>) likewise did not show any significant difference in the duration of hospital stay, with a median duration of 64 days (interquartile range 37 to 92 days) in the IVIG group and 64 days (interquartile range 37 to 93 days) in the placebo group. </p> <p>The bacteriological failure rate was reported in only one polyclonal IVIG trial involving adult medical and surgical patients (<a href="./references#CD001090-bbs2-0013" title="DeSimoneC , DeloguG , CorbettaG . Intravenous immunoglobulins in association with antibiotics: a therapeutic trial in septic intensive care unit patients. Critical Care Medicine1988;16:23‐6. [PUBMED: 3276446] ">De Simone 1988</a>). It showed a significantly higher bacteriological eradication rate in the IVIG group compared to the control group (40% versus 8%, P &lt; 0.01). </p> <p>Severity and duration of sepsis were not uniformly defined or stated in the various trials hence no subgroup analyses could be done for these outcomes. </p> </section> <section id="CD001090-sec-0078"> <h4 class="title">Adverse effects</h4> <p>Only seven polyclonal IVIG trials in adults and four trials in neonates included adverse events in their reports. Of the four trials on neonates, two reported no adverse events attributable to IVIG (<a href="./references#CD001090-bbs2-0035" title="SamathaS , JalaluMP , HegdeRK , VishwanathD , MaiyaPP . Role of IgM‐enriched intravenous immunoglobulin as an adjuvant to antibiotics in neonatal sepsis. Karnataka Pediatric Journal1997;11:1‐6. ">Samatha 1997</a>; <a href="./references#CD001090-bbs2-0037" title="ShenoiA , NageshNK , MaiyaPP , BhatSR , Subba RaoSD . Multicenter randomized placebo controlled trial of therapy with intravenous immunoglobulin in decreasing mortality due to neonatal sepsis. Indian Pediatrics1999;36:1113‐8. [PUBMED: 10745332] ">Shenoi 1999</a>) and one trial (<a href="./references#CD001090-bbs2-0039" title="WeismanLE , StollBJ , KueserTJ , RubioTT , FrankCG , HeimanHS , et al. Intravenous immune globulin therapy for early onset sepsis in premature neonates. Journal of Pediatrics1992;121:434‐43. [PUBMED: 1517923 ] ">Weisman 1992</a>) reported two suspected infusion‐related adverse reactions, specifically hypotension and hypoglycaemia. In the large polyclonal IVIG trial on neonates (<a href="./references#CD001090-bbs2-0007" title="The INIS Collaborative Group. Treatment of neonatal sepsis with intravenous immune globulin. The New England Journal of Medicine2011;365:1201‐11. The INIS Study Collaborative Group. The INIS Study. International Neonatal Immunotherapy Study: Non‐specific intravenous immunoglobulin therapy for suspected or proven neonatal sepsis: an international, placebo‐controlled, multicentre randomised trial. BMC Pregnancy and Childbirth2008;8:1‐13. ">Brocklehurst 2011</a>), no significant differences in adverse events were found. </p> <p>In adults, adverse events reported as likely to be related to polyclonal IVIG were allergic reactions (<a href="./references#CD001090-bbs2-0023" title="HentrichM , FehnleK , OstermannH , KlenastJ , CornelyO , SalatC , et al. IgMA‐enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple‐center trial. Critical Care Medicine2006;34:1319‐25. [PUBMED: 16540956] ">Hentrich 2006</a>; <a href="./references#CD001090-bbs2-0040" title="WerdanK , PilzG , BujdosoO , FraubergerP , NeeserG , SchmeiderRE , et al. Score‐based immunoglobulin G therapy of patients with sepsis: The SBITS study. Critical Care Medicine2007;35:2693‐701. [PUBMED: 18074471] ">Werdan 2007</a>); skin reactions such as erythema and exanthem (<a href="./references#CD001090-bbs2-0023" title="HentrichM , FehnleK , OstermannH , KlenastJ , CornelyO , SalatC , et al. IgMA‐enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple‐center trial. Critical Care Medicine2006;34:1319‐25. [PUBMED: 16540956] ">Hentrich 2006</a>; <a href="./references#CD001090-bbs2-0040" title="WerdanK , PilzG , BujdosoO , FraubergerP , NeeserG , SchmeiderRE , et al. Score‐based immunoglobulin G therapy of patients with sepsis: The SBITS study. Critical Care Medicine2007;35:2693‐701. [PUBMED: 18074471] ">Werdan 2007</a>); pruritus (<a href="./references#CD001090-bbs2-0029" title="MasaokaT , HasegawaH , TakakuF , MizoguchiH , AsanoS , IkedaY , et al. The efficacy of intravenous immunoglobulin in combination therapy with antibiotics for severe infections. Japanese Journal of Chemotherapy2000;48:199‐217. [CENTRAL: CN‐00418781; EMBASE: 2000159529] ">Masaoka 2000</a>); nausea and vomiting (<a href="./references#CD001090-bbs2-0023" title="HentrichM , FehnleK , OstermannH , KlenastJ , CornelyO , SalatC , et al. IgMA‐enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple‐center trial. Critical Care Medicine2006;34:1319‐25. [PUBMED: 16540956] ">Hentrich 2006</a>; <a href="./references#CD001090-bbs2-0027" title="LindquistL , LundberghP , MaasingR . Pepsin‐treated human gamma globulin in bacterial infections. A randomized study in patients with septicemia and pneumonia. Vox Sanguinis1981;40:329‐37. [PUBMED: 6166128 ] ">Lindquist 1981</a>; <a href="./references#CD001090-bbs2-0029" title="MasaokaT , HasegawaH , TakakuF , MizoguchiH , AsanoS , IkedaY , et al. The efficacy of intravenous immunoglobulin in combination therapy with antibiotics for severe infections. Japanese Journal of Chemotherapy2000;48:199‐217. [CENTRAL: CN‐00418781; EMBASE: 2000159529] ">Masaoka 2000</a>); dyspnoea (<a href="./references#CD001090-bbs2-0029" title="MasaokaT , HasegawaH , TakakuF , MizoguchiH , AsanoS , IkedaY , et al. The efficacy of intravenous immunoglobulin in combination therapy with antibiotics for severe infections. Japanese Journal of Chemotherapy2000;48:199‐217. [CENTRAL: CN‐00418781; EMBASE: 2000159529] ">Masaoka 2000</a>); congestion (<a href="./references#CD001090-bbs2-0040" title="WerdanK , PilzG , BujdosoO , FraubergerP , NeeserG , SchmeiderRE , et al. Score‐based immunoglobulin G therapy of patients with sepsis: The SBITS study. Critical Care Medicine2007;35:2693‐701. [PUBMED: 18074471] ">Werdan 2007</a>); shock (<a href="./references#CD001090-bbs2-0027" title="LindquistL , LundberghP , MaasingR . Pepsin‐treated human gamma globulin in bacterial infections. A randomized study in patients with septicemia and pneumonia. Vox Sanguinis1981;40:329‐37. [PUBMED: 6166128 ] ">Lindquist 1981</a>); and fever and chills (<a href="./references#CD001090-bbs2-0027" title="LindquistL , LundberghP , MaasingR . Pepsin‐treated human gamma globulin in bacterial infections. A randomized study in patients with septicemia and pneumonia. Vox Sanguinis1981;40:329‐37. [PUBMED: 6166128 ] ">Lindquist 1981</a>). Two trials reported no adverse events attributable to IVIG (<a href="./references#CD001090-bbs2-0015" title="DominioniL , BianchiV , ImperatoriA , MinoiaG , DionigiR . High‐dose intravenous IgG for treatment of severe surgical infections. Digestive Surgery1996;13:430‐4. [CENTRAL: CN‐00169903; PUBMED: 1996308558] ">Dominioni 1996</a>; <a href="./references#CD001090-bbs2-0036" title="SchedelI , DreikhausenU , NentwigB , HöckenschniederM , RauthmannD , BalikciogluS , et al. Treatment of Gram‐negative septic shock and an immunoglobulin preparation: A prospective randomized clinical trial. Critical Care Medicine1991;10:1104‐13. [PUBMED: 1884609] ">Schedel 1991</a>) and one trial reported adverse events but none that were assessed as related to IVIG (<a href="./references#CD001090-bbs2-0011" title="DarenbergJ , IhendyaneN , SjölinJ , AufwerberE , HaidlS , FollinP , et al. StreptIg Study Group. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double‐blind placebo‐controlled trial. Clinical Infectious Diseases2003;37:333‐40. [PUBMED: 12884156 ] ">Darenberg 2003</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001090-sec-0079" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001090-sec-0079"></div> <section id="CD001090-sec-0080"> <h3 class="title" id="CD001090-sec-0080">Summary of main results</h3> <p>The use of novel immunotherapeutic agents to combat the intense endotoxin and inflammatory mediator excesses in sepsis has been of major interest in the past decade. This updated meta‐analysis conclusively showed that standard polyclonal IVIGs did not decrease mortality among neonates with sepsis, with the inclusion of the large multi‐centre high quality trial on polyclonal standard IVIG (<a href="./references#CD001090-bbs2-0007" title="The INIS Collaborative Group. Treatment of neonatal sepsis with intravenous immune globulin. The New England Journal of Medicine2011;365:1201‐11. The INIS Study Collaborative Group. The INIS Study. International Neonatal Immunotherapy Study: Non‐specific intravenous immunoglobulin therapy for suspected or proven neonatal sepsis: an international, placebo‐controlled, multicentre randomised trial. BMC Pregnancy and Childbirth2008;8:1‐13. ">Brocklehurst 2011</a>) (<a href="./full#CD001090-tbl-0001">summary of findings Table for the main comparison</a>). Likewise, among adults with sepsis no reduction in mortality was observed with standard polyclonal IVIG in high quality trials (<a href="./full#CD001090-tbl-0002">summary of findings Table 2</a>). However, for IgM‐enriched polyclonal IVIGs, the evidence of benefit remains insufficient and inconclusive for both adults and neonates with sepsis because of the paucity of large, high quality trials (<a href="#CD001090-fig-0005">Figure 5</a>; <a href="#CD001090-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD001090-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 2 Polyclonal IVIG versus placebo or no intervention, outcome: 2.1 All‐cause mortality, adults, by type of polyclonal IVIG." data-id="CD001090-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 2 Polyclonal IVIG versus placebo or no intervention, outcome: 2.1 All‐cause mortality, adults, by type of polyclonal IVIG. </p> </div> </div> </div> <div class="figure" id="CD001090-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 2 Polyclonal IVIG versus placebo or no intervention, outcome: 2.3 All‐cause mortality, neonates, by type of polyclonal IVIG." data-id="CD001090-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 2 Polyclonal IVIG versus placebo or no intervention, outcome: 2.3 All‐cause mortality, neonates, by type of polyclonal IVIG. </p> </div> </div> </div> <p>None of the monoclonal IVIG preparations to date show clinically significant benefit for patients with sepsis. The pooled as well as subgroup analyses of randomized controlled trials of these experimental agents do not demonstrate a significant reduction in mortality among patients with severe sepsis or septic shock. Furthermore, the large trials on E5 (<a href="./references#CD001090-bbs2-0004" title="AngusDC , BirminghamMC , BalkRA , ScannonPJ , CollinsD , KruseJA , et al. E5 murine monoclonal antiendotoxin antibody in gram‐negative sepsis: a randomized controlled trial. E5 Study Investigators. JAMA2000;283:1723‐30. [PUBMED: 10755499] ">Angus 2000</a>) and anti‐TNF alpha (<a href="./references#CD001090-bbs2-0002" title="AbrahamE , AnzuetoA , GutierrezG , TesslerS , San PedroG , WunderinkR , et al. Double‐blind randomized controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock.NORASEPT II Study Group. Lancet1998;351:929‐33. [PUBMED: 9734938] ">Abraham 1998</a>) failed to demonstrate any significant benefit in the overall mortality analysis and the post hoc subgroup analysis based on presence of shock, co‐morbidity, organ failure, site of infection, and type of organism. A trial on human monoclonal IgM antibody that is specific against Enterobacteriaceae likewise did not decrease mortality (<a href="./references#CD001090-bbs2-0003" title="AlbertsonTE , PanacekEA , MacArthurRD , JohnsonSB , BenjaminE , MatsuchakG , et al. Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram‐negative sepsis. Critical Care Medicine2003;31:419‐27. [PUBMED: 12576946 ] ">Albertson 2003</a>). One large trial on the anti‐TNF antibody F(ab')<sub>2</sub> fragment afelimomab (<a href="./references#CD001090-bbs2-0032" title="PanacekEA , MarshallJC , AlbertsonTE , JohnsonDH , JohnsonS , MacArthurRD , et al. Monoclonal Anti‐TNF: Randomized Controlled Sepsis Study Investigators. Efficacy and safety of the monoclonal anti‐‐tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin‐6 levels. Critical Care Medicine2004;32:2173‐82. [PUBMED: 15640628 ] ">Panacek 2004</a>) showed only marginal benefit both in the overall mortality analysis and for the patients with elevated IL‐6 levels. See <a href="./full#CD001090-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD001090-tbl-0004">summary of findings Table 4</a>. </p> </section> <section id="CD001090-sec-0081"> <h3 class="title" id="CD001090-sec-0081">Overall completeness and applicability of evidence</h3> <p>We have updated our search from 2003 to 2012 and have included all possible trials on polyclonal and monoclonal preparations for adults and neonates with sepsis. </p> <p>Investigators have postulated that polyclonal IVIG contains immunoglobulin G (IgG) and even IgM (in some preparations), which could boost the immune response of septic patients. Some authors have stressed the potential benefits for immunocompromised patients, such as neonates, who have immunoglobulin and complement deficiencies; and intensive care unit patients, who develop relative immunodepression as a consequence of severe underlying illnesses, surgery, or chemotherapy (<a href="./references#CD001090-bbs2-0009" title="ChenJY . Intravenous immunoglobulin in the treatment of full term and premature newborns with sepsis. Journal of the Formosan Medical Association: Taiwan Yi Zhi1996;11:839‐44. [PUBMED: 8990771] ">Chen 1996</a>; <a href="./references#CD001090-bbs2-0013" title="DeSimoneC , DeloguG , CorbettaG . Intravenous immunoglobulins in association with antibiotics: a therapeutic trial in septic intensive care unit patients. Critical Care Medicine1988;16:23‐6. [PUBMED: 3276446] ">De Simone 1988</a>; <a href="./references#CD001090-bbs2-0050" title="DominioniL , DionigiR , ZanelloM , ChiarandaM , DionigiR , AcquaroloA , et al. Effects of high‐dose IgG on survival of surgical patients with sepsis scores of 20 or greater. Archives of Surgery1991;126:236‐40. [PUBMED: 1992998] ">Dominioni 1991</a>; <a href="./references#CD001090-bbs2-0067" title="KornelisseRF , HazelzetJA , HopWC , SpanjaardL , SuurMH , van derVoortE , et al. Meningococcal septic shock in children: clinical and laboratory features, outcome and development of a prognostic score. Clinical Infectious Diseases1997;25:640‐6. [PUBMED: 9314453 ] ">Kornelisse 1997</a>; <a href="./references#CD001090-bbs2-0039" title="WeismanLE , StollBJ , KueserTJ , RubioTT , FrankCG , HeimanHS , et al. Intravenous immune globulin therapy for early onset sepsis in premature neonates. Journal of Pediatrics1992;121:434‐43. [PUBMED: 1517923 ] ">Weisman 1992</a>). In addition, premature infants are significantly compromised because IgG from the mother is transferred to the infant only after the 32nd week of gestation (<a href="./references#CD001090-bbs2-0009" title="ChenJY . Intravenous immunoglobulin in the treatment of full term and premature newborns with sepsis. Journal of the Formosan Medical Association: Taiwan Yi Zhi1996;11:839‐44. [PUBMED: 8990771] ">Chen 1996</a>). Thus, it has been postulated that the administration of immunoglobulin improves the opsonization and phagocytic functions of the neonates' antibodies (<a href="./references#CD001090-bbs2-0039" title="WeismanLE , StollBJ , KueserTJ , RubioTT , FrankCG , HeimanHS , et al. Intravenous immune globulin therapy for early onset sepsis in premature neonates. Journal of Pediatrics1992;121:434‐43. [PUBMED: 1517923 ] ">Weisman 1992</a>). </p> <p>Antibacterial activity is reported to be much higher with IgM‐enriched preparations compared to the standard IVIG (<a href="./references#CD001090-bbs2-0022" title="HaqueKN , ZaidiMH , BahakimH . IgM‐enriched intravenous immunoglobulin therapy in neonatal sepsis. American Journal of Diseases of Childhood1988;142:1293‐6. [PUBMED: 3195529] ">Haque 1988</a>; <a href="./references#CD001090-bbs2-0041" title="WesolyC , KippingN , GrundmannR . Immunoglobulin therapy of postoperative sepsis [Immunglobulintherapie der postoperativen Sepsis]. Zeitschrift für experimentelle Chirurgie, Transplantation, und künstliche Organe: Organ der Sektion Experimentelle Chirurgie der Gesellschaft für Chirurgie der DDR1990;23:213‐6. [CENTRAL: CN‐00075746; PUBMED: 2095647] ">Wesoly 1990</a>). The proposed mechanism of action is neutralization of endotoxin in the patient's circulation thus preventing the harmful consequences induced by the lipid‐A component of the endotoxin molecule (<a href="./references#CD001090-bbs2-0036" title="SchedelI , DreikhausenU , NentwigB , HöckenschniederM , RauthmannD , BalikciogluS , et al. Treatment of Gram‐negative septic shock and an immunoglobulin preparation: A prospective randomized clinical trial. Critical Care Medicine1991;10:1104‐13. [PUBMED: 1884609] ">Schedel 1991</a>). </p> <p>Another subgroup of septic patients for whom IVIG is proposed to be of likely benefit is those with severe invasive Group A streptococcal infections of varying serotypes. The postulated mechanisms of action include enhancement of bacterial opsonization, complement activation, antigen neutralization, and cytokine modulation resulting in suppression of pro‐inflammatory responses (<a href="./references#CD001090-bbs2-0099" title="Norrby‐TeglundA , IhendyaneN , DarenbergJ . Intravenous immunoglobulin adjunctive therapy in sepsis, with special emphasis on severe invasive group A streptococcal infections. Scandinavian Journal of Infectious Diseases2003;35:683‐9. [PUBMED: 14620155] ">Norrby‐Teglund 2003</a>). </p> <p>It should be noted that there is considerable heterogeneity in the nature and mode of action of the monoclonal antibodies; for example HA‐1A and E5 are postulated to act specifically against the lipid‐A moiety of the endotoxin, and anti‐LPS against the lipopolysaccharide (LPS) molecule of gram‐negative bacteria. Likewise, the anti‐cytokines act on various inflammatory mediators such as TNF alpha and IL‐1 (<a href="./references#CD001090-bbs2-0094" title="DahlbergPS , DavidDL . Endotoxins and sepsis. In: FeinAM , AbrahanEM , et al. editor(s). Sepsis and multiorgan failure. USA: Williams &amp; Wilkins, 1997:45‐61. ">Dahlberg 1997</a>). </p> <p>In spite of the differing modes of action and varying potential benefits for different groups of patients, we included the different immunotherapeutic agents in our meta‐analyses and performed subgroup analyses. In the actual emergent situation of sepsis and septic shock the clinician opts for these agents without the benefit of laboratory results that might be predictive of a good outcome (for example gram‐positive versus gram‐negative bacterial aetiology, and levels of specific antibodies or cytokines). More importantly, there is still no validated bedside marker that could aid the physician in identifying specific subgroups of patients that could respond to these immunoadjuvants. </p> <p>It has been argued by sepsis trialists that perhaps the optimum therapy would be a combination of various immunotherapeutic agents that target different points of the sepsis cascade (<a href="./references#CD001090-bbs2-0088" title="AbrahamE , RaffinTA . Sepsis therapy trials ‐ continued disappointment or reason for hope?. JAMA1994;271:1876‐78. [PUBMED: 8196148 ] ">Abraham 1994</a>; <a href="./references#CD001090-bbs2-0091" title="BoneRC . A critical evaluation of new agents for the treatment of sepsis. JAMA1991;266:1686‐90. [PUBMED: 1886193 ] ">Bone 1991</a>; <a href="./references#CD001090-bbs2-0100" title="NydeggerUE . Sepsis and polyspecific intravenous immunoglobulins. Journal of Clinical Apheresis1997;12:93‐9. [PUBMED: 9263117 ] ">Nydegger 1997</a>; <a href="./references#CD001090-bbs2-0116" title="WerdanK . Pathophysiology of septic shock and multiorgan dysfunction syndrome and various therapeutic approaches with special emphasis on immunoglobulins. Therapeutic Apheresis2001;5:115‐22. [PUBMED: 11354295] ">Werdan 2001</a>). However, to date there are no randomized controlled trials on such combinations. At this point, adjuvant therapy with monoclonal IVIGs for the treatment of sepsis remains largely experimental, with no robust demonstrable evidence of benefit. </p> <p>Evidence‐based guidelines on sepsis recommend early goal‐directed therapy that involves goal‐oriented manipulation of cardiac preload, afterload, and contractility to achieve a balance between systemic oxygen delivery and demand (<a href="./references#CD001090-bbs2-0095" title="DellingerRP , LevyMM , CarletJM , BionJ , ParkerMM , JaeschkeR , et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Medicine2008;34:17‐60. [PUBMED: 18058085] ">Dellinger 2008</a>). This is in addition to controlling the source of infection and providing prompt, rational antibiotic use. A randomized controlled trial has shown that early goal‐directed resuscitation in the emergency room, for patients presenting with septic shock, significantly improved survival (<a href="./references#CD001090-bbs2-0107" title="RiversE , NguyenB , HavstadS , ResslerJ , MuzzinA , KnoblichB , et al. Early Goal‐Directed Therapy Collaborative Group. Early goal‐directed therapy in the treatment of severe sepsis and septic shock. The New England Journal of Medicine2001;345:1368‐77. [PUBMED: 1794169 ] ">Rivers 2001</a>). </p> <p>Other investigators have suggested further improvements in the design of clinical trials on sepsis, for example refining the clinical definition of sepsis, lengthening the duration of observation, and defining other endpoints of benefit (<a href="./references#CD001090-bbs2-0108" title="SibbaldWJ , VincentJL . Round table conference on clinical trials for the treatment of sepsis. Critical Care Medicine1995;23:394‐9. [PUBMED: 7867364] ">Sibbald 1995</a>). Only a few of the trials included in this review reported long‐term mortality, using variable cut‐offs ranging from 56 to 180 days. These trials also did not show significant reductions in mortality. A recent systematic review (<a href="./references#CD001090-bbs2-0090" title="AnnaneD . Improving clinical trials in the critically ill: unique challenge ‐sepsis. Critical Care Medicine2009;37 Suppl 1:117‐28. ">Annane 2009</a>) suggested six key points for the design and conduct of future sepsis trials, to minimize the sources of heterogeneity. </p> <p> <ol id="CD001090-list-0012"> <li> <p>Avoid mixing patients with severe sepsis and with septic shock.</p> </li> <li> <p>Restrict the time window to less than 24 hrs from onset of the first organ dysfunction or shock. </p> </li> <li> <p>Include only definite sepsis.</p> </li> <li> <p>Use the sepsis‐related organ failure assessment score for eligibility.</p> </li> <li> <p>Include a first interim analysis after enrolment of 25% of the planned sample size to check the actual baseline risk of death and to recalculate the number of patients needed. </p> </li> <li> <p>Strictly control for concomitant evidence‐based interventions as recommended in the 'Surviving Sepsis Campaign' guidelines, such as early goal‐directed therapy, source control, and prompt administration of antibiotics (<a href="./references#CD001090-bbs2-0095" title="DellingerRP , LevyMM , CarletJM , BionJ , ParkerMM , JaeschkeR , et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Medicine2008;34:17‐60. [PUBMED: 18058085] ">Dellinger 2008</a>; <a href="./references#CD001090-bbs2-0096" title="DellingerRP , LevyMM , RhodesA , AnnaneD , GerlachH , OpalS , et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2012. Critical Care Medicine2013;41:580‐637. ">Dellinger 2013</a>). </p> </li> </ol> </p> <p>Potential negative effects from administration of IVIG, such as possible risk of transmission of hepatitis C and prion diseases from poor quality IVIG preparations, have also been pointed out (<a href="./references#CD001090-bbs2-0016" title="ErdemG , YurdakökM , TekinalpG , ErsoyF . The use of IgM‐enriched intravenous immunoglobulin for the treatment of neonatal sepsis in preterm infants. The Turkish Journal of Pediatrics1993;35:277‐81. [PUBMED: 8160279] ">Erdem 1993</a>; <a href="./references#CD001090-bbs2-0101" title="NydeggerUE , SturzeneggerM . Adverse effects of intravenous immunoglobulin therapy. Drug Safety1999;21:171‐85. ">Nydegger 1999</a>). Not all polyclonal studies reported on adverse effects. Of the adverse effects described most were immediate and delayed reactions to the infusion, for example allergic and skin reactions. None of the trials looked at late adverse effects such as transmission of infectious agents. </p> </section> <section id="CD001090-sec-0082"> <h3 class="title" id="CD001090-sec-0082">Quality of the evidence</h3> <p>While this updated meta‐analysis provides some evidence of benefit from polyclonal IVIGs in adult patients with sepsis, it should be noted that most of the studies on polyclonal IVIG are small studies, which is in contrast to the 'large', multi‐centre studies for monoclonal antibody preparations. Sensitivity analysis of five published trials with low risk of bias (<a href="./references#CD001090-bbs2-0008" title="BurnsER , LeeV , RubinsteinA . Treatment of septic thrombocytopenia with immune globulin. Journal of Clinical Immunology1991;11:363‐8. [PUBMED: 1761642] ">Burns 1991</a>; <a href="./references#CD001090-bbs2-0011" title="DarenbergJ , IhendyaneN , SjölinJ , AufwerberE , HaidlS , FollinP , et al. StreptIg Study Group. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double‐blind placebo‐controlled trial. Clinical Infectious Diseases2003;37:333‐40. [PUBMED: 12884156 ] ">Darenberg 2003</a>; <a href="./references#CD001090-bbs2-0023" title="HentrichM , FehnleK , OstermannH , KlenastJ , CornelyO , SalatC , et al. IgMA‐enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple‐center trial. Critical Care Medicine2006;34:1319‐25. [PUBMED: 16540956] ">Hentrich 2006</a>; <a href="./references#CD001090-bbs2-0034" title="RodriguezA , RelloJ , NeiraJ , MaskinB , CerasoD , VastaL , et al. Effects of high‐dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery. Shock2005;23:298‐304. [PUBMED: 15803051 ] ">Rodriguez 2005</a>; <a href="./references#CD001090-bbs2-0040" title="WerdanK , PilzG , BujdosoO , FraubergerP , NeeserG , SchmeiderRE , et al. Score‐based immunoglobulin G therapy of patients with sepsis: The SBITS study. Critical Care Medicine2007;35:2693‐701. [PUBMED: 18074471] ">Werdan 2007</a>) did not show a reduction in mortality in adults. Hence caution must be taken in the interpretation of statistically significant results from the pooled analysis of small studies (<a href="./references#CD001090-bbs2-0093" title="CappelleriJC , IoannidisJP , SchmidCH , deFerrantiSD , AubertM , ChalmersTC , et al. Large trials vs meta‐analysis of smaller trials ‐ how do their results compare?. JAMA1999;276:1332‐8. [PUBMED: 8861993] ">Cappelleri 1995</a>; <a href="./references#CD001090-bbs2-0114" title="VillarJ , CarroliG , BelizanJM . Predictive ability of meta‐analyses of randomized controlled trials. Lancet1995;345:772‐6. [PUBMED: 7891492 ] ">Villar 1995</a>), particularly those with poor methodologic quality. For instance, some of the small studies were noted to have methodologic flaws. Wortel in a letter to the editor (<a href="./references#CD001090-bbs2-0117" title="WortelCH . Treatment of gram‐negative septic shock with an immunoglobulin preparation: a prospective randomized clinical trial (Letter to the Editor). Critical Care Medicine1993;21:163‐5. [PUBMED: 8420724] ">Wortel 1993</a>) noted some methodological deficiencies, such as multiple interim analyses, in one of the studies showing a significant reduction in mortality (<a href="./references#CD001090-bbs2-0036" title="SchedelI , DreikhausenU , NentwigB , HöckenschniederM , RauthmannD , BalikciogluS , et al. Treatment of Gram‐negative septic shock and an immunoglobulin preparation: A prospective randomized clinical trial. Critical Care Medicine1991;10:1104‐13. [PUBMED: 1884609] ">Schedel 1991</a>). </p> <p>For the meta‐analysis of polyclonal IVIG trials on adults, there was evidence of significant funnel plot asymmetry (<a href="#CD001090-fig-0005">Figure 5</a>) when using Egger's statistic (bias ‐1.3, P = 0.01) but not when using the Begg‐Mazumdar statistic (Kendall's tau ‐0.07, P = 0.66). While publication bias may partly explain the asymmetry, it is likely that the poor methodologic quality of the small studies is also contributing to the asymmetry. As stated above, the sensitivity analysis of studies with low risk of bias showed no reduction in mortality for both adults and neonates. Thus small study effects and poor methodologic quality are likely to contribute to the lack of robustness of the observed reduction in mortality seen in the pooled analysis of all the studies. It is also of note that, except for one trial (<a href="./references#CD001090-bbs2-0008" title="BurnsER , LeeV , RubinsteinA . Treatment of septic thrombocytopenia with immune globulin. Journal of Clinical Immunology1991;11:363‐8. [PUBMED: 1761642] ">Burns 1991</a>), the high quality polyclonal IVIG trials in adults (<a href="./references#CD001090-bbs2-0011" title="DarenbergJ , IhendyaneN , SjölinJ , AufwerberE , HaidlS , FollinP , et al. StreptIg Study Group. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double‐blind placebo‐controlled trial. Clinical Infectious Diseases2003;37:333‐40. [PUBMED: 12884156 ] ">Darenberg 2003</a>; <a href="./references#CD001090-bbs2-0023" title="HentrichM , FehnleK , OstermannH , KlenastJ , CornelyO , SalatC , et al. IgMA‐enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple‐center trial. Critical Care Medicine2006;34:1319‐25. [PUBMED: 16540956] ">Hentrich 2006</a>; <a href="./references#CD001090-bbs2-0034" title="RodriguezA , RelloJ , NeiraJ , MaskinB , CerasoD , VastaL , et al. Effects of high‐dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery. Shock2005;23:298‐304. [PUBMED: 15803051 ] ">Rodriguez 2005</a>; <a href="./references#CD001090-bbs2-0040" title="WerdanK , PilzG , BujdosoO , FraubergerP , NeeserG , SchmeiderRE , et al. Score‐based immunoglobulin G therapy of patients with sepsis: The SBITS study. Critical Care Medicine2007;35:2693‐701. [PUBMED: 18074471] ">Werdan 2007</a>) were all published after the year 2000, after the first version of our review (<a href="./references#CD001090-bbs2-0089" title="AlejandriaMM , LansangMA , FonbuenaGE , FadreguilanE , TimbrezaF , deLunaM , et al. Epidemiology and predictors of mortality from sepsis in medical patients at UP‐PGH. Philippine Journal of Microbiology and Infectious Diseases2000;29:23‐32. ">Alejandria 2000</a>). This updated review confirms the lack of robust strong evidence on the effectiveness of IVIG in reducing mortality among patients with sepsis. </p> </section> <section id="CD001090-sec-0083"> <h3 class="title" id="CD001090-sec-0083">Agreements and disagreements with other studies or reviews</h3> <p>The addition of the large trial on standard polyclonal IVIG (<a href="./references#CD001090-bbs2-0007" title="The INIS Collaborative Group. Treatment of neonatal sepsis with intravenous immune globulin. The New England Journal of Medicine2011;365:1201‐11. The INIS Study Collaborative Group. The INIS Study. International Neonatal Immunotherapy Study: Non‐specific intravenous immunoglobulin therapy for suspected or proven neonatal sepsis: an international, placebo‐controlled, multicentre randomised trial. BMC Pregnancy and Childbirth2008;8:1‐13. ">Brocklehurst 2011</a>) to our meta‐analysis of polyclonal IVIG for neonatal sepsis conclusively showed no benefit in reducing mortality, in contrast to a previous meta‐analysis (<a href="./references#CD001090-bbs2-0061" title="JensonHB , PollockBH . Meta‐analyses of intravenous immune globulin for prevention and treatment of neonatal sepsis. Pediatrics1997;99(2):E2. [PUBMED: 9099759 ] ">Jenson 1997</a>). A comparison of the studies that were included in our meta‐analysis and those in Jenson et al showed that the latter review did not include thee trials that had no significant reduction in mortality among neonates (<a href="./references#CD001090-bbs2-0007" title="The INIS Collaborative Group. Treatment of neonatal sepsis with intravenous immune globulin. The New England Journal of Medicine2011;365:1201‐11. The INIS Study Collaborative Group. The INIS Study. International Neonatal Immunotherapy Study: Non‐specific intravenous immunoglobulin therapy for suspected or proven neonatal sepsis: an international, placebo‐controlled, multicentre randomised trial. BMC Pregnancy and Childbirth2008;8:1‐13. ">Brocklehurst 2011</a>; <a href="./references#CD001090-bbs2-0009" title="ChenJY . Intravenous immunoglobulin in the treatment of full term and premature newborns with sepsis. Journal of the Formosan Medical Association: Taiwan Yi Zhi1996;11:839‐44. [PUBMED: 8990771] ">Chen 1996</a>; <a href="./references#CD001090-bbs2-0016" title="ErdemG , YurdakökM , TekinalpG , ErsoyF . The use of IgM‐enriched intravenous immunoglobulin for the treatment of neonatal sepsis in preterm infants. The Turkish Journal of Pediatrics1993;35:277‐81. [PUBMED: 8160279] ">Erdem 1993</a>); in addition, we excluded a study by Sidiropolous (<a href="./references#CD001090-bbs2-0077" title="SidiropolousD , BohmeU , vonMuraltG , MorellA , BarandunS . Immunoglobulin substitution in the treatment of neonatal septicemia. Schweizerische Medizinische Wochenschrift1981;111:1649‐55. [PUBMED: 7302548] ">Sidiropolous 1981</a>) which used alternate allocation of the interventions. Our meta‐analysis is in agreement with another Cochrane review (<a href="./references#CD001090-bbs2-0102" title="OhlssonA , LacyJB . Intravenous immunoglobulin for suspected or proven infection in neonates. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD001239.pub4] ">Ohlsson 2013</a>), which focused on polyclonal IVIG for suspected or subsequently proven infection in neonates and analysed a similar set of studies. Ohlsson et al concluded that the evidence is insufficient to support the routine administration of IVIG to prevent mortality in infants with suspected or proven neonatal infection. Another meta‐analysis (<a href="./references#CD001090-bbs2-0068" title="KreymannKG , deHeerG , NierhausA , KlugeS . Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Critical Care Medicine2007;35:2677‐85. [PUBMED: 18074464] ">Kreymann 2007</a>), which included more trials, showed significant reductions in mortality for both standard (RR 0.63; 95% CI 0.42 to 0.96; 7 trials, n = 358) and IgM‐enriched polyclonal IVIG trials (RR 0.50; 95% CI 0.34 to 0.73; 5 trials, n = 352). However, the additional trials in this meta‐analysis were also of small sample size and either used alternate allocation (<a href="./references#CD001090-bbs2-0051" title="El‐NawawyA , El‐KinanyH , Hamdy El‐SayedM , BoshraN . Intravenous polyclonal immunoglobulin administration to sepsis syndrome patients: a prospective study in a pediatric intensive care unit. Journal of Tropical Pediatrics2005;51:271‐8. [PUBMED: 15917261 ] ">El Nawawy 2005</a>; <a href="./references#CD001090-bbs2-0056" title="GökalpAS , ToksoyHB , TürkayS , BakiciMZ , KayaR . Intravenous immunoglobulin in the treatment of Salmonella typhimurium infections in preterm neonates. Clinical Pediatrics1994;33:349‐52. [PUBMED: 8200169 ] ">Gokalp 1994</a>; <a href="./references#CD001090-bbs2-0077" title="SidiropolousD , BohmeU , vonMuraltG , MorellA , BarandunS . Immunoglobulin substitution in the treatment of neonatal septicemia. Schweizerische Medizinische Wochenschrift1981;111:1649‐55. [PUBMED: 7302548] ">Sidiropolous 1981</a>) or had unclear allocation concealment (<a href="./references#CD001090-bbs2-0057" title="GunesT , KokluE , BuyukkayhanD , KurtogluS , KarakukcuM , PatirogluT . Exchange transfusion or intravenous immunoglobulin therapy as an adjunct to antibiotics for neonatal sepsis in developing countries: a pilot study. Annals of Tropical Paediatrics2006;26:39‐42. [PUBMED: 16494703 ] ">Gunes 2006</a>), which could have led to an overestimate of the treatment effects. The completion of the large polyclonal IVIG trial on neonates has provided definitive high quality evidence that standard polyclonal IVIG does not effectively reduce mortality among neonates with sepsis (<a href="./references#CD001090-bbs2-0007" title="The INIS Collaborative Group. Treatment of neonatal sepsis with intravenous immune globulin. The New England Journal of Medicine2011;365:1201‐11. The INIS Study Collaborative Group. The INIS Study. International Neonatal Immunotherapy Study: Non‐specific intravenous immunoglobulin therapy for suspected or proven neonatal sepsis: an international, placebo‐controlled, multicentre randomised trial. BMC Pregnancy and Childbirth2008;8:1‐13. ">Brocklehurst 2011</a>). One small study from Turkey on polyclonal IVIG in 60 neonates with blood culture confirmed sepsis that is awaiting quality assessment is unlikely to change the conclusions (<a href="./references#CD001090-bbs2-0087" title="YildizidasD , YapiciogluH , TumgorG , ErbeyF . Does polyclonal intravenous immunoglobulin reduce mortality in septic children in pediatric intensive care unit? [Cocuk yogun bakim unitesi'nde sepsis nedeni ile izlenen hastalarda poliklonal intravenoz immunglobulin tedavisi mortaliteyi azaltiyor mu?]. Cocuk Sagligi Ve Hastaliklari Dergisi2005;48:136‐41. [CENTRAL: CN‐00569372; EMBASE: 2005248022] ">Yildizdas 2005</a>). </p> <p>In contrast to the meta‐analysis on neonatal sepsis, the meta‐analysis on adult patients showed a significant reduction in mortality with the use of polyclonal IVIG. The results of our meta‐analysis of 17 trials is consistent with the results of three meta‐analyses on polyclonal IVIG for adults with sepsis (<a href="./references#CD001090-bbs2-0068" title="KreymannKG , deHeerG , NierhausA , KlugeS . Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Critical Care Medicine2007;35:2677‐85. [PUBMED: 18074464] ">Kreymann 2007</a>; <a href="./references#CD001090-bbs2-0070" title="LauplandKB , KirkpatrickAW , DelaneyA . Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta‐analysis. Critical Care Medicine2007;35:2686‐92. [PUBMED: 18074465 ] ">Laupland 2007</a>; <a href="./references#CD001090-bbs2-0080" title="TurgeonAF , HuttonB , FergussonDA , McIntyreL , TinmouthAA , CameronDW , et al. Meta‐analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Annals of Internal Medicine2007;146:193‐203. [PUBMED: 17283351 ] ">Turgeon 2007</a>), which all showed a survival benefit among patients who received polyclonal IVIG despite the variations in the number of trials included. Additionally, our subgroup analysis by type of polyclonal IVIG is in agreement with the subanalysis by Kreymann (<a href="./references#CD001090-bbs2-0068" title="KreymannKG , deHeerG , NierhausA , KlugeS . Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Critical Care Medicine2007;35:2677‐85. [PUBMED: 18074464] ">Kreymann 2007</a>), which also showed reductions in mortality for both standard IVIG and IgM‐enriched polyclonal immunoglobulin. On the other hand, the meta‐analysis of Pildal and Goetzsche (<a href="./references#CD001090-bbs2-0104" title="PildalJ , GøtzschePC . Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. Clinical Infectious Diseases2004;39:38‐46. [PUBMED: 15206051] ">Pildal 2004</a>) showed no reduction in mortality in a sensitivity analysis of two high quality trials in adults (<a href="./references#CD001090-bbs2-0008" title="BurnsER , LeeV , RubinsteinA . Treatment of septic thrombocytopenia with immune globulin. Journal of Clinical Immunology1991;11:363‐8. [PUBMED: 1761642] ">Burns 1991</a>; <a href="./references#CD001090-bbs2-0011" title="DarenbergJ , IhendyaneN , SjölinJ , AufwerberE , HaidlS , FollinP , et al. StreptIg Study Group. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double‐blind placebo‐controlled trial. Clinical Infectious Diseases2003;37:333‐40. [PUBMED: 12884156 ] ">Darenberg 2003</a>); one in neonates (<a href="./references#CD001090-bbs2-0028" title="Mancilla‐RamírezJ , González‐YunesR , Castellanos‐CruzC , García‐RocaP , Santos‐PreciadoJI . Intravenous immunoglobulin in the treatment of neonatal septicemia [Inmunoglobulina intravenosa en el tratamiento de septicemia neonatal.]. Boletín Médico del Hospital Infantil de México1992;49:4‐11. [PUBMED: 1304766] ">Mancilla‐Ramirez 1992</a>); and another trial that was an unpublished study (<a href="./references#CD001090-bbs2-0115" title="WerdanK , PilzG , the SBITs Study Group. Polyvalent immune globulins [Abstract 18]. Shock1997; Vol. 7 Suppl 5:1918. ">Werdan 1997</a> abstract). While we included the same trials, we also subanalysed the trials into adults and neonates. Our sensitivity analysis of high quality trials in adults, which includes a large study on polyclonal IVIG that was published 10 years after its completion (<a href="./references#CD001090-bbs2-0040" title="WerdanK , PilzG , BujdosoO , FraubergerP , NeeserG , SchmeiderRE , et al. Score‐based immunoglobulin G therapy of patients with sepsis: The SBITS study. Critical Care Medicine2007;35:2693‐701. [PUBMED: 18074471] ">Werdan 2007</a>) plus two studies published after 2004 (<a href="./references#CD001090-bbs2-0023" title="HentrichM , FehnleK , OstermannH , KlenastJ , CornelyO , SalatC , et al. IgMA‐enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple‐center trial. Critical Care Medicine2006;34:1319‐25. [PUBMED: 16540956] ">Hentrich 2006</a>; <a href="./references#CD001090-bbs2-0034" title="RodriguezA , RelloJ , NeiraJ , MaskinB , CerasoD , VastaL , et al. Effects of high‐dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery. Shock2005;23:298‐304. [PUBMED: 15803051 ] ">Rodriguez 2005</a>), also showed no reduction in mortality. The sensitivity analysis according to methodologic quality likewise demonstrated a lack of robustness of the survival benefit that was initially seen when all the trials were pooled. </p> <p>Another meta‐analysis included in a recent health technology assessment report (<a href="./references#CD001090-bbs2-0109" title="SoaresMO , WeltonNJ , HarrisonDA , PeuraP , Shankar‐HariM , HarveySE , et al. An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review,meta‐analysis and value of information analysis. Health Technology Assessment2012;16(7):1‐186. [DOI: 22361003] ">Soares 2012</a>), which simultaneously analysed the type of IVIG, dosing regimen and quality indicators, reached similar conclusions as our review despite some variations in the assessment and interpretation of quality and in the studies included and excluded. The modelling process identified trial quality, publication bias, small study effects and dosing regimen as factors contributing to the heterogeneity of the treatment effects of IVIG. Value of information analysis and a cost‐effectiveness decision model identified uncertainties in the mechanism of action of IVIG, dose and duration of IVIG therapy, and the heterogenous nature of severe sepsis as important issues that need to be addressed in future reviews and basic research. This information is needed to inform the design of a definitive RCT and re‐evaluate its impact on the expected value of the information before investing resources on such potentially costly research. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001090-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/urn:x-wiley:14651858:media:CD001090:CD001090-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_t/tCD001090-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Search flow diagram." data-id="CD001090-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Search flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/full#CD001090-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001090-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/urn:x-wiley:14651858:media:CD001090:CD001090-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_t/tCD001090-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgments about each methodological quality item for each included study." data-id="CD001090-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgments about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/full#CD001090-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001090-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/urn:x-wiley:14651858:media:CD001090:CD001090-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_t/tCD001090-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD001090-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/full#CD001090-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001090-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/urn:x-wiley:14651858:media:CD001090:CD001090-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_t/tCD001090-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Polyclonal IVIG versus placebo or no intervention, outcome: all‐cause mortality by type of polyclonal IVIG, sensitivity analysis, low risk of bias trials." data-id="CD001090-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Polyclonal IVIG versus placebo or no intervention, outcome: all‐cause mortality by type of polyclonal IVIG, sensitivity analysis, low risk of bias trials. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/full#CD001090-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001090-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/urn:x-wiley:14651858:media:CD001090:CD001090-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_t/tCD001090-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 2 Polyclonal IVIG versus placebo or no intervention, outcome: 2.1 All‐cause mortality, adults, by type of polyclonal IVIG." data-id="CD001090-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 2 Polyclonal IVIG versus placebo or no intervention, outcome: 2.1 All‐cause mortality, adults, by type of polyclonal IVIG. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/full#CD001090-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001090-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/urn:x-wiley:14651858:media:CD001090:CD001090-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_t/tCD001090-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 2 Polyclonal IVIG versus placebo or no intervention, outcome: 2.3 All‐cause mortality, neonates, by type of polyclonal IVIG." data-id="CD001090-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot of comparison: 2 Polyclonal IVIG versus placebo or no intervention, outcome: 2.3 All‐cause mortality, neonates, by type of polyclonal IVIG. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/full#CD001090-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001090-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/urn:x-wiley:14651858:media:CD001090:CD001090-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_t/tCD001090-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IVIG versus placebo or no intervention, Outcome 1 All‐cause mortality by type of IVIG, random effects." data-id="CD001090-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 IVIG versus placebo or no intervention, Outcome 1 All‐cause mortality by type of IVIG, random effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/references#CD001090-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001090-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/urn:x-wiley:14651858:media:CD001090:CD001090-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_t/tCD001090-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IVIG versus placebo or no intervention, Outcome 2 Low risk of bias studies, all‐cause mortality." data-id="CD001090-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 IVIG versus placebo or no intervention, Outcome 2 Low risk of bias studies, all‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/references#CD001090-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001090-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/urn:x-wiley:14651858:media:CD001090:CD001090-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_t/tCD001090-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Polyclonal IVIG versus placebo or no intervention, Outcome 1 All‐cause mortality, adults, by type of polyclonal IVIG." data-id="CD001090-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Polyclonal IVIG versus placebo or no intervention, Outcome 1 All‐cause mortality, adults, by type of polyclonal IVIG. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/references#CD001090-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001090-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/urn:x-wiley:14651858:media:CD001090:CD001090-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_t/tCD001090-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Polyclonal IVIG versus placebo or no intervention, Outcome 2 Sensitivity analysis, low risk of bias adult studies, by type of polyclonal IVIG, mortality all‐cause." data-id="CD001090-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Polyclonal IVIG versus placebo or no intervention, Outcome 2 Sensitivity analysis, low risk of bias adult studies, by type of polyclonal IVIG, mortality all‐cause. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/references#CD001090-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001090-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/urn:x-wiley:14651858:media:CD001090:CD001090-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_t/tCD001090-CMP-002-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Polyclonal IVIG versus placebo or no intervention, Outcome 3 All‐cause mortality, neonates, by type of polyclonal IVIG." data-id="CD001090-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Polyclonal IVIG versus placebo or no intervention, Outcome 3 All‐cause mortality, neonates, by type of polyclonal IVIG. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/references#CD001090-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001090-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/urn:x-wiley:14651858:media:CD001090:CD001090-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_t/tCD001090-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Polyclonal IVIG versus placebo or no intervention, Outcome 4 Sensitivity analysis, low risk of bias, standard polyclonal IVIG, neonates, mortality all‐cause." data-id="CD001090-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Polyclonal IVIG versus placebo or no intervention, Outcome 4 Sensitivity analysis, low risk of bias, standard polyclonal IVIG, neonates, mortality all‐cause. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/references#CD001090-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001090-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/urn:x-wiley:14651858:media:CD001090:CD001090-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_t/tCD001090-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Polyclonal IVIG versus placebo or no intervention, Outcome 5 Mortality from sepsis / septic shock." data-id="CD001090-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Polyclonal IVIG versus placebo or no intervention, Outcome 5 Mortality from sepsis / septic shock. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/references#CD001090-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001090-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/urn:x-wiley:14651858:media:CD001090:CD001090-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_t/tCD001090-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Polyclonal IVIG versus placebo or no intervention, Outcome 6 Length of hospital stay, survivors." data-id="CD001090-fig-0014" src="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Polyclonal IVIG versus placebo or no intervention, Outcome 6 Length of hospital stay, survivors. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/references#CD001090-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001090-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/urn:x-wiley:14651858:media:CD001090:CD001090-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_t/tCD001090-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Polyclonal IVIG versus placebo or no intervention, Outcome 7 Sensitivity analysis by quality, length of hospital stay, neonates." data-id="CD001090-fig-0015" src="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Polyclonal IVIG versus placebo or no intervention, Outcome 7 Sensitivity analysis by quality, length of hospital stay, neonates. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/references#CD001090-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001090-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/urn:x-wiley:14651858:media:CD001090:CD001090-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_t/tCD001090-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Polyclonal IVIG versus placebo or no intervention, Outcome 8 All‐cause mortality, adults, by type of patients." data-id="CD001090-fig-0016" src="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Polyclonal IVIG versus placebo or no intervention, Outcome 8 All‐cause mortality, adults, by type of patients. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/references#CD001090-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001090-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/urn:x-wiley:14651858:media:CD001090:CD001090-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_t/tCD001090-CMP-002-09.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Polyclonal IVIG versus placebo or no intervention, Outcome 9 Sensitivity analysis, high quality trials, all‐cause mortality polyclonal IVIG." data-id="CD001090-fig-0017" src="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Polyclonal IVIG versus placebo or no intervention, Outcome 9 Sensitivity analysis, high quality trials, all‐cause mortality polyclonal IVIG. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/references#CD001090-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001090-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/urn:x-wiley:14651858:media:CD001090:CD001090-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_t/tCD001090-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Monoclonal antibodies versus placebo, Outcome 1 Anti‐endotoxins vs. placebo, all‐cause mortality." data-id="CD001090-fig-0018" src="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Monoclonal antibodies versus placebo, Outcome 1 Anti‐endotoxins vs. placebo, all‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/references#CD001090-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001090-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/urn:x-wiley:14651858:media:CD001090:CD001090-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_t/tCD001090-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Monoclonal antibodies versus placebo, Outcome 2 Sensitivity analysis by quality, anti‐endotoxin, all‐cause mortality." data-id="CD001090-fig-0019" src="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Monoclonal antibodies versus placebo, Outcome 2 Sensitivity analysis by quality, anti‐endotoxin, all‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/references#CD001090-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001090-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/urn:x-wiley:14651858:media:CD001090:CD001090-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_t/tCD001090-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Monoclonal antibodies versus placebo, Outcome 3 Anti‐cytokines vs. placebo, all‐cause mortality." data-id="CD001090-fig-0020" src="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Monoclonal antibodies versus placebo, Outcome 3 Anti‐cytokines vs. placebo, all‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/references#CD001090-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001090-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/urn:x-wiley:14651858:media:CD001090:CD001090-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_t/tCD001090-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Monoclonal antibodies versus placebo, Outcome 4 Sensitivity analysis by quality, anti‐cytokine, all‐cause mortality." data-id="CD001090-fig-0021" src="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Monoclonal antibodies versus placebo, Outcome 4 Sensitivity analysis by quality, anti‐cytokine, all‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/references#CD001090-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001090-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/urn:x-wiley:14651858:media:CD001090:CD001090-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_t/tCD001090-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Monoclonal antibodies versus placebo, Outcome 5 Monoclonal antibody to Enterobacteriaceae common antigen." data-id="CD001090-fig-0022" src="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Monoclonal antibodies versus placebo, Outcome 5 Monoclonal antibody to Enterobacteriaceae common antigen. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/references#CD001090-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/media/CDSR/CD001090/image_n/nCD001090-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001090-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Polyclonal intravenous immunoglobulin (IVIG) versus placebo or no intervention for sepsis, severe sepsis and septic shock</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Polyclonal IVIG versus placebo or no intervention for sepsis, severe sepsis and septic shock</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> neonates with sepsis, severe sepsis and septic shock<br/> <b>Intervention:</b> polyclonal IVIG<br/> <b>Comparison:</b> placebo or no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo or no intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Polyclonal IVIG </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>All‐cause mortality, neonates, standard polyclonal IVIG</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1</b> <br/> (0.92 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3667<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>380 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>380 per 1000</b><br/> (349 to 410) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>280 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>280 per 1000</b><br/> (258 to 302) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>All‐cause mortality, neonates, IgM‐enriched polyclonal IVIG</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.57</b> <br/> (0.31 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>164<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>274 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>156 per 1000</b><br/> (85 to 285) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>267 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>152 per 1000</b><br/> (83 to 278) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Low risk of bias neonate studies, mortality all‐cause ‐ standard IVIG</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.01</b> <br/> (0.93 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3561<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>387 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>391 per 1000</b><br/> (360 to 421) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>294 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>297 per 1000</b><br/> (273 to 320) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Two studies are of low quality (Chen 1996; Shenoi 1999)<br/> <sup>2</sup> Two studies are of low quality (Erdem; Samatha)<br/> <sup>3</sup> Wide confidence intervals, small studies </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Polyclonal intravenous immunoglobulin (IVIG) versus placebo or no intervention for sepsis, severe sepsis and septic shock</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/full#CD001090-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001090-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Polyclonal intravenous immunoglobulin (IVIG) versus placebo or no intervention for sepsis, severe sepsis and septic shock</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Polyclonal IVIG versus placebo or no intervention for sepsis, severe sepsis and septic shock</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> adult patients with sepsis, severe sepsis and septic shock<br/> <b>Intervention:</b> polyclonal IVIG<br/> <b>Comparison:</b> placebo or no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo or no intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Polyclonal IVIG </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>All‐cause mortality, adults, standard polyclonal IVIG</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.81</b> <br/> (0.7 to 0.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1430<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>365 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>296 per 1000</b><br/> (256 to 340) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>423 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>343 per 1000</b><br/> (296 to 393) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>All‐cause mortality, adults, IgM‐enriched polyclonal IVIG</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.66</b> <br/> (0.51 to 0.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>528<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>375 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>247 per 1000</b><br/> (191 to 318) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>412 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>272 per 1000</b><br/> (210 to 350) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Low risk of bias adult studies, by type of polyclonal IVIG, mortality all‐cause</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.97</b> <br/> (0.81 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>945<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>354 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>344 per 1000</b><br/> (287 to 408) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>364 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>353 per 1000</b><br/> (295 to 419) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Low risk of bias adult studies, mortality all‐cause ‐ standard IVIG</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.02</b> <br/> (0.84 to 1.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>683<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>367 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>374 per 1000</b><br/> (308 to 455) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>364 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>371 per 1000</b><br/> (306 to 451) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Low risk of bias adult studies, mortality all‐cause ‐ IgM‐enriched IVIG</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.82</b> <br/> (0.56 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>262<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>323 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>265 per 1000</b><br/> (181 to 384) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>382 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>313 per 1000</b><br/> (214 to 455) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Only 3 studies on standard polyclonal IVIG are of high quality (Burns 1991; Darenberg 2003; Werdan 2007)<br/> <sup>2</sup> Only 2 studies on IgM‐enriched IVIG are of high quality (Hentrich 2006; Rodriguez 2005)<br/> <sup>3</sup> There are only 2 studies, summary effect with wide confidence intervals </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Polyclonal intravenous immunoglobulin (IVIG) versus placebo or no intervention for sepsis, severe sepsis and septic shock</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/full#CD001090-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001090-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Monoclonal antibodies compared to placebo for sepsis, severe sepsis, septic shock</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Anti‐endotoxins compared to placebo for sepsis, severe sepsis, septic shock</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with sepsis, severe sepsis, septic shock<br/> <b>Settings:</b> <br/> <b>Intervention:</b> anti‐endotoxins<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Anti‐endotoxins </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Anti‐endotoxins versus placebo, all‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.92</b> <br/> (0.79 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>4676<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>369 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>340 per 1000</b><br/> (292 to 391) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>406 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>374 per 1000</b><br/> (321 to 430) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Anti‐endotoxin E5 versus placebo, all‐ cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.98</b> <br/> (0.88 to 1.1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1975<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>385 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>377 per 1000</b><br/> (338 to 423) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>406 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>398 per 1000</b><br/> (357 to 447) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Anti‐endotoxin ‐ HA‐1A versus placebo, all‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.8</b> <br/> (0.54 to 1.2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2668<br/> (3 studies<sup>4</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>4,5</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>356 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>285 per 1000</b><br/> (192 to 428) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>356 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>285 per 1000</b><br/> (192 to 427) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Anti‐endotoxins Anti‐LPS versus placebo, all‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.15</b> <br/> (0.02 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>33<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>474 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>71 per 1000</b><br/> (9 to 502) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>474 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>71 per 1000</b><br/> (9 to 502) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Sensitivity analysis by quality, anti‐endotoxin, all‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.01</b> <br/> (0.94 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>4443<br/> (6 studies<sup>3</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>364 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>367 per 1000</b><br/> (342 to 397) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>380 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>384 per 1000</b><br/> (357 to 414) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Anti‐endotoxin, all‐cause mortality ‐ low risk of bias studies</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.67</b> <br/> (0.42 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>269<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>275 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>184 per 1000</b><br/> (116 to 289) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>275 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>184 per 1000</b><br/> (115 to 289) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Anti‐endotoxin, all‐cause mortality ‐ unclear risk of bias</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.03</b> <br/> (0.95 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>4174<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>370 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>381 per 1000</b><br/> (351 to 410) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>403 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>415 per 1000</b><br/> (383 to 447) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across the included studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Five studies with unclear allocation concealment<br/> <sup>2</sup> There is a significant subgroup difference<br/> <sup>3</sup> Unclear allocation concealment<br/> <sup>4</sup> Two studies with unclear allocation concealment<br/> <sup>5</sup> Significant heterogeneity of the three trials<br/> <sup>6</sup> One trial only, with wide confidence interval </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Monoclonal antibodies compared to placebo for sepsis, severe sepsis, septic shock</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/full#CD001090-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001090-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Monoclonal antibodies compared to placebo for sepsis, severe sepsis, septic shock</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Anti‐cytokines compared to placebo for sepsis, severe sepsis, septic shock</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with sepsis, severe sepsis, septic shock<br/> <b>Settings:</b> <br/> <b>Intervention:</b> anti‐cytokines<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Anti‐cytokines </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Anti‐cytokines versus placebo, all‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.92</b> <br/> (0.86 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>7893<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>377 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>347 per 1000</b><br/> (324 to 366) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>395 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>363 per 1000</b><br/> (340 to 383) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Anticytokine ‐ anti‐TNF‐alpha versus placebo, all‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.92</b> <br/> (0.87 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>6200<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>382 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>352 per 1000</b><br/> (333 to 378) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>405 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>373 per 1000</b><br/> (352 to 401) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Anti‐cytokines ‐ human interleukin‐1receptor antagonist versus placebo, all‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.88</b> <br/> (0.76 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1693<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>355 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>313 per 1000</b><br/> (270 to 359) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>364 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>320 per 1000</b><br/> (277 to 368) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Sensitivity analysis by quality, anti‐cytokine, all‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.91</b> <br/> (0.86 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>7752<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>376 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>342 per 1000</b><br/> (323 to 365) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>364 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>331 per 1000</b><br/> (313 to 353) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Anti‐cytokine, all‐cause mortality ‐ low risk of bias studies</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.92</b> <br/> (0.86 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>5065<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>388 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>357 per 1000</b><br/> (334 to 384) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>395 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>363 per 1000</b><br/> (340 to 391) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Anti‐cytokine, all‐cause mortality ‐ uncertain risk of bias</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.89</b> <br/> (0.8 to 1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2687<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>347 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>309 per 1000</b><br/> (278 to 347) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>351 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>312 per 1000</b><br/> (281 to 351) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Six studies with unclear allocation concealment<br/> <sup>2</sup> Three studies with unclear allocation concealment<br/> <sup>3</sup> Unclear allocation concealment 4 studies </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Monoclonal antibodies compared to placebo for sepsis, severe sepsis, septic shock</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/full#CD001090-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001090-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">IVIG versus placebo or no intervention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality by type of IVIG, random effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Polyclonal IVIG, adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1958</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.58, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Polyclonal IVIG, neonates</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3831</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.91, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Anti‐endotoxins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4676</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.79, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Anti‐cytokines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7893</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.86, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Low risk of bias studies, all‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Polyclonal IVIG, adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>945</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.74, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Polyclonal IVIG, neonates</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3561</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.92, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Anti‐endotoxins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.42, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Anti‐cytokines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5065</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.86, 0.99]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">IVIG versus placebo or no intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/references#CD001090-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001090-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Polyclonal IVIG versus placebo or no intervention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality, adults, by type of polyclonal IVIG <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1958</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.68, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Standard polyclonal IVIG, adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1430</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.70, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 IgM‐enriched polyclonal IVIG, adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>528</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.51, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Sensitivity analysis, low risk of bias adult studies, by type of polyclonal IVIG, mortality all‐cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>945</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.81, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Standard IVIG, adults, low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.84, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 IgM‐enriched IVIG, adults, low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.56, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 All‐cause mortality, neonates, by type of polyclonal IVIG <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3831</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.91, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Standard polyclonal IVIG, neonates</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.92, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 IgM‐enriched polyclonal IVIG, neonates</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.31, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Sensitivity analysis, low risk of bias, standard polyclonal IVIG, neonates, mortality all‐cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3561</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.92, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mortality from sepsis / septic shock <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Polyclonal IVIG, adult</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.29, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Polyclonal IVIG, neonate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.8 [0.34, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Length of hospital stay, survivors <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Polyclonal IVIG, adult</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.00 [‐6.37, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Polyclonal IVIG, neonate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.84 [‐9.72, ‐1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Sensitivity analysis by quality, length of hospital stay, neonates <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [‐12.18, 14.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 All‐cause mortality, adults, by type of patients <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1958</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.68, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Surgical patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>294</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.45, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Medical patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.51, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Mixed medical‐surgical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>677</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.85, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Sensitivity analysis, high quality trials, all‐cause mortality polyclonal IVIG <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Standard IVIG, adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.84, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 IgM enriched IVIG, adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.56, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Standard IVIG, neonates</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3561</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.92, 1.08]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Polyclonal IVIG versus placebo or no intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/references#CD001090-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001090-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Monoclonal antibodies versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Anti‐endotoxins vs. placebo, all‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4676</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.79, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 E5 vs. placebo, all‐ cause mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1975</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.88, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 HA‐1A vs. placebo, all‐cause mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2668</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.54, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Anti‐LPS vs placebo, all‐cause mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.02, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Sensitivity analysis by quality, anti‐endotoxin, all‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4443</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.94, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.42, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Unclear risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.95, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Anti‐cytokines vs. placebo, all‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7893</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.86, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Anti‐TNF‐alpha vs. placebo, all‐cause mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.87, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Human interleukin‐1receptor antagonist vs. placebo, all‐cause mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.76, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Sensitivity analysis by quality, anti‐cytokine, all‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7752</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.86, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5065</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.86, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Uncertain risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2687</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.80, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Monoclonal antibody to Enterobacteriaceae common antigen <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>826</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.91, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Monoclonal antibodies versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001090.pub2/references#CD001090-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001090.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD001090-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD001090-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001090-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD001090-note-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD001090-note-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD001090-note-0003">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD001090-note-0002">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001090\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001090\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001090\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001090\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001090\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001090\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001090\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001090\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001090\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001090\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001090\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001090\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001090\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001090\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001090\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001090\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001090\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001090\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=7a2tKMcJ&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001090.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001090.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001090.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001090.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001090.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715637404"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001090.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715637408"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001090.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d8bf19b9b9371',t:'MTc0MDcxNTYzNy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 